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Abstract 
Highly toxic aromatic halogenated compounds such as PCB’s, PCDF’s and PCDD’s act 
as persistent organic pollutants and can bio-accumulate. These compounds are highly stable to 
oxidation, reduction and thermal degradation. Current remediation technologies are expensive 
and can cause the formation of even more toxic byproducts. It is clear that an environmentally 
friendly and inexpensive remediation technology is required.  
Our goal was the synthesis of dehalogenation catalysts incorporating aromatic side arms 
for the pre-concentration of the substrates to the catalysts. We envisioned that aromatic side arms 
would allow the aggregation of catalyst and substrate to form a pre-complex that would enhance 
rates of dehalogenation. Rapid and stereochemically predictable synthesis of N and C 
functionalized nickel cyclam complexes were a priority for this project.  
Synthesis of N-functionalized cyclam molecules and subsequent metal incorporation 
proceeds smoothly to form trans(III) nickel cyclam complexes. However longer reaction times, 
initiation periods and short catalyst lifetimes made these complexes unsuitable for long-term 
study. 
Cyclization of dipeptides and tetrapeptides using a metal template in basic conditions led 
to the formation of cyclopeptide nickel complexes with stereochemistry retained from the 
peptide precursors. Free cyclopeptides could be isolated from the nickel complexes by treatment 
with HCl. 
Cyclopeptides are reduced to the cyclam molecules via a LAH reduction in low to 
moderate yields. Nickel incorporation into the cyclam molecules produced C-functionalized 
nickel catalysts with stereochemical integrity maintained throughout the synthesis. 
Intermolecular CH-π interactions can be seen in the solid state for the nickel cyclam complexes 
with aromatic side arms. 
Reduction data show that the C-functionalized catalysts do not show improved rates of 
reduction for several aromatic substrates but small rate enhancements are observed for the 
reduction of chloronaphthalene over the unfunctionalized catalyst. 
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CHAPTER 1 - Non-functionalized and N-functionalized Nickel 
Cyclam Complexes and Hydrodehalogenation. 
1.1 Introduction 
 
There are many halogenated aromatic hydrocarbons that have been produced 
either intentionally as useful chemicals1 or as side products of reactions/remediation of 
compounds over the years. These range from simple halogenated benzenes (used as 
intermediates in synthesizing pesticides2) to more complex polyhalogenated and 
polyaromatic systems such as polychlorinated biphenyls (PCB’s) which were 
intentionally synthesized during most of the 20th century3, polychlorinated dibenzo-p-
dioxins (PCDD’s), and polychlorinated dibenzofurans (PCDF’s) both are unintentionally 
produced as by-products of the incineration of organic compounds4 (Figure 1.1).  These 
compounds are costly to remove with clean up of PCB’s from the Hudson River 
exceeding 460 million dollars5. There are two main processes by which halogenated 
organic pollutants are removed from the environment, plasma burning and sodium 
columns6. Homogeneous catalysis in aqueous solutions may one day provide an efficient 
and cost effective means of remediation of these pollutants. 
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Figure 1.1: -Pollutants of concern. 
1.1.1 Previous Methods of Hydrodehalogenation. 
 
There are many methods available for the dehalogenation of aromatic 
compounds7. Alkaline earth metals for single electron transfer reductions (SET)8. Metal 
hydrides such as silanes9 act as good hydrogen donors in SET reactions with aryl halides.  
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Pd/C, Pd/TiO2 or Pd/Al2O3 catalysts can reduce aryl halides though 
hydrogenation reactions in polar media such as propanol/methanol mixtures at 30oC10 or 
ethanol:water mixtures11. Pd(OAc)2 has also been utilized as a dehalogenation catalyst. It 
is very effective under basic conditions in alcoholic solvents for the dehalogenation of a 
wide range of halogenated materials12.  
Electrochemical dechlorination of polychlorinated benzenes occurs readily in 
acetonitrile in the presence of naphthalene and occurs via SET mechanism13. Hydroxide 
ions can be utilized as an electron source for photo-dehalogenation reactions in high 
yields14.  
Homogenous ruthenium catalysts with phosphine ligands have been utilized in the 
reduction of sp2 hybridised C-halogen bonds via insertion elimination mechanisms15.  
Active homogenous FeCl2 catalysts in the presence of Li powder and an electron 
carrier such as 4,4’-di-tert-butylbiphenyl (DTBB) can reduce many aryl halides in THF16. 
Sodium borohydride acts as a dehalogenation promoter at high temperatures and 
have been shown to work better in glyme solvents17. 
Raney nickel catalysts have been utilized in the removal of halogens from 
polychlorinated benzene to some effect under high temperatures in the presence of base 
and protic solvents18. Na-H nanoparticles in the presence of Ni(OAc)2 and I-PrONa show 
a strong ability to dehalogenate polychlorinated biphenyls in >99% yields19. NiCl2 in the 
presence of Li and DTBB at –20oC work in over 85% yields to remove chlorines from 
aryl halides and again occur though electron transfer mechanisms20.  
Biological C-Cl bond breaking may well occur utilizing vitamin B12 (Co) and its 
derivatives21, factor F430 (Ni)22 or hematin (Fe)21a. F430 is a nickel-hydrocorphinoid 
prosthetic group of the enzyme methyl coenzyme M reductase22 (MCR) (Figure 1.2). 
However F430 not a very efficient catalyst for the reduction and remediation of 
halogenated aromatic compounds23.   
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Figure 1.2: - Structure of F430. 
 
Several examples of nickel complexes based on F430 have been developed to study 
the dehalogenation reaction with Ni(I)/Ni-H species24/22 and some are shown below 
(Figure 1.3). 
N
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(a) (b)
(c) (d)  
Figure 1.3: - Several catalysts developed to study hydrodehalogenation reactions. 
  
There is much confusion over the apparent mechanism of dehalogenation 
mediated by F430 and its analogues with SET24, hydride delivery25 and 
insertion/elimination26 pathways all being proposed. 
Stiles utilized a limited series of tetraazamacrocyclic compounds ( a and b Figure 
1.3) and performed reactions incorporating deuterium or protons into the dehalogenated 
product (naphthalene) and noticed that the vast majority of the protons/deuterons came 
from the borohydride (84%) (borohydride has the ability to donate hydrogen atoms24) 
with some hydrogen atoms coming from the solvent (16%) (Ethanol, water, AcCN were 
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used as solvents) (Figure 1.23) Cumene was also seen to retard the reaction indicating 
radical pathways24.  
EPR experiments led to the discovery of a possible nickel hydride formation in 
F430. Possible insertion and β-hydride elimination mechanisms for non-aromatic 
substrates have been deduced using this system22. 
Dunach’s cyclization of aromatic halides suggests Ni-Aryl intermediates based on 
a 2e- reaction. Ni(I) inserts into a C-Br bond to give a Ni(III) species that rearranges to 
form a cyclized intermediate and is then reduced to Ni(II) whereby the C deprotonates a 
solvent molecule and the catalyst is regenerated. Evidence for this process can be seen in 
the CV data obtained for the reaction and the generation of coupled products26/24b 
(Figure1.22). 
1.1.2 Artificial Enzymes 
 
Much work has been performed in the field of artificial enzymes in recent years 
with many examples available in the literature27. These enzymes have been designed to 
mimic natural enzymes by utilizing hydrogen bonding and hydrophobic effects to pre-
organize substrates for reaction and to stabilize transition states27. 
One of the most well known example of artificial enzymes are functionalized 
cyclodextrins that catalyze the hydrolysis of cyclic phosphates with an apparent 120fold 
rate acceleration over the uncatalyzed process28. Neighboring imidazoles cooperate, show 
stronger binding to the starting material and can control the outcome of the reaction 
(Figure 1.4). 4-tert-butylcatechol cyclic phosphate binds though complementary size and 
hydrophobic effects to the interior of the cyclodextrins with binding being entropically 
favorable28.   
Cooperative binding and pre-alignment of starting materials to a catalyst is often 
cited as the cause of rate increases during the course of a reaction27. It has also been 
shown that hydrophobic interactions can contribute to the binding of substrates to active 
sites of enzymes and appear to be the dominant effect for the induced fit model of drugs 
into binding sites29. 
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Figure 1.4: - (a) β-Cyclodextrin; (b) Proposed cooperation of imidazoles in 
hydrolysis of the phosphate27a. 
 
1.1.3 π-π stacking effects in catalysis 
 
Several papers have recently shown that π-π interactions can play a role in the 
outcome of chemical reactions. The development of alternating styrene-pentaflurostyrene 
co-polymers has been noted due to the favorable interaction of one π-surface to the other 
has been demonstrated for a radical polymerisation reaction30.  
Interestingly π-π interactions have also been shown to aid in the increase of ee of 
a reaction based upon the orientation of π-π compatible catalysts and substrates (Figure 
1.5)31. The alignment of the π-π interaction (as well as the hydrogen bonding interactions) 
helps to dictate the orientation of the 1,4 unsaturated aldehydes. This π-π interaction 
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effectively blocks one side of the starting material forcing cyclopentene to approach the 
alkene from only one direction, leading to an increase in the ee. 
  
R1 CHO
+
CHO
R1
R/S > 200:1
Exo/endo 96:4
N-tosyl-(S)-
tryptophan-derived 
oxazaborolidinone
CH2Cl2,
-78oC  
(a) 
 
(b) 
Figure 1.5: - (a) Diels Alder reaction of functionalized aldehydes with 
cyclopentadiene in the presence of a N-tosyl-(S)-tryptophan-derived 
oxazaborolidinone  catalyst; (b) Proposed intermediate leading to high ee for the 
Diels Alder reaction31.  
 
Perhaps one of the most interesting and impressive aspects of π-π interactions in 
catalysis maybe the increase in rates of reaction observed for certain examples. Sharpless 
et al performed a comprehensive study on osmium-catalyzed asymmetric dihydroxylation 
reactions and found that aromatic ligands combined with aromatic alkene substrates gave 
drastically higher k values than that of aliphatic substrates or ligands32 (Figure1.6). It is 
believed that mutually attractive π-π interactions bring the reactants into close proximity 
to one another, allowing a pre-concentration and alignment of the reactant and catalyst to 
occur. This effect is enhanced in more polar solvent (such as t-butanol) and with a larger 
degree of π surface in the ligand30 (Figure 1.6). 
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Figure 1.6: - Sharpless ligand system, showing increased rates of alkene oxidation 
due to aromatic π-π interactions. 
1.2 Aims 
 
The goal of our research was the generation of nickel tetraazamacrocyclic 
compounds with aromatic side arms capable of interacting with the planar aromatic 
halogenated molecules via π-π or π-CH interactions in a similar fashion to that shown by 
Sharpless system (Figures 1.6). These interactions were hoped to artificially increase 
concentrations and orientate the substrate toward the reactive center of the Ni catalyst. 
Whilst π-π and T-stacking interactions are electrostatic in nature, their effect is 
relatively weak, with the energy of the interactions known to be around 2-5.5 KJmol-1 33. 
PCB’s and other halogenated polyaromatic pollutants have extremely low water 
solubility34 and as such they self assemble due to hydrophobic effects. This coming 
together of hydrophobic molecules has shown large rate increases for various reactions in 
polar solvents such as water35. 
We wished to utilize π-π/π-CH interactions between catalysts and reactants to pre-
bind the substrate to the catalyst. The pre-binding of the substrate followed by its 
reduction should lead to an increase in observed rates when compared to catalysts 
without this pre-concentration. Mutual aggregation is the bringing together of compounds 
of a similar nature. In this case the hydrophobic effects in polar solvents should aggregate 
the non-polar catalyst side arms and substrates, artificially enhancing their concentrations 
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and aligning the substrate with the reactive center of our complex, allowing reduction to 
occur at a quicker rate.  
The ligand systems that we have chosen to investigate are based around the 
cyclam molecules utilized by Stolzenberg20 (Figure 1.7). The ligand periphery shall be 
functionalized with aromatic side arms of varying sizes either on one of the nitrogen 
atoms or on one or two of the carbons atoms indicated below in figure 1.8. 
 
NH
NH
HN
HN
Cyclam moleule
Nitrogen for 
functionalization
Carbon for 
functionalization
Carbon for 
functionalization
 
Figure 1.7: - Diagram of the basic cyclam ligand system showing where 
functionalization will occur. 
 
It was our intent study the hydrodehalogenation of aromatic hydrocarbons in the 
presence of nickel-based catalysts. To this end compounds such as bromonaphthalene, 
chloronaphthalene, P and M-bromobiphenyl and 2-bromofluroene were chosen, having 
flat aromatic surfaces with which to bind to the aromatically functionalized catalysts 
(Figure 1.1). These compounds contain varying degrees of planarity, stacking ability and 
have a range of reduction potentials36 that was hoped would allow us to investigate the 
dehalogenation reactions. 
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Singularly halogenated aromatic compounds are more difficult to reduce than 
multiply functionalized ones due to the aromatic rings being more electron rich, leading 
to higher reduction potentials. It is often the final dehalogenation step that takes the 
longest and as such these rates become interesting in comparative studies. The 
dehalogenation of singularly halogenated aromatic compounds also allows us to identify 
just one product in the reaction mixture. 
We wished to utilize π-π/π-CH interactions between catalysts and reactants in the 
reduction of halogenated aromatic compounds to increase rates of reaction through 
mutual aggregation.  
N-functionalised cyclam molecules with aromatic side arms ranging from the 
small phenyl ring up to the larger 4-fused ring system pyrene were to be synthesized as a 
means of testing this theory. We hoped that π-π/π-CH interactions between the side arm 
on the catalyst and the aromatic halogenated substrates, such as bromonaphthalene, in 
polar solvents such as DMSO, DMSO:EtOH mixtures would lead to a rate increase due 
to close contact aggregation of the substrate and the catalyst through mutual attraction37 
(Figure 1.8). 
 
N
N
N
N
XNi N
N
N
NNi
X H
H
H
H
H
H
+
N
N
N
NNi
H
H
H
+
Substrate bound 
to Catalyst X = Halogen
 
Figure 1.8: - Halogenated substrate bound to catalyst showing pre-concentration.  
 
 Second generation catalysts were to focus on C-functionalized cyclam molecules 
however mono-N-functionalized cyclam molecules were seen as a rapidly generated 
series of catalysts with the correct properties to ascertain the viability of the π-stacking 
idea. We wished to utilize mono-functionalized cyclams because the Bis-functionalized 
cyclams have several drawbacks.  
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The first drawback of Bis-functionalized cyclams is the controllable 
functionalization of the cyclam molecule with respect to the attachment of the second 
alkyl group. One can form either the cis or the trans cyclam with the Cis having a 2:1 
statistical advantage over the Trans. Isolation and characterization of these molecules 
would take a lot of time. Cis Bis-alkylated cyclam synthesis has been accomplished 
selectively utilizing protecting groups to block off two amines yielding only the 1, 4-
dialkylated products38. 
Another drawback of Bis-functionalized cyclams is the distance between the aryl 
units. In both the Cis and Trans Bis-functionalized cyclams the distance between the aryl 
units is less than 6Å, less than twice the distance of a π-π interaction39 and thus would not 
enhance binding through cooperative binding (the formation of a tweezer like pincer that 
could bind the aromatic substrate, Figure 1.9b), but may through the catalysts having a 
higher degree of π surfaces with which to bind.  
N
N
N
N
Ni
H
H H
N
N
N
N
Ni
H H
BrBr
(a) (b)  
Figure 1.9: - (a) Binding of aromatic substrate to the catalyst. (b) Tweezer like 
complex utilizing cooperative binding not formed. 
 
The final and most prominent drawback of utilizing multiple N-functionalized 
cyclam catalysts is that cyclam-metal complexes are known to have several isomers 
pertaining to the relative positions of the N-H or N-R groups that do not make up the 
macrocycle scaffold40 (Figure 1.10). 
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Figure 1.10: - The five configurations of metal cyclam complexes2 
 
 Determining the exact geometry of each complex and isolating the desired one is 
very difficult as the complex has the ability to form any of the configurations discussed in 
figure 1.3. For example (IR,2R,4S,7S,8R,9R,11S,14S)-1,2,4,7,8,9,11,14-Oetamethyl- 
1,4,8,11-tetraazacyclotetradecanenickel(II)perchlorate adopts the trans(I) configuration41, 
although the trans(III) isomer tends to be preferred in the solid state as it is the most 
thermodynamically stable42. Hence selective and controllable stereochemistry derived 
from multiple N-alkylation reactions is impractical. 
1.3     Mono N-Functionalized Cyclams: - Synthesis 
 
There have been several examples of papers showing the synthesis of N-
functionalized cyclam molecules from the basic 1,4,8,11-tetraazacyclotetradecane 
starting material, each with a unique way to avoid over-alkylation43,44. These methods can 
include cyclam protection6 and alkylation or the use of stoichiometry to overcome the 
over-alkylation problem. 
Perhaps one of the simplest ways to avoid over-alkylation is to use the 1,4,8,11-
tetraazacyclotetradecane in large excess and in high dilution45. Statistically one is more 
likely to find a mono-alkylated cyclam molecule than the Bis, tris or tetra-alkylated 
cyclams (Figure 1.11).   
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HN
HN
NH
NH 0.1eq R-X
Chloroform
HN
N
NH
NH
R
+
HN
HN
NH
NH
X = Cl, Br  
Figure 1.11: - Mono-alkylation via high dilution and excess of cyclam. 
 
The main drawback to this method is the large excesses of cyclam needed11. This 
problem is however overcome by the fact that recovery of the starting material does not 
tend to be problematic11. Either a column or even simple filtration of the product from the 
starting material using differences in solubility can be utilized for starting material 
recovery in high yields11. 
Utilizing the high dilution low equivalence technique several cyclam ligands were 
synthesized in high yield (Figure 1.12) Purification of these ligands was very simple. All 
products were soluble in cold acetone whilst the starting material, 1,4,8,11-
tetraazacyclotetradecane was not. Simple filtration purified the reactions and the starting 
material was recovered and reused. 
 
HN
HN
NH
NH RCH2Cl
HN
N
NH
NH R
R = Phenyl (1.2a), 9-anthracenyl (1.2b), 1-pyrenyl (1.2c)
K2CO3
 
Figure 1.12: - Synthesis of N-functionalized cyclam ligands. 
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Table 1.1: - Yield of synthesized mono N-functionalized cyclams. 
 
Compound 
Number 
R Yield% 
1.2a Phenyl 85 
1.2b 9-Anthracenyl 85 
1.2c 1-Pyrenyl 100 
 
1.4 Synthesis of N-Functionalized Nickel Cyclam Complexes 
 
With the ligands synthesized, incorporation of the metal centre proved to be fairly 
straightforward. Simply refluxing each ligand with NiX2 in methanol leads to complex 
formation46 (Figure 1.13).  
HN
N
NH
NH NiX2.6H2O
N
N
N
N
R
R = H, CH2-Phenyl, CH2-9-anthracenyl, CH2-1-pyrenyl
Ni
2X-
+2
Methanol
R
X = Cl, ClO4, BPh4
H H
H
 
Figure 1.13: - Synthesis of nickel cyclam complexes. 
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Table 1.2: - Yields of the nickel complexes formed in solution. 
Compound 
Number 
X R Yield% 
1.3 ClO4 CH2Phenyl47 30 
1.4 ClO4 
CH2(9-
Anthracenyl)48 
36.8 
1.5 ClO4 
CH2(1-
Pyrenyl) 
30 
1.6a Cl H49 95 
1.6b BPh4 H50 76 
1.6c ClO4 H51 95 
1.6d BH4 H 81.4 
1.6e BD4 H 75.7 
 
Ni(II) species can exist in an octahedral  environment, which is paramagnetic52, or 
a square planar environment, which is diamagnetic53. Much of the coordination geometry 
of the complexes depends on the anion and the solvent it is dissolved in. Solvents that 
have lone pairs to donate such as acetonitrile, water, pyridine and acetic acid can form the 
octahedral complexes that are paramagnetic. 1HNMR data was checked over a range of –
100 to 100ppm as the paramagnetic nature of the complexes causes such large changes in 
ppm values. 
Several of these nickel cyclam complexes were purified by 
recrystallization/precipitation and X-ray quality crystals were grown for compounds 1.3, 
1.4, 1.6a, 1.6b, and 1.6c with X-ray crystal data being obtained for compounds 1.4, 1.6b 
and 1.6d, whilst the other compounds (1.3, 1.6a and 1.6c) have crystal structure data 
previously reported in the literature14,15,16.  
Complex 1.3 sits in the thermodynamically favored trans(III) configuration, with 
no π-π interactions visible in the packing (for the copper complex)12. The 1HNMR data 
for 1.3 proved to be complicated with conformational isomers present in small amounts, 
even from a very crystalline purified solid, indicating some isomerization in solution54. 
Excellent 1HNMR data was gathered for complex 1.4 (Figures 1.14). The ligand 
ring structure gives a somewhat complex set of proton signals between –1.24ppm and 
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3.3ppm that can be attributed to the formation of several stereocenters on the nitrogens of 
the ligand. In this case one configuration seems to be preferred although exact details are 
difficult to decipher due to the complexity of the 1HNMR spectrum. This complexity did 
not allow the assignment of one particular configuration from the data available. There 
are some large splittings for several NH and CH protons, most like due to the proximity 
of these protons to the metal center. Having a 1HNMR that shows low broadening and a 
small ppm range also indicate that the complex is square planar and has no axial ligands 
(either the counter anion or solvent). The reaction of 1.2b with nickel perchlorate (an 
non-coordinating counter anion) in methanol generated the 1.4 without axial ligands. In 
this case it appears the solvent was not a strong enough coordinator to interact with the 
nickel. This suggests that the nickel is diamagnetic, having a square planar geometry 
around the metal and not paramagnetic, having an octahedral geometry around the metal 
center. For complex 1.6a axial ligands (chloride) induce paramagnetism leading to broad 
and wide ranging 1HNMR spectra (Figure 1.15).  
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Figure 1.14: - (1, Blue line) NMR of 1.4 with NH bonds, (2, green line) NMR of 1.4 
with ND bonds after treatment with D2O. 
   
Complex 1.5, isolated as a sandy solid, has a 1HNMR showing the characteristic 
wide-ranging spectra observed for paramagnetic octahedral nickel complexes. The nickel 
centre had generated peaks that can be seen as high as 32ppm and as low as –24ppm. 
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H H
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D
D D
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Although a reasonably good spectrum was obtained, not all of the protons have been 
accounted for. Broad peaks in the baseline and peaks overlapping solvent peaks make 
characterization of the ligand periphery difficult. Full characterization of the pyrene 
protons was accomplished because of the increased distance from the metal centre. 
It is possible that dissolving the complexes allows for equilibrium to form 
between different configurations. Sadler et al showed that the uptake of Zn by cyclam 
ligands form an equilibrium of trans(III), cis(V) and trans(I) configurations in solution 
after 100 minutes55 . The reaction mixture for the complexes 1.3 and 1.5 could not be 
purified to give one configuration in solution. It is probable that the side arm in complex 
1.4 forces the complex to adopt the trans(III) configuration, even in solution, due to the 
1,3 syn axial steric repulsion experienced between the functionalized and 
unfunctionalized nitrogens, which is much less of a problem when non of the nitrogens 
are functionalized.   
1HNMR data for the 1,4,8,11-tetraazacyclotetradecane nickel complex 1.6a shows 
broadening indicating a paramagnetic complex (Figure 1.15). In this case there is Cl- in 
the axial positions of the complex as shown by the crystal structure previously obtained56.  
 
60 55 50 45 40 35 30 25 20 15 10 5 0 -5 -10 -15 -20
Chemical Shift (ppm)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
0.11
0.12
N
or
m
al
iz
ed
 In
te
ns
ity
4.003.837.477.72
DMSO-d6
2.
49
 
Figure 1.15: - NMR of the (1,4,8,11-tetraazacyclotetradecane)Nickel(II) Bis chloride 
complex 1.6a in DMSO (δ –20-75) 
 
The 1HNMR of complex 1.6b also suggested that it was paramagnetic, typical of 
octahedral complexes. BPh4- is a none-coordinating anion and as such would not take up 
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the coordination sites in the axial position. However in 1.6b two acetonitrile molecules, 
delivered during crystallization from acetonitrile, occupy the axial positions leading to an 
overall octahedral and thus paramagnetic complex.  
The presence of more than one configuration in solution is somewhat of a concern 
when it comes to comparative rate studies. It is possible to have 6 different configurations 
of the complex in the solution, which may lead to 6 different rate constants in one 
reaction mixture (Figure 1.10). Any rate increase/decrease observed for each complex 
may not be related to its overall structure but to the configurations that the complex can 
achieve in solution.  
 
1.4.1 X-ray Crystal Structures of Nickel Cyclam Complexes. 
 
Crystals of the 1-(9-Anthraceneyl)-1,4,8,11-tetraazacyclotetradecane nickel 
Bis(perchlorate) complex (1.4) (Figure 1.16). and 1,4,8,11-tetraazacyclotetradecane 
nickel Bis(chloride) complex (1.6b) (Figure 1.17) and - X-ray crystal structure of the 
(1,4,8,11-tetraazacyclotetradecane)nickel(II) Bis-borohydride complex 1.6d were isolated 
and X-ray crystal structures were obtained (Figure 1.18). The other complexes generated 
(1.3, 1.5, 1.6a, 1.6c) have all had crystal structures previously reported in the literature. 
 
Figure 1.16: - X-ray of (1-(9-Anthraceneyl)-1,4,8,11-Tetraazacycotetradecane) 
Nickel(II) Bis(perchlorate) complex 1.4 (perchlorate removed for clarity). 
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Figure 1.17: - X-ray of (1,4,8,11-Tetraazacycotetradecane)nickel(II) 
Bis(tetraphenylborate) complex 1.6b (BPh4- Removed for Clarity) . 
 
 
Figure 1.18: - X-ray crystal structure of the (1,4,8,11-
tetraazacyclotetradecane)nickel(II) Bis-borohydride complex 1.6d. 
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Table 1.3: - Selected X-ray crystal structure information for complexes 1.4, 1.6b and 
1.6d. 
Complex Configuration 
Selected Bond 
Lengths 
Selected Bond Angles 
1.4 Trans(III) 
N(11)-Ni (1.971Å), 
N(15)-Ni (1.961Å), 
N(18)-Ni (1.950Å), 
N(22)-Ni (1.940Å). 
N(11)-Ni-N(15) (93.96o), 
N(15)-Ni-N(18) (86.51o), 
N(18)-Ni-N(22) (91.13o), 
N(22)-Ni-N(11) (88.47o), 
N(11)-Ni-N(18) (179.19o), 
N(22)-Ni-N(15) (173.93o). 
1.6b Trans(III) 
N(11/11A)-Ni 
(2.066Å), 
N(14/14A)-Ni 
(2.059Å), 
N(1S/1SA)-Ni 
(2.143Å). 
N(11)-Ni-N(14A) (85.92o), 
N(14A)-Ni-N(11) (94.09o), 
N(11)-Ni-N(14) (85.92o), 
N(14)-Ni-N(11) (94.08o), 
N(1S)-Ni-N(11) (87.88o), 
N(1S)-Ni-N(11) (92.12o), 
N(1S)-Ni-N(14) (88.43o), 
N(1S)-Ni-N(14A) (91.57o), 
N(11)-Ni-N(11A) (180o), 
N(14)-Ni-N(14A) (180o). 
1.6d Trans(III) 
N(11/11A)-Ni 
(2.061Å), 
N(15/15A)-Ni 
(2.065Å), 
H(1)-Ni (1.819Å), 
H(1)-B (1.166Å), 
H(2)-B (1.039Å), 
H(3)-B (1.053Å), 
H(4)-B (1.098Å). 
N(11)-Ni-N(15A) (85.13o), 
N(15A)-Ni-N(11A) (94.87o), 
N(11A)-Ni-N(15) (85.13o), 
N(15)-Ni-N(11) (94.87o), 
H(1)-Ni-N(11) (93.00o), 
H(1)-Ni-N(15A) (88.93o), 
H(1)-Ni-N(11A) (87.00o), 
H(1)-Ni-N(15) (91.07o), 
N(11)-Ni-N(11A) (180o), 
N(15)-Ni-N(15A) (180o). 
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As was speculated from the 1HNMR data obtained for 1.4 the crystal structure 
shows no axial ligands on the metal center and thus can be diamagnetic57. The N-Ni bond 
lengths in 1.4 are shorter than that seen for 1.6b or 1.6d. A possible explanation is that 
the extra electron density pushed onto the nickel by the axial ligands in 1.6b or 1.6d 
means that less electron density is needed from the equatorial ligands. The crystal 
structure of 1.4 shows no intermolecular or intramolecular π-π or π-CH interactions.  
The X-ray data for 1.6b shows acetonitrile acting as axial ligands forming an 
octahedral paramagnetic nickel complex. Bond lengths increase between the equatorial 
nitrogens and the nickel, when compared to complex 1.4, due to the increased electron 
density pushed onto the metal from the axial acetonitrile.  Complex 1.6c was synthesized 
and crystallized in methanol to overcome the axial ligand problem encountered from 
acetonitrile crystallizations. Other solvents for the crystallization of complex 1.6b could 
be used however these options were never attempted due to the formation of complex 
1.6c and the choice of complex 1.6a as the reference complex for halide reductions 
monitored by HPLC (chapter 4).  
From the reaction of 1.6c with sodium borohydride in acetonitrile a green 
crystalline solid was isolated. IR and X-ray spectroscopy on this complex revealed that it 
to be the complex 1.6d (Figure 1.18). Multiple attempts at repeating this reaction in 
acetonitrile did not yield the desired complex as a crystalline solid. However repeating 
the reaction in THF yielded the complex as a powder (identified by IR, figure 1.19). 
Repeating this reaction with NaBD4 led to the formation of the deuteride analogue 1.6e as 
characterized by the large shifts in wave numbers (cm-1) for the borohydride/deuteride 
peaks (2320cm-11744cm-1, 2197cm-11605cm-1, 2116cm-11548cm-1) (Figure 1.19). 
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Figure 1.19: - IR of 1.6d (red line). IR of 1.6e (blue line). 
 
The bond lengths between the terminal hydrogens and the boron in complex 1.6d 
are shorter than the bridging hydrogen coordinated to the nickel centre. The Ni-H bond 
length in 1.6d is close to that reported in the literature for other bridging borohydrides 
(1.84Å and 1.93Å58, 1.71Å59). Ni-H-Ni (µ2) bonds have been reported in the order of 
1.58Å60, whilst cyanoborohydride complexes have shown slightly longer Ni-H bonds of 
2.145Å61 
1.5 Mechanistic studies 
 
Whilst several papers have undertaken mechanistic studies involving 
hydrodehalogenations coupled with nickel catalysts much conjecture still remains as to 
the actual mechanism/mechanisms62.  
Mechanisms including single electron transfer63 (Figure 1.20), hydride 
reductions64 (Figure 1.21) and nickel insertion/elimination reaction have all been 
proposed27b (Figure 1.22) and each is viable for the reaction conditions used. We have 
attempted to elucidate the mechanism under our reaction conditions. 
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Ni(II)L
Ni(I)L
BH4-
BH4.R-X
R-X.-R. + X-
R-R, R-H, R(-H)  
Figure 1.20: - Proposed single electron transfer (SET) mechanism of 
hydrodehalogenation (L = tetraazamacrocyclic ligand) 
 
[Ni(II)L]2X-
[Ni(II)L]2BH4-
NaBH4
NaX
R-X
R-H
[Ni(II)L]2H-
EtOH
B(OEt)3 + 3H2
 
Figure 1.21: - Proposed hydride reduction mechanism of hydrodehalogenation (L = 
tetraazamacrocyclic ligand, X = halogen) 
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Figure 1.22 Nickel insertion mechanism proposed by Dunach ((L = 
tetraazamacrocyclic ligand). 
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1.5.1 Deuterium Incorporation Experiments 
 
Deuterium labeling experiments utilizing NaBH4 in deuterated DMSO:CD3OD 
and a separate experiment was performed utilizing NaBD4 in protio DMSO:Ethanol to 
ascertain where the proton(deuterium)/hydride(deuteride) originates during the reduction 
of the bromonaphthalene under our conditions (Figure 1.23). 
 
Br H/D
DMSO:Ethanol(1:1) 
NaBD4, 24 Hours or 
DMSO-d6:CD3OD (1:1) 
NaBH4, 24 Hours
Complex 1.6a
 
Figure 1.23: - Labeling study using NaBD4 in protio DMSO:EtOH (1:1) or NaBH4 in 
DMSO-d6:CD3OD (1:1). 
  
For the experiment utilizing NaBD4 in none deuterated solvents 84% deuterium 
incorporation into naphthalene is observed by integration in 1HNMR. The protons on 
carbons 4, 6 and 9 give an integration of 3.16 (84% D incorporation) at 7.86ppm when 
compared to the 4.00 (100% protons) for the protons on carbons 2, 3, 7 and 8 shown at 
7.48ppm in the 1HNMR. This result would suggest that the vast majority of the 
hydride/deuteride comes from the NaBD4 with solvent having only a 16% incorporation 
of protons into the naphthalene product (Figure 1.24).  
The second experiment utilizing NaBH4 in deuterated solvents DMSO-d6:CD3OD 
showed no deuterium incorporation by 1HNMR. Again this reinforces the concept that 
the borohydride is the major source of the proton/deuteron attached at the 1 position of 
the naphthalene (Figure 1.25). These results are in concurrence with labeling experiments 
performed by Stiles (84% deuteride incorporation with NaBD4 in D2O:CH3CN, 0% 
incorporation with  NaBH4 in D2O:CH3CN for tetrachlorobenzene)28d. Our results also 
show that naphthyl anions are not a major contributor to the mechanism, as deprotonation 
of the methanol would occur from the OH if this were the case. 
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Figure 1.24: - 1HNMR of naphthalene product (reaction conditions: - NaBD4 and 
DMSO:EtOH (1:1)) with integration values compared against each other. 
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Figure 1.25: - 1HNMR of naphthalene product (reaction conditions: - NaBH4 in 
DMSO-d6:CD3OD (1:1)) with integration values compared against each other. 
 
There are several conceivable mechanisms for the incorporation of the hydride 
from the sodium borohydride.  
Figure 1.20 show the formation of a Ni(I) species from the reduction of the 
Ni(II)cyclam complex by the sodium borohydride. This Ni(I)cyclam can then perform a 
single electron transfer, probably through an outer-sphere electron transfer into the π* 
orbital of the aromatic ring, although the oxidation potential for the Ni(I) complex is 
significantly lower than that of the reduction potential of the halogenated substrate. The 
radical anion then breaks down to give a radical and an anion. The radical can then 
further react with the borohydride to extract a hydrogen atom28d.  
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Another possibility is the formation of a nickel hydride species capable of 
delivering the hydride directly to the substrate or to form hydride radicals that can react 
with the substrate (Figure 1.21). 
A 1HNMR study of 1.6d in acetonitrile shows that no change occurs in the spectra 
upon the addition of bromonaphthalene over 12hours. However when a drop of D2O was 
added to the mixture bubbling was observed (the formation of hydrogen) and some 
naphthalene was generated (Figure 1.26) the dehalogenation observed after 10 minutes 
did not change over a period of 3 days.  
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Figure 1.26: - A stack plot of the aromatic region of the reaction of 
bromonaphthalene (6eq) with the 1.6d in acetonitrile at 10 minute intervals over 3 
hours. The final spectrum was taken after the addition of D2O (10 minutes) after 12 
hours of having the bromonaphthalene mixed with the complex showing no sign 
disappearance of starting material. 
 
 The reduction of bromonaphthalene utilizing complex 1.6d (10%) generates 
17.3% of the naphthalene product in DMSO:EtOH (1:1), indicating that only 2 of the 
hydrides in complex 1.6d are utilized in the reaction (Figure 1.27).  
Naphthalene 
generated 
after the 
addition of 
D2O 
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Br H
17.3%
1.6d (10%)
DMSO:EtOH (1:1)
 
Figure 1.27: - Reduction of bromonaphthalene utilizing complex 1.6d (10%) in 
DMSO:EtOH (1:1) 
 
Looking at the results observed in figures 1.26 and 1.27 it is reasonable to assume 
that the formation of borates increases leaving ability of the hydride and facilitates the 
formation of the nickel hydride species through increased electron donation to the boron 
and increased back strain from the alkoxy units (Figure 1.28).  
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Figure 1.28: - Possible reaction of 1.6d with alcohols/water to produce a nickel 
hydride complex and borates. 
 
 Further evidence to support the reaction of hydrides with the bromonaphthalene 
came from a reaction run utilizing complex 1.6a in DMSO:EtOH (1:1) with excess 
NaBH4 performed in the presence of air.  
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In the presence of oxygen the formation of Ni(I) should be perturbed and if the 
reaction involves Ni(I) species the reduction should not occur, or occur at a much slower 
rate. After 2.5 hours at 25oC nearly all of the bromonaphthalene had been completely 
converted to naphthalene (>94%) and the purple colour of the solution remained strong 
perhaps indicating that Ni(II)-H/BH4 play an important role in the reduction of aryl 
halides not Ni(I) under these reaction conditions.  
A reduction run without the catalyst produced a small quantity of the naphthalene 
product (3.5%) after 2.5 hours at 25oC, significantly slower than without the catalyst.  
1.5.2 Ni(I) and Na/Hg Amalgam Reductions of Bromonaphthalene  
 
Reduction of a 1.6c in acetonitrile utilizing Hg/Na amalgam generated a Ni(I) 
complex 1.7 that was isolated by filtration (Figure 1.29). Complex 1.7 shows a 
characteristic purple color in the UV-Vis spectra at 559nm indicative of Ni(I) 
complexes65 (Figure 1.30).  
N
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H H
H H
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N
N
N
Ni(I)
H H
H H
Na/Hg
AcCN
2ClO4- ClO4-
1.6c 1.7  
Figure 1.29: - Generation of a Ni(I) 1.7 from the Ni(II) complex 1.6c 
  
 
Figure 1.30: - UV-Vis spectra of 1.7.  
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1.7, in acetonitrile, was treated with bromonaphthalene for 12 hours at 50oC under 
inert conditions (a change in color from purple to brown was observed after 5-6 hours). 
At the end of the reaction, when the Ni(I) had be oxidized to Ni(II) as observed by a loss 
of the peak at 559nm, a sample was taken for 1HNMR analysis. No conversion of the 
bromonaphthalene was observed. Previous experience with complex 1.7 suggests that the 
lifetime of this complex is over several hours. 
A UV/Vis experiment was also performed where monitoring of the 559nm 
wavelength (d-d transition for Ni(I)) in 1.7 over several hours showed no signs of the 
disappearance of this peak after the addition of bromonaphthalene. Overall every peak on 
the spectra decreased over time at the same extent, a consequence of a baseline error. No 
reduction of the bromonaphthalene was observed (by HPLC analysis). It was observed 
that Ni(I) generated from Na/Hg amalgam is air sensitive. The purple color of the 
solution in acetonitrile rapidly converts to an orange colored solution upon exposure to 
air confirming the presence of the Ni(I) species. 
The fact that independently synthesized Ni(I) complexes were unable to convert 
bromonaphthalene to naphthalene excludes that Ni(I) species play an important role 
under catalytic hydro-dehalogenation reactions.  
Previous experiments have however shown that Ni(I), generated via a variety of 
methods, can act as a reductant following the formation of alkyl-nickel intermediates27b, 
that break down to radical intermediates. However most of these reactions were carried 
out on alkyl-halides not aryl-halides and similar reductions were not observed under these 
conditions in our experiments.  
A run whereby Na/Hg was allowed to react with the bromonaphthalene in DMSO 
without the presence of the nickel cyclam complex shows that the single electron 
reduction from this reductant can indeed reduce the bromonaphthalene to naphthalene66. 
Na is a much stronger electron donor than Ni(I) and has previously been used as a large 
scale method of dehalogenation67 and although Na/Hg is a weaker electron donor than Na 
it is strong enough to perform the reaction as well. 
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1.6 Cyclam and N-functionalized Cyclam Nickel Complexes As 
Hydrodehalogenation Catalysts. 
 
1HNMR testing was performed to identify the reactivity of the nickel cyclam 
complexes hydrodehalogenation reactions. Bromonaphthalene was chosen as the test 
compound due to its flat aromatic surface, which was hoped, may interact with the side 
arms built into the complexes (Figure 1.31). 
 
Br
(~10 mol%)
10eq K[HBEt3]
DMSO
H1.3, 1.4, 1.5, 
1.6b, 1.6c
 
Figure 1.31: - Reduction of bromonaphthalene utilizing nickel cyclam complexes 
under 1HNMR conditions with superhydride. 
 
Each of the catalysts was weighed into an NMR tube and the co-reductant, in this 
case super hydride (potassium triethylborohydride) was added. This was shaken for a few 
minutes to allow the generation of the active reductive species. To this mixture was 
added the bromonaphthalene and 1HNMR’s were taken at regular intervals. By measuring 
the relative peak heights for the bromonaphthalene and the naphthalene product one 
could monitor conversion over time (Figure 1.32). 
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Figure 1.32: - Stack plot 1HNMR of bromonaphthalene reduction using 13.1 Mol% 
1.6b and Superhydride, in DMSO over time (1=19min, 2=25min, 3=29min). 
 
By using the BPh4 peaks as an internal standard it was possible to accurately 
integrate the bromonaphthalene peaks in order to obtain a rate constant for the reduction 
(Figure 1.33). 
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Figure 1.33: - Plot of Ln(Concentration) vs. Time(s) for bromonaphthalene 
reduction using 13.1 Mol% 1.6b and Superhydride in DMSO. 
 
 The graph gives us a kobs value from the slope which, when divided by the 
concentration of the catalyst, yields the k value (rate constant) for the reaction. In this 
1-Bromonaphthalene 
BPh4 Counter ions naphthalene
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case when you divide the slope (-0.0063Ms-1) by the concentration of the catalyst 
(0.0187M) you arrive at the number –0.337s-1 at 25oC. 
1.6.1 1HNMR Monitored Reduction Tests on Bromonaphthalene Utilizing 
Benzyl and Anthracenyl Functionalized Nickel Cyclam Complexes with 
Superhydride as the Co-reductant/hydride source. 
 
 When attempts were made at performing the 1HNMR reduction test as performed 
on complex 1.6b utilizing the benzyl and anthracenyl nickel cyclam complexes (1.3 and 
1.4) measurement of rates became impossible. Under these conditions the reaction occurs 
so fast that during the shimming procedure on the NMR machine the reaction had gone to 
completion, between 4-5 minutes (the time taken to shim the machine) even with extra 
dilution and lowering catalyst concentrations. This means that N-functionalized 
compounds react significantly faster than the unfunctionalized ones (at least 7.5 times 
faster) under these reaction conditions. There are several explanations for this. 
N-alkylation produces a tertiary amine; in this case the benzyl/anthracenyl arm 
pulls electron density away from the amine and ultimately from the nickel center. This 
makes the Ni(II) more electrophilic68 and thus a rate increase may be observed by having 
forming the hydride/borohydride nickel complex more quickly. This theory would mean 
that the formation of the Ni(II)-H intermediate would have to be part of the rate law and 
as such the rate of hydride formation may be on a longer or on a  similar scale  to the 
actual reduction. In this case the rate-determining step (RDS) could be the hydride 
formation. This theory my be reinforced by previous work undertaken by Stolzenberg22 
showing that a tetramethylated Ni-cyclam complex is actually ten times less active in the 
reduction of bromocyclohexane than the unfunctionalized cyclam nickel complex (Figure 
1.34). The extra electron density pushed onto the nickel center by the methyl groups, 
inductively, may decrease the rate at which the hydride is formed, reducing its activity. 
This theory would only be correct if the rate-determining step (RDS) in this reaction is 
the Ni(II) hydride formation not the actual hydride delivery/halide loss.  
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The tetramethylated complex also has a large amount of steric hindrance and thus 
the formation of a possible hydride/borohydride complex may be more difficult and 
interactions with substrates may also become less favorable (Figure 1.34).  
 
N N
N N
Ni(II)
H H
H H
Or
N N
N N
Ni(II)Br H
NaBH4  
Figure 1.34: - Reduction of bromocyclohexane utilizing nickel cyclam catalysts34. 
 
 π stacking attraction may bring the substrate into close proximity and the reaction 
proceeds as was initially hoped, although such large reduction rates for the phenyl 
complex was not expected due to the small π surface in this complex. Reduction rates on 
similar to that of complex 1.6b might be expected for such a small π surface if only 
electrostatic interactions, not electronic effects were to play a role in the reduction rates. 
 A final explanation for this rather large reduction rate would be the formation of 
other active nickel species such as Ni(0) during the course of the reaction that maybe 
more reactive than hydride species (small amounts of black metallic material was 
observed after then reaction in the NMR machine). In order to better understand the 
reaction, reduction runs were performed under milder conditions with HPLC monitoring. 
 
1.6.1.1  HPLC Monitored Reduction Tests on Bromonaphthalene Using Non-
functionalized and N-functionalized Nickel Cyclam Catalysts Utilizing Sodium 
Borohydride as the Co-reductant/hydride source. 
 
 To test the reaction under different conditions runs were performed with 1.3, 1.4, 
and 1.6c in a DMSO:EtOH mixture using sodium borohydride as the reductant and 1,3-
dimethoxybenzene (DMB) as the internal standard (Figure1.35).  
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Br
(~10 mol%)
10eq NaBH4
DMSO:EtOH(1:1)
H1.3, 1.4, 1.5, 
1.6b, 1.6c
 
Figure 1.35: - HPLC reaction conditions for bromonaphthalene reductions. 
 
 The reduction of bromonaphthalene under our reaction conditions was presumed 
to follow the rate equation 1 below, where the active catalyst is generated and reformed 
more quickly than the actual reduction occurs. In this case the reduction of 
bromonaphthalene to naphthalene is assumed to be the rate determining step (RDS) for 
the reaction. This therefore means that the rate can be perceived as pseudo first order with 
respect to bromonaphthalene (equation 2). In this case plots of Ln[bromonaphthalene t = 
x]/ ][Bromonaphthalene t=0] vs. time (s) should lead to a straight line with the slope of 
that line being kobs. k can be obtained by dividing kobs by the concentration of the catalyst 
(equation 3). This proved to be the case for complexes 1.6c, 1.3 and 1.5, leading us to 
believe that the RDS is in fact the reduction of the substrate not the formation of the 
active species. 
 
1. Rate = k[Active catalyst][Bromonaphthalene] 
2. Rate = k[Bromonaphthalene] 
3. k = kobs/[catalyst] 
 
For reaction monitoring we took small aliquots out of the reaction mixture and 
quench them in saturated ammonium chloride at given time intervals (to kill the active 
complex). The sample is extracted using ethyl acetate and run on the HPLC system to 
give integrations for each component. It is known that different solvent conditions show 
differences in product distribution and rates24 so only the same solvent mixtures can be 
compared against each other. An observation made during the hydrodehalogenation 
experiments is that the complexes 1.3-1.5 have life times of several hours (2-4 hours) in 
DMSO:EtOH (1:1) with an excess of borohydride whereas 1.6a-1.6c have lifetimes on 
the order of 48 hours under the same condition by color change (the active species 
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appears to be violet/purple in solution whereas the inactive species becomes orange in 
solution and Ni metal drops out of the mixture). 
 
Table 1.4: - Selected reduction data from bromonaphthalene reductions in 
DMSO:EtOH as monitored by HPLC with dimethoxybenzene as the internal 
standard (DMB) at 22oC. 
Catalyst 
(mol%) 
Time 
(s) 
Conc of 
BrNap 
(M) 
Starting 
Conc of 
BrNap (M) 
kobs(Ms-1) k(s-1) krel R2 
1.6c 
(10) 
0 
240 
360 
960 
1200 
0.05 
0.0488 
0.0486 
0.0477 
0.0474 
0.05 -3.936X10-5 -0.0068 1 92.0 
1.3 
(5.7) 
300 
600 
900 
1800 
3600 
0.0493 
0.0492 
0.0491 
0.0490 
0.0488 
0.05 -2.95X10-6 -0.001 -6.8 99.5 
1.5 
(8.4) 
300 
600 
900 
1200 
1800 
0.0405 
0.0145 
0.00349 
0.00164 
0.000416 
0.05 -3.1X10-3 -0.525 77.2 97.4 
 
The reduction of bromonaphthalene using complex 1.6c in DMSO:EtOH (1:1) 
gave a reduction rate constant of -0.0068s-1, 49 times slower than the superhydride 
system with complex 1.6b in DMSO. Complex 1.3 gave a rate constant 6.8 times slower 
than that of the unfunctionalized complex 1.6c (Table 1.4). Complex 1.5 gave a reduction 
rate 77 times faster than complex 1.6c after an apparent initiation period (to be discussed 
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in more detail shortly). These reductions showed the formation of only naphthalene, as 
identified via HPLC (Figure 1.36). 
 
Figure 1.36: - HPLC trace of a 1-bromonaphthalene reduction using 1.6a, 
DMSO:EtOH (1:1) with sodium borohydride co-reductant and 1,3-
dimethoxybenzene internal standard (IS) at 254nm (after 20minutes). 
 
Complications arose when reacting complex 1.4 under these conditions. During 
the reaction the formation of a dark particulate suspension was observed.  After 40 
minutes the dark suspension had disappeared to be replaced by the original purple 
solution. The HPLC spectrum of this reaction shows the build up of several new, and 
unknown, peaks in the trace (Figure 1.37).  
 
 
Figure 1.37: - HPLC trace of a 1-bromonaphthalene reduction using N-9-
anthracenyl-cyclam nickel perchlorate, DMSO:EtOH (1:1) with sodium 
borohydride co-reductant (after 20minutes). 
BrNap 
Nap 
DMB 
(IS) 
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Products 
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BrNap 
Nap 
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When studies were performed with complex 1.5 the reaction appears to have an 
initiation period, somewhat surprising, as the other catalysts in this series do not show 
this. Under the 1HNMR experimental conditions no reduction was observed over a period 
of 8 minutes. As the 1HNMR reaction was deemed to be inactive it was halted and the 
NMR tube removed from the machine. Shortly after the removal of the NMR tube from 
the instrument a sharp change in color from violet to orange was observed. A 1HNMR 
was immediately run to check the reaction. No starting material was seen after 27 
minutes (Figure 1.38).  
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Figure 1.38: - NMR data showing the reduction of bromonaphthalene by 2.2c after 
(1) T=0min, (2) T=3min, (3) T=7Min 30s (4) 28min. 
 
 A reduction run for this complex was performed using sodium borohydride in a 
DMSO:EtOH mixture and  HPLC monitoring of the reaction was employed to overcome 
the time issues involved with 1HNMR monitoring. Samples were taken at 5, 10, 20, 30, 
40, 74 minutes.  
It was observed that a small amount of reduction had occurred over the 5 minute 
time period that did not change up to the 40-minute sample. When a sample was taken 
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after 74 minutes an orange color was observed in the solution and almost all of the 
bromonaphthalene had been converted to naphthalene product (Figure 1.39).  
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Figure 1.39: - Bar chart showing conversion of bromonaphthalene to naphthalene in 
DMSO:EtOH (1:1) using complex 1.5 and sodium borohydride as a co-reductant. 
 
A blank run where no bromonaphthalene was added to the reaction mixture 
produced no change in color over a 2-hour period, perhaps indicating that something in 
the mixture is reacting over this time before hydrodehalogenation is affected. The catalyst 
lifetime appear to be between 4-5 hours as the purple color disappears and small traces of 
nickel metal can be seen after this time.  
A second run was performed whereby 1.5 was allowed to react with NaBH4 for 2-
hours before the bromonaphthalene was added. This reaction showed that the purple Ni 
species of the complex 1.5 could be maintained over this period. This species might be 
the borohydride/hydride complex of 1.5 (Figure 1.40) Addition of the bromonaphthalene 
caused a large amount of bubbling (hydrogen production) in the initial stages. Samples 
were taken every 5 minutes for 30 minutes until the solution turned orange and the 
bubbling ceased (Figure 1.41). In this case no products bar naphthalene were observed in 
the HPLC trace and reduction proceeded smoothly over the given time period. 
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Figure 1.40: - Proposed intermediates in the reduction of bromonaphthalene 
utilizing complex 1.5. 
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Figure 1.41: - Reduction graph of bromonaphthalene to naphthalene in 
DMSO:EtOH (1:1) using complex 1.5 and sodium borohydride as a co-reductant (2 
hour delay before the addition of bromonaphthalene). 
 
 It is likely that there may be an unidentified intermediate built up before the 
reaction takes place to allow the dehalogenation to occur. The build up of a purple 
solution with 1.5 and borohydride/superhydride occurs rapidly as it does for all other 
complexes (1.3-1.6c) in either DMSO or DMSO:EtOH (1:1) solutions.  
The large size of the pyrene ring maybe sterically inhibiting the formation of the 
reactive species and thus the initiation period for this reaction might be longer than for 
other similar complexes. 
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Another explanation for this delay time is that there is an impurity in the pyrene 
complex that is being consumed before the reaction with bromonaphthalene is initiated. 
1HNMR data for this complex is unclear due its paramagnetic nature although the 
aromatic region is sharp and clean for one product (Figure 1.42). 
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   (a)      (b) 
Figure 1.42: - (a) 1HNMR of complex 1.5. (b) expanded 1HNMR of the aromatic 
region for complex 1.5. 
 
The rate constant for the reduction of bromonaphthalene using complex 1.6c gave 
a reduction rate constant of -0.0068s-1 in the DMSO:EtOH (1:1) solvent. This is just 
under 77 times slower than the complex 1.5 meaning that the side arm does provide a 
large rate increase over 1.6c (Table 1.4).  
1.7 Conclusions 
 
Synthesis of the N-functionalized cyclam ligands proved to be straightforward 
with high yielding reactions and simple isolation. Nickel complex formation was 
straightforward. However paramagnetic complexes 1.6b, 1.6d and 1.6e were difficult to 
identify by 1HNMR. In these cases IR, MS and X-ray crystallography were utilized to 
identify the compounds. 
Mechanistic studies suggest that the reaction occurs through the formation of 
active borohydride/hydride intermediate as isolated in complexes 1.6d, and 1.6e as no 
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reactive was observed utilizing 1.7. The complex 1.6d reacted with roughly two 
equivalents of bromonaphthalene in solution. This result suggests that only two of the 
hydrides in 1.6d are active in this reaction. 1.6d does not react (over 12 hours) with 
bromonaphthalene in AcCN or DMSO. When D2O (in AcCN) or CD3OD (in DMSO) 
was added to the reduction of bromonaphthalene was observed. This result might suggest 
that a reactive intermediate is generated from 1.6d. As we have concluded that Ni(I) does 
not play a major role in this reduction it is envisioned that Ni-H intermediates are the 
reactive species69. 
kobs values were not obtained for the complexes 1.3, 1.4, and 1.5 in the 1HNMR 
experiments with superhydride. However these rates were clearly much greater than those 
obtained for 1.6c. The slower analogous reactions in DMSO:EtOH mixtures utilizing 
sodium borohydride as the hydride source gave interesting results. 1.3 shows a slower 
rate of reduction under these conditions than the unfunctionalized complex 1.6c whilst 
complex 1.4 reacted unpredictably with the formation of side products.  Complex 1.5 is 
very much a quandary. An apparent initiation period, followed by rapid reduction rates 
was observed under both reaction conditions. No solid explanation for this process is 
available.  It may be possible that reaction of complexes 1.3, 1.4, and 1.5 with 
superhydride progress by an alternate reaction pathway to the analogous reaction with 
sodium borohydride as no reduction was seen utilizing sodium borohydride in DMSO of 
catalyst 1.6d. The possibility of Ni(0) (black metal was observed after the reaction) or 
single electron transfer reductions cannot be ruled out. 
The N-functionalized nickel cyclam complexes have shown to be very 
unpredictable in their reaction with bromonaphthalene with the generation of side 
products (possibly binaphthalene using complex 1.4, initiation periods for complex 1.5, 
and slower rates than the unfunctionalized cyclams noted for complex 1.3 in 
DMSO:EtOH(1:1) with NaBH4.  
Overall it became obvious that N-functionalized nickel cyclam complexes had far 
too many complications to be a viable candidate for the long-term study of the pre-
concentration hypotheses and an alternative solution was needed. Under that notion the 
synthesis of the second generation, C-functionalized nickel cyclam complexes, became a 
target. C-functionalized nickel cyclam complexes will allow for the formation of tweezer 
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like cavities to trap the halogenated aromatic substrates and keeping the nitrogens in the 
cyclam complex free of substitution will minimize 1,3-synaxial interactions and 
electronic effects through the R-N-Ni bonds. Efforts toward the synthesis, 
characterization and application of C-functionalized nickel cyclam complexes shall be 
discussed in the following chapters. 
1.8   Experimental. 
All chemicals were purchased from Aldrich, Acros Organics and Fischer and used 
without further purification.   
1.8.1 N-Functionalized Cyclam Ligand Synthesis. 
 
1-(Chloromethyl)pyrene (1.1) 
 
Cl  
 
1-methylhydroxypyrene (500mg, 2.15mmol) was suspended in toluene (20mL) 
and thionyl chloride (0.32mL, 4.5mmol) added dropwise. The mixture was then heated to 
reflux for 2.5 hours. The solvent was removed in vacuo to yield the product. Yield 
539mg, 100%. 1H NMR (400 MHz, CDCl3)  5.31 (s, 2 H) 7.97 - 8.08 (m, 4 H) 8.10 (t, 
J=8.00 Hz, 1 H) 8.14 - 8.23 (m, 3 H) 8.36 (d, J=9.37 Hz, 1 H). 13C NMR (101 MHz, 
CDCl3).  44.75, 122.71, 124.71, 125.62, 126.16, 127.26, 127.64, 127.99, 128.21, 128.35, 
129.01, 129.12, 130.27, 130.67, 131.14, 131.95. 
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General Synthesis of Mono N-Functionalized Cyclams 
 
To 1,4,8,11-tetraazacyclotetradecane (500mg, 2.50mmol) in chloroform (20mL) 
was added the aryl chloride (0.25mmol) and potassium carbonate (500mg, 3.62mmol). 
This was stirred at RT for 12 hours and filtered to remove any solid potassium carbonate. 
The solvent was removed in vacuo and the product extracted from the solid 5 times with 
acetone. 
 
1-Benzyl-1,4,8,11-tetraazacyclotetradecane (1.2a) 
 
NH
NH
HN
N
 
 
Yield 71.1mg, 80%. 1H NMR (400 MHz, CHLOROFORM-D)  1.73 (dt, 
J=10.54, 5.27 Hz, 2 H) 1.81 - 1.90 (m, J=10.79, 5.66, 5.44, 5.44 Hz, 2 H) 2.51 - 2.59 (m, 
4 H) 2.60 - 2.66 (m, 4 H) 2.69 - 2.76 (m, 4 H) 2.78 - 2.83 (m, 2 H) 2.83 - 2.87 (m, 2 H) 
3.48 (m, 3 H) 3.57 (s, 2 H) 7.24 - 7.36 (m, 5 H). 13C NMR (101 MHz, CDCl3)  26.05, 
27.99, 47.31, 47.80, 49.04, 49.22, 49.50, 50.67, 53.71, 54.28, 58.12, 127.18, 128.34, 
129.43, 138.86. 
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1-(Anthracen-9-ylmethyl)-1,4,8,11-tetraazacyclotetradecane (1.2b) 
 
NH
NH
HN
N
 
 
Yield 122mg, 85%. 1H NMR (400 MHz, CDCl3)  1.53 (ddd, J=10.74, 5.27, 5.08 
Hz, 2 H) 1.78 (ddd, J=11.13, 5.86, 5.66 Hz, 2 H) 2.14 - 2.26 (m, 3 H) 2.40 - 2.48 (m, 4 
H) 2.52 - 2.61 (m, 6 H) 2.65 - 2.74 (m, 6 H) 4.47 (s, 2 H) 7.39 - 7.50 (m, 4 H) 7.95 (d, 
J=7.81 Hz, 2 H) 8.37 (s, 1 H) 8.51 (d, J=8.59 Hz, 2 H). 13C NMR (101 MHz, CDCl3)  
26.82, 27.72, 47.94, 48.05, 48.76, 49.12, 50.22, 50.83, 52.51, 54.43, 55.14, 124.90, 
125.01, 125.17, 125.85, 127.93, 129.36, 131.48, 131.60. 
 
1-(1-pyrenylmethyl)-1,4,8,11-tetraazacyclotetradecane (1.2c) 
 
NH
NH
HN
N
 
 
Yield 250mg, 100%. 1H NMR (400 MHz, CDCl3)  1.62 (dt, J=10.54, 5.27 Hz, 2 
H) 1.88 (dt, J=10.93, 5.47 Hz, 2 H) 2.45 - 2.51 (m, 2 H) 2.51 - 2.56 (m, 2 H) 2.59 - 2.65 
(m, 2 H) 2.66 - 2.71 (m, 4 H) 2.73 (s, 1 H) 2.75 - 2.80 (m, 3 H) 2.81 - 2.88 (m, 2 H) 3.22 
- 3.34 (m, 3 H) 4.20 (s, 2 H) 7.95 - 8.00 (m, 1 H) 8.02 (s, 2 H) 8.06 - 8.08 (m, 1 H) 8.10 
(d, J=3.90 Hz, 2 H) 8.12 - 8.18 (m, 2 H) 8.48 (d, J=9.37 Hz, 1 H). 13C NMR (101 MHz, 
CDCl3)  26.58, 27.93, 47.61, 47.70,48.43, 48.84, 49.05, 50.44, 54.34, 54.86, 57.21, 
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123.73, 124.75, 124.96, 125.02, 125.07, 125.23, 125.98, 127.22, 127.32, 127.58, 128.31, 
129.80, 130.76, 130.87, 131.45, 132.97. 
 
1.8.2 N-Functionalized Nickel Cyclam Ligand Synthesis. 
 
(1-Benzyl-1,4,8,11-tetraazacyclotetradecane)Nickel(II) Bis(perchlorate) (1.3) 
 
N
N
N
N
Ni
H
H H
2+ 2ClO4-
 
 
1-Benzyl-1,4,8,11-tetraazacyclotetradecane (71.1mg, 0.23mmol) and Ni(ClO4)2 
(80mg, 0.23mmol) were dissolved in methanol (5mL) and mixed together. The initial 
orange color of the cyclam became darker upon the addition of the nickel. The solvent 
was removed in vacuo and the sample taken up in a little methanol. Crystals formed 
quickly. The mixture was placed in the fridge for a few minutes then removed and left at 
RT overnight. The orange solid was filtered off and washed with a little methanol. The 
crystals were then dried in vacuo. Yield 37mg, 30%. MS: m/z calculated for C17H30N4Ni 
= 348.1824, actual m/z (M-H) = 347.133. IR: υ 3201, 2958, 2887, 1659, 1548, 1453, 
1429, 1067, 733, 710, 618cm-1.  
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(1-(Anthracen-9-ylmethyl)-1,4,8,11-tetraazacyclotetradecane)Nickel(II) 
Bis(perchlorate) (1.4) 
 
N
N
N
N
Ni
H
H H
2+ 2ClO4-
 
 
To 1-(Anthracen-9-ylmethyl)-1,4,8,11-tetraazacyclotetradecane (122mg, 0.31mmol) in 
methanol (5mL) was added the Ni(ClO4)2 (113mg, 0.31mmol) in methanol (2mL). The 
product was crystallized from methanol. Yield 74mg, 36.8%. 1H NMR (200 MHz, 
DMSO-D6)  ppm -1.24 (s, 1 H) -0.21 (s, 1 H) 0.56 - 0.80 (m, 1 H) 1.22 (d, J=15.38 Hz, 
1 H) 1.64 (s, 2 H) 1.92 (s, 7 H) 2.59 - 2.81 (m, 3 H) 2.82 - 3.04 (m, 4 H) 3.04 - 3.19 (m, 2 
H) 4.56 (d, J=13.92 Hz, 2 H) 5.36 (d, J=12.82 Hz, 1 H) 7.55 - 7.75 (m, 2 H) 7.88 (t, 
J=8.06, 7.33 Hz, 1 H) 8.22 (d, J=7.69 Hz, 1 H) 8.38 (m, 2 H) 8.66 (d, J=8.06 Hz, 1 H) 
8.95 (s, 1 H) 11.19 (d, J=8.42 Hz, 1 H). 13C NMR (101 MHz, DMSO-D6)  23.61, 25.20, 
46.77, 47.26, 49.07, 49.82, 53.58, 58.53, 62.89, 124.42, 125.77, 126.03, 127.46, 128.37, 
129.45, 130.07, 130.36, 130.41, 131.03, 131.22, 131.35, 132.10.  MS: m/z calculated for 
C25H34N4Ni = 448.2137, actual m/z (M-H) = 447.941. See X-ray crystal structure for 
structural configuration. 
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(1-(1-pyrenylmethyl)-1,4,8,11-tetraazacyclotetradecane)Nickel(II) Bis(perchlorate) 
(1.5) 
 
N
N
N
N
Ni
H
H H
2+ 2ClO4-
 
 
To 1-(1-pyrenylmethyl)-1,4,8,11-tetraazacyclotetradecane (101mg, 0.244mmol) 
in methanol (5mL) was added the Ni(ClO4)2 (89.2mg, 0.244mmol) in methanol (2mL). 
The product was crystallized from methanol. Yield 44.7mg, 29.1%. (Not all protons are 
accounted for) 1H NMR (400 MHz, DMSO-D6)  ppm -20.37 (bs, 2 H) -16.37 (bs, 5 H) 
-0.47 (s, 2 H) -0.07 - 0.57 (m, 2 H) 1.33 - 1.96 (m, 1 H) 3.62 - 4.58 (m, 1 H) 5.64 (s, 2 H) 
8.23 (s, 2 H) 8.29 - 8.53 (m, 4 H) 9.07 (s, 1 H) 9.22 - 9.43 (m, 1 H) 10.72 (s, 1 H) 13.76 - 
16.95 (m, 1 H). MS: m/z calculated for C27H34N4Ni = 472.2137, actual m/z (M-H) = 
471.144. IR: υ 3252, 3193, 2962, 2939, 2875, 1627, 1592, 1457, 1429, 1059, 1019, 849, 
714, 630cm-1.  
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(1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(chloride) (1.6a) 
 
N
N
N
N
H H
H H
Ni
Cl
Cl
 
 
The cyclam (162mg, 0.681mmol) was dissolved in ethanol (20mL) and the NiCl2 
(137mg, 0.681mmol) was added. The reaction mixture was heated for ten minutes and 
allowed to cool. A purple crystalline solid fell out of solution and was collected by 
filtration and washed with cold methanol. Yield 71.2%. MS: m/z calculated for 
C10H24N4Ni = 258.1354, actual m/z (M-H) = 256.918. 1H NMR (400 MHz, DMSO-D6)  
-14.83 - -12.26 (m, 4 H) -6.32 - -2.46 (m, 4 H) 18.42 - 26.06 (m, 8 H) 52.96 - 60.40 (m, 8 
H) IR (KBr pellet): υ 3264, 3211, 2932, 2859, 1633, 1447, 1096, 1003, 983, 943, 870cm-
1. 
 
(1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(Tetraphenylborate) (1.6b) 
 
N
N
N
N
Ni
H H
H H
+2 2BPh4-
N
N
 
 
The 1,4,8,11-tetraazacyclotetradecane (500mg, 2.5mmol) and NiCl2 (320mg, 
2.5mmol) were dissolved in methanol and water (2:5, 20mL) and refluxed for 10 minutes 
until a change of colour to orange was observed. To this mixture was added the sodium 
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tetraphenylborate (171mg, 5mmol). The solvent was then removed and the crude taken 
up into acetonitrile and filtered to remove any excess salt. The compound was then left to 
recrystallize from acetonitrile. Yield 1.84g, 76% IR: υ 3154, 3129, 3117, 3060, 2978, 
2953, 1580, 1474, 1462, 1417, 1298, 1270, 1241, 1127, 1094, 1070, 882, 833, 804, 747, 
702, 612cm-1. Structure confirmed by X-ray crystal analysis. 
 
(1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(perchlorate) (1.6c) 
 
N
N
N
N
Ni
H H
H H
+2 2ClO4-
 
 
To a solution of 1,4,8,11-tetraazacyclotetradecane (294, 1.47mmol) in Methanol 
(10mL) was added the nickel perchlorate (511mg, 1.47mmol). The crystalline product 
dropped out of solution and collected by filtration. Yield 595mg, 88.4%. IR: υ 3358, 
3309, 3207, 3141, 2966, 2880, 1666, 1621, 193, 1462, 1446, 1384, 1225, 1074, 1066, 
1049, 1008, 767, 726, 616cm-1.  
 
(1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(Borohydride) (1.6d) 
 
N
N
N
N
Ni
H H
H H
BH4
BH4  
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To a suspension of (1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(perchlorate) 
(173mg, 0.378mmol) in THF (10mL) was added potassium borohydride (40.8mg, 
0.756mmol). This mixture was allowed to stir for 12 hours. The generated light green 
powder was then collected by filtration. Yield 86.6mg, 79.4%. IR: υ 3260, 3235, 2933, 
2864, 2328, 2279, 2197, 2124, 1470, 1454, 1425, 1098, 1012, 951, 874, 620cm-1. 
Structure confirmed by X-ray crystal analysis. 
 
(1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(Borodeuteride) (1.6d) 
 
N
N
N
N
Ni
H H
H H
BD4
BD4  
 
To a suspension of (1,4,8,11-Tetraazacyclotetradecane)nickel(II) Bis(perchlorate) 
(47.2mg, 0.103mmol) in THF (10mL) was added sodium borodueteride (8.62mg, 
0.206mmol). This mixture was allowed to stir for 12 hours. The generated light green 
powder was then collected by filtration. Yield 23.1mg, 75.7%. IR: υ 3268, 3235, 2945, 
2859, 1736, 1642, 1605, 1556, 1458, 1421, 1339, 1307, 1286, 1102, 1061, 1012, 947, 
878, 800, 747, 710cm-1. 
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CHAPTER 2 - C-Functionalized Cyclam Synthesis: - Linear 
Dipeptide and Tetrapeptide Precursors For Cyclopeptide 
Synthesis. 
2.1 Introduction 
 
Our previous N-functionalized nickel cyclam catalysts with 1.3 and 1.5 showed 
increased rates of hydrodehalogenation when compared to the unfunctionalized versions 
1.6a-1.6c, depending on conditions used (Table 1.4). However several problems with 
these molecules quickly became evident. The first is that the catalyst lifetimes are much 
lower than that of the unfunctionalized version. The second is that the exact nature of the 
change in rates is not immediately evident. The rate increases could be due to the electron 
withdrawing nature of the side arms pulling electron density out of the coordinating 
ligand, this in turn makes the nickel more willing to accept the hydride from the 
borohydride and ultimately the reactive intermediate. Possible Ni(0) formation also 
became an issue in DMSO:EtOH:NaBH4 and DMSO:KHBEt3 mixtures.  
Synthesis of C-functionalized cyclam molecules with well-defined and controlled 
stereochemistry became a goal for this project. With well-defined stereochemistries in 
catalysts rate changes can be attributed to differences in the catalyst side arms or 
stereochemistry. However if the stereochemistry of the catalysts are not controlled and 
multiple stereochemistries are present in the reaction mixture difficulties are encountered 
in defining any rate increases/losses as these could be attributed to one or two minor 
complexes in the mixture.  
It was theorized that incorporation of aromatic side arms on cyclam nickel 
complexes would allow the formation of π-π interactions with aromatic halogenated 
hydrocarbons1, while a 3-bond distance between the sidearm and the coordinating amine 
in the cyclam should mean the reduction potentials of the complex are left unaffected. 
The π-π interactions were expected to pre-bind the substrate to the catalyst and any 
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increase in rates of dehalogenation or enhance selectivity for halogenated aromatics2 
would then only be due to the pre-binding. Any reduction in rate could in turn be 
attributed to increased steric hindrance on the catalyst. It was also hoped that the absence 
of side arms on the nitrogens would allow a longer catalytic lifetime, more comparable to 
the un-functionalized nickel cyclam catalysts. Whilst the factors governing lifetimes for 
these catalysts is not fully understood experimental visualization suggests that catalysts 
that are not functionalized on the nitrogens (1.6a-1.6c) have longer lifetimes than those 
that are (1.3-1.5)  
We envisioned four types of C-substituted Ni-cyclam complexes that can 
theoretically cause pre-binding of aromatic substrates. The first kind is known as a 
molecular tweezer, conformation 2.1, and according to molecular modeling would have a 
distance between aromatic side arms of 6.5-7Å, roughly twice that of the average π-π 
interaction3. This was modeled to occur when the C-functionalization occurs on the 1-6 
carbons (Figures 2.1, 3.2). The second kind of cyclam would be conformation 2.2, an L-
shaped complex with one wall and one floor as π surfaces (Figures 2.1, 3.2). This catalyst 
has one sidearm in the plane of the cyclam and the other sits orthogonally to it and is 
capable of causing not only π-π interaction but also T-stacking (herringbone stacking) of 
aromatic substrates to the catalyst. The third kind of complex, conformation 2.3, is the 
paddle wheel (Figure 2.1). This cyclam has one aromatic unit that is used for binding on 
either side of the ligand equator in both the T-stacking and face to face stacking π-π 
motifs. The final complex, conformation 2.4 is the single walled catalyst, similar in 
nature to the N-functionalized compounds that have only one sidearm that can be used as 
either a π-π stacker, or a T-stacker (Figure 2.1) 
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Figure 2.1:- Diagram showing (2.1) Tweezer shaped nickel cyclam (2.2) L shaped 
nickel cyclam (2.3) paddle wheel shaped nickel cyclam (2.4) Single walled nickel 
cyclam 
 
(2.1) (2.2) 
Figure 2.2: - Molecular modeling of 2.1 (naphthyl side arms) Tweezer shaped nickel 
cyclam complex binding a PCB, a representative aromatic substrate. 2.2 is a model 
of the  L-shaped nickel cyclam complex binding a PCB.  
2.1.1 Introduction to General Cyclam Synthesis 
 
Previous efforts of macrocycle formation (leading to cyclam synthesis) have 
mostly focused around the formation of a macrocyclic amide through the ring closure of 
linear amines. There are many reported methods of doing this and include, but are not 
limited to, the reaction of polyamines (with primary amine termini) 2.5 with diethyl 
malonate 4, diacid chlorides or diazide5 (2.6) (Figure 2.3), methyl acrylates6 (2.9) (Figure 
2.4) or diacids (2.13) and DCC7 (Figure 2.5). Metal templated imine formation from 2.15 
leads to 2.16, which can be reduced to form the cyclen 2.17, a close relative to cyclams8 
(Figure 2.6). 
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Figure 2.3: - Ring closure using malonates, diacids chlorides or diazides. 
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Figure 2.4: - Ring closure using methyl acrylates. 
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Figure 2.5: - Ring formation using amide bond formations. 
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Figure 2.6: - Ring formation using metal templated imine formation followed by 
reduction. 
 
There are many methods to form marcocycles and most (as in the given 
examples) utilize amines to form amides, which can later be reduced to form the cyclam 
molecules.   
In the above examples carbon functionalization can be seen in the case of methyl 
acrylate ring closure and metal templated imine formation, however stereochemical 
control of the cyclam/cyclen was not achieved.  
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2.1.2 Stereoselective Carbon-Functionalized Cyclam Synthesis 
 
In order to achieve the goal of stereoselectively synthesizing C-functionalized 
cyclams a synthesis was required that would allow the incorporation of various side arms 
in a controllable and selective manner. Of the examples of macrocycle formation selected 
(Figures 2.3-2.6) one can clearly see that the formation of amides usually occurs during 
the ring synthesis. These amides can then simply be reduced using the appropriate 
reductant (BH3, LAH) to form the cyclams.  
In order to control the orientation of the aromatic group on the cyclam ligand we 
must have the ability to control R and S configurations during the synthesis. To increase 
the efficiency of the cyclam synthesis it was concluded that starting materials should be 
purchasable with defined stereochemistry, should be relatively inexpensive and should 
lend itself to rapid automated synthesis. Amino acids fit all of these parameters. They are 
purchased enantiomerically pure, they are inexpensive and peptide synthesis lends itself 
readily to automation both in solution phase9 and solid phase chemistries.10 
 
2.1.2.1 Stereospecific Synthesis of 1-5 C-Functionalized Cyclam Precursors. 
 
Literature searches on the formation of stereospecifically synthesized carbon 
functionalized 14-membered amide containing macrocycles/cyclam/cyclen molecules 
produced very few hits (as will discussed shortly) and all seemed to use amino acids as 
the method of introducing the predefined stereocenters, as we envisioned.  
C. J. Burrows developed a synthesis that incorporated two stereo-specifically 
defined carbon centres into a cyclam precursor11 this was based on Tabushi’s method 
(Figure 2.3)4. The synthesis, outlined in figure 2.6, shows the formation of a macrocyclic 
cyclam precursor 2.20 with side arm configurations predefined from the amino acid 
starting material 2.18 (Figure 2.7). 
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Figure 2.7: - Stereo-controlled synthesis of a macrocyclic cyclam precursor (Yield 7 
12%). 
 
 There are two problems with this synthesis that make it an unfavourable route for 
our cyclam formation. The first is that the carbons that have been functionalized (1 and 5) 
are not the carbons that we wish to functionalize (1 and 6) and the second is that 
modifications to this route to allow SR stereocenters to be involved would require a 
mono-protected amine and the use of S and R amino acids in order to achieve the cis 
configuration of the side arms. The yield of the macrocycle formation is also very bad 7-
12%. 
2.1.2.2 Synthesis of 1-6 C-functionalized Cyclam Precursors and Cyclams 
 
 J. Jurczak et al used linearly synthesized tetraaza compounds to generate C2 
symmetric C-functionalized cyclams with 1-6 carbon functionalization12. In this case a 
diamine-ester was synthesized from an N-protected, O-activated ethanolamine followed 
by a divergent-convergent synthesis leading to a linear tetraaza compound. This 
compound was then cyclized in solution to yield a cyclopeptide precursor that was then 
reduced to yield the C-functionalized cyclams (Figure 2.8) 
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Figure 2.8: - 1-6 C-functionalized cyclams from amino acid starting materials. (a) 
TEA, MeCN heat. (b) H2O Heat. (c) H2 Pd/C, HCl MeOH (d) tButOCOCl, TEA, 
DCM -20oC-0oC, H2 Pd/C (e) NaOMe or NaOH in MeOH (f) BMS, THF, reflux, 
20h. 
 
 Whilst an intriguing synthesis, there are several setbacks to this technique. One 
major setback to this synthesis is the length of time it takes to cyclize the material in 
solution, 28 days. Another problem is the synthesis can yield a 2:1 mixture of the SS and 
SR product, therefore increasing the workload via excessive purifications. In the authors 
opinion racemization occurs at the saponification stage of the synthesis and not during 
the cyclization, however this was not proven. The authors also note the formation of 2.28 
as a side product of the cyclization, (Figure 2.9), indicating an intramolecular 6-exo-trig 
cyclization (favored by the Baldwin rules13) to form a 6-membered macrocycle. 
NH
N
O
2.28  
Figure 2.9: - (8aS)-hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one (2.28), a side product 
of cyclization in the Jurczak’s cyclization. 
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2.1.2.3 Cyclization of linear tetraamine ligands. 
 
Another method of forming C-functionalized cyclam complexes is derived from 
the metal templated cyclization of linear amines14 in a similar fashion to figure 2.6 
(nickel template is used in this case). Here a tetraamine is coordinated to a nickel metal 
center and a condensation reaction with glycol proceeds to form an imine intermediate. 
This intermediate is then reduced with NaBH4 to yield the metal complex. This 
methodology has several lacks stereochemical control of final products and as such was 
not pursued. However it must be noted that many crystal structures of C-functionalized 
cyclam complexes have been analyzed in literate15.  
2.1.2.4 Metal Templated Dipeptide and Tetrapeptide Cyclizations. 
 
Several papers by Beck et al16 have shown the formation of both the 1-6 C-
functionalized cyclopeptides and crucially the formation of the 1-6 C-functionalized 
cyclams from those cyclopeptides. In these cases dipeptides (2.29) were synthesized and 
cyclized around a metal template (Pd, Ni, Cu) in good yield 70-80%. The metal template 
ensures that no unwanted intramolecular cyclizations occur. The cyclization leads to the 
formation of a metal containing tetrapeptide species and does not require high dilution or 
long reaction times. Freeing the cyclopeptide ligand from the metal involves treating the 
complex with HCl to yield 2.30 and reduction of 2.30 leads to the cis C2 cyclam molecule 
2.31 (Figure 2.10).  
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Figure 2.10: - Beck’s route to cyclams utilizing amino acid cyclization. 
 
 64
This route was chosen as our means to synthesize the cyclams and modifications 
to the peptides used were envisioned to allow us to incorporate aromatic side arms 
including (L)-phenylalanine (previously accomplished by Beck14a) and 2-naphthylalanine 
(both L and D), a commercially available unnatural amino acid. 
Modifications to Beck’s approach can be utilized to form any C2, Ci or C1 14-
membered cyclopeptide/cyclams from tetrapeptides. It must be noted that a 13-membered 
cyclopeptide has previously been synthesized by Beck from the tetrapeptide 3.32, MeO-
βala-ala-gly-gly-NH214c (Figure 2.11).  
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Figure 2.11: - Synthesis of a 13-membered cyclopeptide palladium complex from a 
tetrapeptide precursor. 
 
Tetrapeptides can be generated by solution or solid phase chemistries, by either 
sequential or segment condensations. These linear peptides can then be cyclized around a 
nickel template to form a cyclopeptide nickel complex in a similar fashion to that shown 
in figure 2.11. The cyclopeptide can then be isolated by nickel removal, and the 
cyclopeptide can be subsequently reduced to form the desired cyclam 2.31 (Figure 2.10) 
Beck’s synthesis will be discussed in more detail in chapter 4 but is the basis for the 
generation of our cyclam ligands. 
 For the synthesis of a 14-membered cyclam macrocycle the tetrapeptide used to 
form the cyclopeptide must contain two β-amino acids and two α-amino acids. Molecular 
modelling indicates that the aromatic arms would be more likely to form a cooperative 
interaction with the aromatic substrate (Figure 2.2) in the five membered rings of the 
nickel cyclam complex than those placed in the six membered rings of the nickel 
complex. This can be achieved by staring with functionalized α-amino acids in the 
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peptide starting materials. β-alanine is used to generate the six membered ring in the 
nickel cyclam complex (Figure 2.12). This is fortunate as stereospecific functionalized β-
amino acids are less common and more expensive than α-amino acids. 
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Figure 2.12: - A diagram of a nickel cyclam complex, showing the five and six 
membered ring systems. 
 
2.2 Solution Phase Synthesis of Dipeptides 
 
In order to form cyclopeptides and cyclams the linear dipeptide (2.29) and 
tetrapeptide precursors (2.34) must be synthesized (Figure 2.13).  
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R1, R2 = H, Ph, 2-Nap, (4Me)Phe.  
Figure 2.13: - (a) Dipeptide precursor to 14-membered cyclopeptides (b) 
Tetrapeptide precursor to 14-membered cyclopeptides. 
 
The following describes the procedures and protocols developed to allow the 
synthesis of a large amount of dipeptide (2.29) and tetrapeptide (2.34) starting materials. 
Standard methods of peptide synthesis involve the use of HOBt and DCC in dry peptide 
grade DMF17. However low yields plagued this methodology in my hands. Alternative 
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reaction conditions were sought that would negate the DCC urea side product and allow 
the use of a less expensive and more easily removed solvent than DMF.  
A reagent known as EDCI, a DCC mimic, was seen to have desirable properties 
such as increased water solubility of the urea side product due to its charge18. Performing 
the peptide coupling reaction in DCM generates products in >95% yields after 3 hours 
(Figure 2.14). Work up involves simply washing the DCM with water and brine to 
remove excess HOBt and EDCI urea with no column chromatography required to further 
purify the compounds generated (Figure 2.14).  
 
NH(BOC)
NHO
R
OO
NH3Cl
OO
+
NH(BOC)
OHO
R
1) HOBt, DIPEA, EDCI
2) Water and Brine
DCM
2.35 2.36
2.37
R = H, Ph, Ph(4Me), 2-Nap  
Figure 2.14: - Dipeptide synthesis utilizing EDCI, HOBt and DIPEA in DCM. 
 
The dipeptides synthesized were a good starting point for the synthesis of the 
tetrapeptides and several were synthesized in good yield (Table 2.1).  
 
Table 2.1: - Dipeptides synthesized. 
Compound 
Name/number 
Yield % 
Compound Name/number 
Yield % 
Boc-Phe(L)-βala-OMe 
(2.37a) 
95 
Boc-Nap(D)-βala-OMe 
(2.37d) 
94 
Boc-Phe(D)-βala-OMe 
(2.37b) 
95 
Boc-Para methyl-Phe(L)-
βala-OMe (2.37e) 
93 
Boc-Nap(L)-βala-OMe 
(2.37c) 
93 Boc-Ala(L)-βala-OMe (2.37f) 90 
 
2.2.1 Crystal structure of Boc-Phe(L)-ßala-OMe 2.37a 
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Crystals of compound 2.37a were grown from DCM and analysed by X-ray 
crystallography (Figure 2.15). The structure shown has only one configuration and is 
presumed to be S as was dialled into the molecule. 
 
(a) (b) 
Figure 2.15: - (a) X-ray crystal structure of dipeptide 2.37a. (b) Unit cell of the 
dipeptide 2.37a showing hydrogen bond N-H…O interactions between two peptides 
and a water molecule bridging the dipeptides with O…H-O hydrogen bond 
interactions in 2.37a. 
 
2.3 Synthesis: - Tetrapeptide Synthesis Through Selective Dipeptide 
De-protection and Coupling Reactions 
2.3.1 Boc Protecting Group Removal 
 
The BOC deprotection was accomplished via standard protocols using 
trifluoroacetic acid (TFA)19 or HCl20. In most cases HCl was preferred as the reaction 
afforded a solid salt instead of oils when TFA was used (Figure 2.16). 
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Figure 2.16: - BOC deprotection with HCl. 
 
It is important that the reaction is monitored carefully by TLC and stopped as 
soon as possible. Too much acid combined with a long reaction time and heat may lead to 
racemization of the peptides21. A two-fold excess of acid was used at room temperature 
and the reaction was usually quenched after an hour (or when starting material was 
consumed by TLC). Some of the ammonium salts synthesized are shown in table 2.2. It 
should be noted that stereochemical integrity of the dipeptides in table 2.3 were not 
established at this stage of our synthesis. 
 
Table 2.2: - Ammonium salts formed by Boc removal. 
Compound 
Name/Number 
Yield % Compound Name/Number Yield % 
ClNH3-Phe(L)- βala-
OMe (2.29a) 
95 
ClNH3-Para methyl-
Phe(L)- βala-OMe (2.29d) 
99 
ClNH3-Nap(L)- βala-
OMe (2.29b) 
99 
ClNH3-Ala-(L)- βala-OMe 
(2.29e) 
99 
ClNH3-Nap(D)- βala-
OMe (2.29c) 
98   
 
2.3.3 Tetrapeptide Synthesis From Dipeptide Segment Condensations. 
 
Retrosynthetic analysis of the desired tetrapeptides (Figure 2.17) showed that they 
could be synthesized from selectively deprotected dipeptides via a segment condensation.  
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Figure 2.17: - Retrosynthetic analysis of tetrapeptide formation. 
 
Both the ammonium salt (compounds 2.29a-e) and the carboxylic acid dipeptide 
derivatives (compounds 2.38a-e) can be synthesized directly form the dipeptide by 
removing the appropriate protecting group. Ester functionalities are base sensitive22 while 
BOC groups are acid sensitive10-11. This orthogonal protecting group combination allows 
for the selective removal of one protecting group over the other. 
 
2.3.4 Saponification of the Dipeptide Ester. 
 
Ester groups can be removed easily using hydroxides in water mixtures. Some 
reports indicate that amino acid stereo-integrity can be compromised by prolonged 
exposure to strongly basic conditions23. Therefore during the synthesis it is important to 
use only a minimum amount of hydroxide (2 equivalents), monitor the conversion by 
TLC and work up the reaction as soon as the starting material is consumed. In this case 
stereochemical integrity is maintained more easily than in other cases as it is usually the 
carbon alpha to the ester/carboxylic acid that is affected most by basic conditions. 
Fortunately the dipeptide ester moiety is located on the β-alanine and this has no alpha 
stereocenter. Alpha protons in peptides are known to racemize under prolonged exposure 
to bases at elevated temperatures21, so the reaction was closely monitored by TLC and 
worked up when the starting material was consumed.  
Work up of the saponification reaction involves protonating the carboxylate salt 
and extracting the product into organic solvent. At this stage it is important to use a weak 
acid to protonate the salt as the acid sensitive BOC protecting group must be left in tact. 
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Our experiments found that 25% phosphoric acid works well for the protonation of the 
carboxylate salt without affecting the BOC group (Figure 2.18) 
 
R = H, Phe, 2-Nap
NHBOC
NHO
R
OHO
NHBOC
NHO
R
OO
1) LiOH
THF:EtOH:H2O (1:1:1)
2) Phosphoric acid
2.37 2.38
 
Figure 2.18: - Saponification of the dipeptide ester. 
 
 Several carboxylic acid dipeptides were synthesized to create a stock for 
tetrapeptide formations (Table 2.3).  
 
Table 2.3: - Carboxylic acid dipeptides isolated. 
Compound 
Name/Number 
Yield % 
Compound 
Name/Number 
Yield % 
Boc-Phe(L)-βala-OH 
(2.38a) 
90.0 
Boc-Nap(D)-βala-OH 
(2.38d) 
84.0 
Boc-Phe(D)-βala -OH 
(2.38b) 
84.6 
Boc-Ala(L)-βala -OH 
(2.38e) 
81.0 
Boc-Nap(L)-βala -OH 
(2.38c) 
90.0   
 
2.3.5 Coupling of the Dipeptide Ammonium Salt and Dipeptide Carboxylic 
Acid: - A Segment Condensation. 
 
The coupling of two larger peptide components (where the number of amino acids 
is two or more for both sides) is known as a segment condensation. This type of reaction 
has one major drawback. The C-terminus of the segment to be coupled often experiences 
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racemization when coupled and usually requires special conditions to overcome this 
failing24. However when the C-terminus does not contain any stereocenters such as in 
glycine and β-alanine these special conditions are no longer required and a simple 
EDCI/HOBt coupling can be employed with no racemization incurred. It is therefore 
fortunate that the C-terminus of our dipeptide acid is β-alanine or stepwise additions 
would need to be employed. 
The coupling of a dipeptide ammonium salt (2.29) and a dipeptide carboxylic acid  
(2.38) precedes smoothly using similar conditions to that used to synthesize the 
dipeptides 3.37 (Figure 2.19). The coupling reaction takes a longer time (12-24 hours) 
most likely due to the increased steric bulk of the α-amino acids as the amine 
component25.  
 
NH3Cl
NHO
R2
OO
+
HN
HN
NH
NHO
O
O
R1
R2
OO
R1, R2 = H, Ph, 2-Nap
NH(BOC)
NHO
R1
OHO
HOBt
EDCI
DIPEA
DCM
BOC
2.382.29 2.39
 
Figure 2.19: - Tetrapeptide synthesis from dipeptide ammonium salts and 
carboxylic acids. 
 
Many of the tetrapeptides synthesized simply fell out of solution after synthesis. 
Once the product has fallen out of solution it is simply filtered and washed with water to 
remove any HOBt or EDCI. The tetrapeptides that did not fall out of solution (2.39e, 
2.39f, 2.39h and 2.39i) were worked up in the same manner as the dipeptides (Table 2.4). 
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Table 2.4: - Yields of tetrapeptides synthesized. 
Compound 
Name/Number 
Yield % Compound Name/Number Yield % 
Boc-Phe(L)- ßala -
Phe(L)- ßala -OMe 
(2.39a) 
70-80 
Boc-Nap(L)- ßala -Nap(D)- 
ßala -OMe (2.39f) 
73.3 
Boc-Phe(D)- ßala -
Phe(L)- ßala -OMe 
(2.39b) 
30.5 
Boc-Phe(L)- ßala -Nap(D)- 
ßala -OMe (2.39g) 
67.7 
Boc-Ala(L)- ßala -
Phe(L)- ßala -OMe 
(2.39c) 
81.9 
Boc-Ala(L)- ßala -Nap(L)- 
ßala -OMe (2.39h) 
89.1 
Boc-Ala(L)- ßala -
Ala(L)- ßala -OMe 
(2.39d) 
28 
Boc-Phe (D)-ßala-Nap(D)- 
ßala-OMe (2.39i) 
94.2 
Boc-Nap(L)- ßala -
Nap(L)- ßala -OMe 
(2.39e) 
82.7   
 
2.3.6 BOC Removal From Tetrapeptides. 
 
 The BOC removal from the tetrapeptides (2.39a-i) occurs in a similar fashion to 
the removal of the BOC from the dipeptides (2.29a-e). In this case TFA is often preferred 
as the reagent to remove the BOC as the salts generated are solid and can be easily 
purified by simple washing with ether and drying (Figure 2.20, Table 2.5). However HCl 
is still utilized for some of the compounds. 
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2.39
R1, R2 = H, Ph, 2-Nap
HN
H2N
NH
NHO
O
O
R1
R2
OO
TFA
DCM
HN
HN
NH
NHO
O
O
R1
R2
OO
BOC .TFA
2.34
 
Figure 2.20: - BOC removal from tetrapeptides. 
 
Table 2.5: - Yields of BOC removal from tetrapeptides. 
Compound 
Name/Number 
Yield % 
Compound 
Name/Number 
Yield % 
H-Phe(L)- βala-Phe(L)- 
ßala-OMe (2.34a) 
70.0 
H-Ala(L)- βala-Phe(L)- 
ßala-OMe (2.34d) 95.0 
H-Phe(L)- βala-Phe(D)- 
ßala-OMe (2.34b) 
80.5 
H-Phe(L)- βala-Nap(L)- 
ßala-OMe (2.34e) 
95.0 
H-Nap(L)- βala-
Nap(L)- ßala-OMe 
(2.34c) 
94.0 
H-Nap(D)- βala-
Nap(L)- ßala-OMe (2.34f) 
95.0 
 
2.4 Tetrapeptide Synthesis on Solid Support. 
 
As well as performing solution phase tetrapeptide synthesis several tetrapeptides 
were synthesized on solid support using standard reaction conditions26 including N-
hydroxybenzotriazole (HOBt), diisopropylamine (DIPEA), dicyclohexyldicarbamide 
(DCC) and O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU) (Figure 2.21, Table 2.6).  
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NH(FMOC)
NHO
Ph
OO
NH2
OO
+
NH(FMOC)
OHO
Ph
1) HOBt, DIPEA, 
DCC, HBTU
DMF
HN
H2N
NH
NHO
O
O
R
Ph
OO
R = H, CH2S(Trt), CH3, (CH2)3NH(Trt), 
O(tBut), His(Trt), COOtBut, CONH2.  
Figure 2.21: - Solid phase synthesis of tetrapeptides. 
  
Unfortunately yields could not be determined due to variations in masses of the 
resins from starting materials to products. Mass spectrum analysis confirmed the presence 
of the products. 
 The stock of the trimer was synthesized in the Tomich lab with the assistance of 
Dr Iwamoto in high yield as shown via the ninhydrin test. Final coupling of the last 
amino acid was performed on a Trident Synthesizer®. 
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Table 2.6: - Tetrapeptides synthesized on solid support. 
Compound 
Name/Number 
Mass Peak(s) m/z 
Compound 
Name/Number 
Mass Peak(s) m/z 
H-Ala(L)- βala-
Phe(L)- ßala-OH 
(2.40a) 
Calculated  
C18H26N4O5 = 
378.191.  
Actual = 379.075 
(M+H) 
FmocHN -
His(L)(Trt)- βala-
Phe(L)- ßala-OH 
(2.40e) 
Calculated 
C55H52N6O7 = 
909.038. 
Actual m/z 667.611 
(M-Trt, +2H) 
FmocHN-Ala- 
βala-Phe(D)- 
ßala-OH (2.40b) 
Calculated 
C33H34N4O7 = 
600.258.  
Actual = 601.561 
(M+H) 
FmocHN –
Asp(L)(tBut)- 
βala-Phe(L)- βala-
OH 
(2.40f) 
Calculated 
C37H42N4O9 = 
686.295. 
Actual = 644.610 
(M-tBut, +H) 
FmocHN –
Lys(L)(Boc)- 
βala-Phe(L)- 
ßala-OH 
(2.40c) 
Calculated 
C41H51N5O9 = 
757.872 
Actual m/z 
658.683 (M-Boc, 
+H) 
FmocHN –
Asn(L)(Trt)- βala-
Phe(L)- βala-OH 
(2.40g) 
Calculated 
C38H44N4O9 = 
700.778. 
Actual = 644.626(M-
Trt, +H) 
FmocHN –
Ser(L)(tBut)- 
βala-Phe(L)- 
βala-OH 
(2.40d) 
Calculated 
C37H44N4O8 = 
672.767. 
Actual m/z 
617.581(M-
tBut+2H) 
FmocHN –Ala-
βala-Phe(L)- βala-
OH 
(2.40h) 
Calculated 
C33H36N4O7 = 
600.662. 
Actual m/z 
601.561(M+H) 
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2.5 Conclusions. 
 
Various N-protected tetrapeptide esters of the generic formula (BOC)-NH-X-
CON-βala-CON-X-CON-βala-OH were generated in high yields from dipeptides 2.29 
and 2.38 using variations on standard coupling conditions. Complimentary solid support 
synthesis using FMOC-protected amino building blocks cleanly produced tetrapeptides as 
well. Yields were not determined but the small quantities obtained did not seem 
compatible with a multi gram demand for the further course of the project. We therefore 
abandoned the solid support approach. 
2.6 Experimental. 
 
All chemicals were purchased from Aldrich, Peptech Corp, Aroz Technologies, 
Acros Organics or Fisher Scientific and used without further purification.   
2.6.1 Dipeptide synthesis. 
 
Methyl 3-aminopropanoate hydrochloride (2.35) 
 
NH3Cl
O
O  
 
To β alanine (10.0g, 112mmol) in MeOH (100mL) at 0 °C was added thionyl 
chloride (19.0g, 160mmol). This was then left to stir for 10 minutes and warmed to RT. 
After stirring overnight the solvent was removed in vacuo. The residue was taken up into 
chloroform and the solid filtered off and dried. The solid was analyzed by NMR and 
showed pure product. Yield 12.8g, 82% 1H NMR (400 MHz, CDCl3)  2.95 (t, J=6.59 
Hz, 2 H), 3.38 (t, J=6.78 Hz, 2 H), 3.73 - 3.76 (s, 3 H). 13C NMR (101 MHz, CD3OD)  
32.07, 36.44, 52.60, 172.54. 
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General synthesis for dipeptides. 
 
To the amino acid (2.36) (1.0 mmol), methyl 3-aminopropanoate hydrochloride 
(2.35), (152.94mg, 1.1mmol), HOBt (148.63mg, 1.1 mmol) and DIPEA (0.182mL, 
1.1mmol) in DCM (20mL) at RT was slowly added EDCI (239.63mg, 1.25mmol) in 
small portions. This was left to stir for 4 hours. The DCM was then washed twice with 
water (20mL) and once with brine (20mL). The DCM was dried over magnesium sulfate 
and the solvent removed in vacuo to yield the product. 
 
Boc-Phe(L)- βala-OMe (2.37a) 
 
N
H
O
NHBoc
O
O
 
 
Yield 3.66g, 100%. MS: m/z calculated for C18H26N2O5 = 350.1842, actual m/z 
(M+Na) = 372.931. 1H NMR (200 MHz, CDCl3)  1.35 - 1.43 (s, 9 H) 2.26 - 2.47 (m, 2 
H) 2.89 - 3.08 (m, 2 H) 3.28 - 3.52 (m, 2 H) 3.61 (s, 3 H) 4.26 (q, J=6.59 Hz, 1 H) 5.13 
(d, J=8.06 Hz, 1 H) 6.37 (t, J=5.49 Hz, 1 H) 7.12 - 7.29 (m, 5 H). 13C NMR (50 MHz, 
CDCl3)  28.18, 33.49, 34.60, 38.74, 51.65, 55.91, 80.05, 126.79, 128.41, 128.52, 129.06, 
129.17, 136.57, 155.19, 171.15, 172.45. IR (KBr cm-1) v = 3339, 3308, 1736, 1680, 1649, 
1173cm-1 
 
Boc-Phe(D)- βala-OMe (2.37b) 
 
N
H
O
NHBoc
O
O
 
Yield 3.4g, 97%. MS: MS: m/z calculated for C18H26N2O5 = 350.1842, actual m/z 
(M+Na) = 372.931. 1H NMR (400 MHz, CDCl3)  1.41 (s, 9 H) 2.33 - 2.44 (m, 2 H) 2.97 
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- 3.08 (m, 2 H) 3.38 (ddd, J=12.40, 6.64, 6.34 Hz, 1 H) 3.48 (dt, J=11.81, 6.78 Hz, 1 H) 
3.64 (s, 3 H) 4.28 (d, J=5.86 Hz, 1 H) 5.08 (s, J=3.51 Hz, 1 H) 6.23 - 6.34 (m, 1 H) 7.17 - 
7.25 (m, 3 H) 7.26 - 7.30 (m, 2 H). 13C NMR (101 MHz, CDCl3)  28.37, 33.69, 34.82, 
38.93, 51.83, 56.02, 80.13, 126.93, 128.66, 129.38, 136.84, 155.46, 171.45, 172.68. 
 
Boc-Nap(L)-ßala-OMe (2.37c) 
 
N
H
O
NHBoc
O
O
 
 
Yield 2.33g, 91.5%. MS: MS: m/z calculated for C22H28N2O5 = 400.1998, actual 
m/z (M+Na) = 422.975. 1H NMR (400 MHz, CDCl3)  ppm 1.39 (s, 9 H) 2.27 (s, 1 H) 
2.33 - 2.44 (m, 1 H) 3.14 (m, 1 H) 3.24 (m, 1H) 3.32 (m, 1 H) 3.45 (s, 3 H) 3.49 (s, 1 H) 
4.35 (d, J=6.04 Hz, 1 H) 5.03 - 5.14 (m, 1 H) 6.19 - 6.30 (m, 1 H) 7.32 (d, J=8.24 Hz, 1 
H) 7.39 - 7.50 (m, 2 H) 7.62 (s, 1 H) 7.73 - 7.82 (m, J=9.34 Hz, 3 H). 13C NMR (50 MHz, 
CDCl3)  ppm 28.22, 33.46, 34.60, 38.96, 51.62, 56.02, 80.25, 125.71, 126.20, 127.29, 
127.54, 127.60, 127.93, 128.36, 132.38, 133.42, 134.10, 155.24, 171.08, 172.44. 
 
Boc-Nap(D)-ßala-OMe (2.37d) 
 
N
H
O
NHBoc
O
O
 
 
Yield 1.2g, 94.6%. 1H NMR (400 MHz, CDCl3)  1.30 - 1.46 (s, 9 H) 2.19 - 2.48 
(m, 2 H) 3.09 - 3.27 (m, 2 H) 3.28 - 3.38 (m, 1 H) 3.42 - 3.47 (m, 3 H) 4.30 - 4.41 (m, 1 
H) 5.12 (m, 1 H) 6.31 (s, 1 H) 7.31 (dd, J=8.42, 1.47 Hz, 1 H) 7.40 - 7.49 (m, 2 H) 7.61 
(s, 1 H) 7.73 - 7.81 (m, 3 H). 13C NMR (101 MHz, CDCl3)  28.40, 33.67, 34.82, 39.15, 
51.76, 56.14, 80.26, 125.84, 126.33, 127.52, 127.70, 127.76, 128.10, 128.47, 132.55, 
133.59, 134.37, 155.44, 171.33, 172.57. 
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Boc-Para methyl-Phe(L)- ßala-OMe (2.37e) 
 
N
H
O
NHBoc
O
O
 
Yield 1.24g, 95%. MS: MS: m/z calculated for C19H28N2O5 = 364.1998, actual 
m/z (M+Na) = 386.992. 1H NMR (200 MHz, CDCl3)  1.42 (s, 9 H) 2.32 (s, 3 H) 2.34 - 
2.54 (m, 2 H) 2.86 - 3.13 (m, 2 H) 3.29 - 3.59 (m, 2 H) 3.65 (s, 3 H) 4.24 (q, J=6.84 Hz, 1 
H) 4.93 - 5.10 (m, 1 H) 6.14 - 6.30 (m, 1 H) 7.02 - 7.14 (m, 4 H). 13C NMR (101 MHz, 
CD3OD)  21.18, 28.42, 33.76, 34.84, 38.49, 51.86, 56.14, 80.18, 129.30, 129.43, 133.64, 
136.57, 155.46, 171.50, 172.72. 
 
Boc-Ala(L)-Bala-OMe (2.37f) 
 
N
H
O
NHBoc
O
O
 
 
Yield 3.26g, 91.5%. MS: MS: m/z calculated for C12H22N2O5 = 274.1529, actual 
m/z (M+Na) = 296.914. 1H NMR (400 MHz, CDCl3)  1.28 (d, J=7.03 Hz, 3 H) 1.38 (s, 9 
H) 2.49 (t, J=6.05 Hz, 2 H) 3.41 - 3.52 (m, 2 H) 3.63 (s, 3 H) 4.08 (s, 1 H) 5.20 (d, 
J=7.03 Hz, 1 H) 6.81 (s, 1 H). 13C NMR (101 MHz, CDCl3)  18.45, 28.20, 33.66, 34.81, 
50.01, 51.65, 79.83, 155.31, 172.61, 172.79. 
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2.6.2 Dipeptide Ammonium Salt Synthesis. 
 
General synthesis of dipeptide ammonium salts 
 
The dipeptide (1mmol) was dissolved in methanol (1 mL) and HCl in methanol 
(1mL, 2mmol) was added. This was stirred for between 20 and 60 minutes until all 
starting material was consumed, as shown by TLC and the solvent was removed in vacuo. 
 
ClNH3-Phe-(L)-Bala-OMe (2.29a) 
 
N
H
O
NH3Cl
O
O
 
 
Yield 1.64g, 97.7%. MS: m/z calculated for C13H18N2O3 = 250.1317, actual m/z 
(M+Na) = 273.869. 1H NMR (200 MHz, D2O)  2.00 - 2.21 (m, 2 H) 2.80 - 2.99 (m, 3 H) 
3.06 - 3.23 (m, 1 H) 3.31 (s, 3 H) 3.79 (dd, J=8.61, 6.78 Hz, 1 H) 6.85 - 6.98 (m, 2 H) 
6.98 - 7.09 (m, 3 H). 13C NMR (50 MHz, CDCl3)  32.93, 35.19, 37.51, 52.01, 55.19, 
128.16, 129.19, 129.25, 133.31, 168.33, 172.69. 
 
ClNH3-Nap(L)-Bala-OMe (2.29b) 
 
N
H
O
NH3Cl
O
O
 
 
Yield 840mg, 99.6%. 1H NMR (200 MHz, D2O)  ppm 1.95 - 2.12 (m, 1 H) 2.16 
- 2.32 (m, 1 H) 2.91 - 3.20 (m, 2 H) 3.25 (s, 3 H) 3.28 - 3.51 (m, 2 H) 3.53 - 3.82 (m, 1 
H) 4.19 (dd, J=9.71, 6.04 Hz, 1 H) 7.34 (d, J=8.42 Hz, 1 H) 7.52 (dd, J=5.68, 2.75 Hz, 2 
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H) 7.68 (s, 1 H) 7.87 (d, J=8.42 Hz, 3 H). 13C NMR (50 MHz, D2O)  ppm 32.55, 34.17, 
36.71, 51.71, 53.92, 126.09, 126.38, 126.60, 127.21, 127.35, 127.84, 128.35, 131.10, 
132.02, 132.71, 168.28, 173.48. 
 
ClNH3-Nap(D)-Bala-OMe (2.29c) 
 
N
H
O
NH3Cl
O
O
 
 
Yield 168mg, 78.9%. 1H NMR (400 MHz, CD3OD)  2.27 - 2.39 (m, 2 H) 3.21 - 
3.32 (m, 4 H) 3.36 - 3.45 (m, 1 H) 3.45 - 3.51 (m, 3 H) 4.18 (t, J=7.42 Hz, 1 H) 7.35 - 
7.45 (m, 3 H) 7.73 (s, 1 H) 7.76 - 7.83 (m, 3 H). 13C NMR (101 MHz, CD3OD)  34.21, 
36.22, 38.70, 52.18, 55.58, 127.11, 127.36, 128.16, 128.67, 128.73, 129.56, 129.72, 
133.05, 134.15, 134.88, 169.52, 173.34. 
 
ClNH3-Phe(4-Me)-(L)-Bala-OMe (2.29d) 
 
N
H
O
NH3Cl
O
O
 
Yield 97.7%. 1H NMR (400 MHz, METHANOL-D4)  2.16 - 2.23 (m, 3 H) 2.29 
- 2.41 (m, 2 H) 2.93 - 3.04 (m, 2 H) 3.19 - 3.30 (m, 2 H) 3.32 - 3.41 (m, 1 H) 3.53 - 3.57 
(m, 3 H) 3.96 (t, J=7.22 Hz, 1 H) 5.18 (none, 1 H) 7.07 (s, 4 H).  13C NMR (101 MHz, 
CD3OD)  19.99, 33.12, 35.07, 37.02. 51.12, 54.56, 129.26, 129.42, 131.31, 137.35, 
168.41, 172.27. 
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TFA.NH3-Ala(L)-Bala-OMe (2.29e) 
 
N
H
O
NH3TFA
O
O
 
 
Yield 651mg, 100%. 1H NMR (400 MHz, DMSO-D6)  1.29 (d, J=7.03 Hz, 3 H) 
2.49 (m, 2 H) 3.27 - 3.38 (m, 2 H) 3.55 - 3.61 (m, 3 H) 3.76 (ddd, J=11.52, 6.05, 5.86 Hz, 
1 H) 8.03 - 8.13 (m, 3 H) 8.49 (t, J=5.47 Hz, 1 H) 13C NMR (101 MHz, DMSO-D6)  
17.16, 33.33, 34.87, 48.16, 51.46, 169.51, 171.57. 
 
2.6.3 Carboxylic Acid Dipeptide Synthesis. 
 
General synthesis of dipeptide acids 
 
The Bis-protected dipeptide (1mmol) was dissolved in Water:THF:Ethanol (1:1:1, 
2mL) and the KOH (2mmol) was added. This was stirred at RT for 30 minutes until all 
starting material was consumed as shown by TLC. To the mixture was added diluted 
phosphoric acid (25%) until the solution was acidified. The product was extracted with 
ethyl acetate, washed with water and brine and dried over magnesium sulfate. The 
organic solvent was removed in vacuo. 
 
Boc-Phe(L)-Bala-OH (2.38a) 
 
N
H
O
NHBoc
O
HO
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Yield 1.09g, 92.3%. 1H NMR (200 MHz, CDCl3)  1.38 (s, 9 H) 2.23 - 2.68 (m, 2 
H) 2.99 (d, J=6.59 Hz, 2 H) 3.25 - 3.66 (m, 2 H) 4.58 (m, 1 H) 5.48 (d, J=6.59 Hz, 1 H) 
6.85 - 7.09 (m, 1 H) 7.12 - 7.37 (m, 5 H) 10.22 - 10.82 (m, 1 H). 13C NMR (101 MHz, 
CDCl3)  28.43, 33.70, 34.66, 39.34, 55.75, 80.80, 127.09, 128.70, 129.46, 136.74, 
156.05, 171.93, 175.64. 
 
Boc-Phe(D)-Bala-OH (2.38b) 
 
N
H
O
NHBoc
O
HO
 
 
Yield 865mg, 90.2%. MS: m/z calculated for C17H24N2O5 = 336.1685, actual m/z 
(M+Na) = 358.946. 1H NMR (200 MHz, CDCl3)  1.23 - 1.53 (s, 9 H) 2.13 - 2.69 (m, 2 
H) 2.98 (d, J=6.96 Hz, 2 H) 3.24 - 3.74 (m, 2 H) 4.23 - 4.70 (m, 1 H) 5.61 (d, J=8.79 Hz, 
1 H) 6.85 - 7.39 (m, 6 H) 9.88 (bs, 1 H). 13C NMR (50 MHz, CDCl3)  28.43, 33.70, 
34.67, 39.33, 55.74, 80.79, 127.09, 128.69, 129.45, 136.73, 156.05, 171.94, 175.63. 
 
Boc-Nap(L)-Bala-OH (2.38c) 
 
N
H
O
NHBoc
O
HO
 
 
Yield 84.4mg, 98.4%. MS: m/z calculated for C21H26N2O5 = 386.1842, actual m/z 
(M+Na) = 409.003. 1H NMR (200 MHz, CDCl3)  1.34 (s, 9 H) 2.35 (d, J=12.45 Hz, 2 
H) 3.14 (d, J=7.33 Hz, 2 H) 3.35 (m, 2 H) 4.60 (m, 1 H) 5.35 (m, 1 H) 6.86 (m, 1 H) 7.36 
- 7.50 (m, 2 H) 7.61 (s, 1 H) 7.70 - 7.84 (m, 4 H). 13C NMR (50 MHz, CDCl3)  27.95, 
33.30, 34.65, 38.81, 55.47, 80.16, 125.37, 125.84, 127.16, 127.31, 127.38, 127.81, 
127.92, 132.16, 133.20, 133.94, 155.75, 172.12, 175.16. 
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Boc-Nap(D)-Bala-OH (2.38d) 
 
N
H
O
NHBoc
O
HO
 
 
Yield 1.06g, 100%. 1H NMR (400 MHz, CDCl3)  1.31 (s, 9 H) 2.23 (m, 1 H) 
2.35 (m, 1 H) 3.05 - 3.16 (m, 2 H) 3.26 (m, 1 H) 3.30 - 3.41 (m, 1 H) 4.62 (q, J=7.03 Hz, 
1 H) 5.57 (d, J=7.42 Hz, 1 H) 7.02 (s, 1 H) 7.21 - 7.30 (m, 1 H) 7.33 - 7.44 (m, 2 H) 7.58 
(s, 1 H) 7.67 - 7.77 (m, 3 H) 10.79 (s, 1 H).  13C NMR (101 MHz, CDCl3)  28.37, 33.62, 
34.68, 39.37, 55.67, 80.85, 125.80, 126.28, 127.51, 127.66, 127.80, 128.17, 128.36, 
132.57, 133.59, 134.22, 156.07, 172.03, 175.67. 
 
Boc-Ala(L)-Bala-OH (2.38e) 
 
N
H
O
NHBoc
O
HO
 
 
Yield 519mg, 99.5%. 1H NMR (200 MHz, CDCl3)  1.34 (d, J=6.59 Hz, 3 H) 
1.43 (s, 9 H) 2.59 (d, J=5.13 Hz, 2 H) 3.54 (d, J=5.13 Hz, 2 H) 4.31 (s, 1 H) 5.44 - 5.77 
(m, 1 H) 7.19 - 7.41 (m, 1 H) 9.84 (s, 1 H). 13C NMR (50 MHz, CDCl3)  18.53, 28.20, 
33.66, 34.79, 49.90, 80.45, 155.83, 173.49, 175.46. 
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2.6.4 Tetrapeptide Synthesis. 
 
General synthesis of tetrapeptides 
 
To dipeptide carboxylic acid 2.38 (1mmol), the dipeptide ammonium salt 2.29 
(0.9mmol), HOBt (1.1mmol) and DIPEA (1.1mmol) in DCM (20mL) was added the 
EDCI (1.25mmol) slowly in small portions. This was left to stir at room temperature 
overnight. A solid precipitate formed and was filtered, washed with DCM, water and 
ether. For compounds that did not drop out of solution (2.39e-i) the DCM was simply 
washed with water, brine and dried with magnesium sulfate. The solvent was then 
removed to yield the product.  
 
Boc-Phe(L)-Bala-Phe(L)-Bala-OMe (2.39a) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
 
Yield 1.51g, 80.6%. MS: m/z calculated for C30H40N4O7 = 568.2897, actual m/z 
(M+Na) = 591.196. 1H NMR (200 MHz, CDCl3) 1.37 (s, 9 H) 2.09 - 2.27 (m, 1 H) 2.28 
- 2.48 (m, 3 H) 2.90 - 3.08 (m, 3 H) 3.08 - 3.22 (m, 1 H) 3.23 - 3.41 (m, 2 H) 3.45 - 3.60 
(m, 2 H) 3.63 (s, 3 H) 4.35 (q, J=6.96 Hz, 1 H) 4.50 (q, J=7.45 Hz, 1 H) 5.23 (d, J=7.69 
Hz, 1 H) 6.34 (s, 1 H) 6.54 (d, J=7.33 Hz, 1 H) 7.00 (s, 1 H) 7.16 - 7.35 (m, 10 H). 13C 
NMR (50 MHz, CDCl3)  28.24, 33.40, 34.80, 36.04, 36.30, 38.09, 38.34, 51.85, 53.42, 
55.32, 56.17, 80.04, 126.85, 127.06, 128.54, 128.72, 129.04, 129.30, 136.47, 136.73, 
136.80, 155.68, 171.15, 171.99, 172.83. 
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Boc-Phe(L)-Bala-Phe(D)-Bala-OMe (2.39b) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
 
Yield 0.9g, 57.3%. MS: m/z calculated for C30H40N4O7 = 568.2897, actual m/z 
(M+Na) = 591.196. 1H NMR (400 MHz, CDCl3)  1.39 (s, 9 H) 2.13 - 2.25 (m, 1 H) 2.28 
- 2.40 (m, 2 H) 2.40 - 2.50 (m, 1 H) 2.95 - 3.05 (m, 4 H) 3.31 - 3.43 (m, 3 H) 3.44 - 3.54 
(m, 1 H) 3.60 - 3.69 (m, 3 H) 4.22 (q, J=7.29 Hz, 1 H) 4.55 (q, J=7.16 Hz, 1 H) 5.14 (d, 
J=7.03 Hz, 1 H) 6.27 - 6.39 (m, 2 H) 6.46 (s, 1 H) 7.11 - 7.21 (m, 5 H) 7.21 - 7.31 (m, 5 
H). 13C NMR (101 MHz, CDCl3)  28.51, 33.71, 34.99, 35.65, 35.98, 38.35, 38.51, 
39.17, 52.06, 54.78, 80.25, 127.07, 127.25, 128.77, 128.89, 129.35, 129.57, 136.98, 
170.75, 171.38, 171.58, 172.91, 183.83. 
 
Boc-Phe(L)-Bala-Ala(L)-Bala-OMe (2.39c) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
 
Yield 81%.  1H NMR (400 MHz, CDCl3)  ppm 1.30 - 1.39 (m, 3 H) 1.39 - 1.44 
(m, 9 H) 2.22 - 2.34 (m, 1 H) 2.36 - 2.46 (m, 3 H) 3.03 (d, J=7.42 Hz, 2 H) 3.22 (s, 1 H) 
3.29 - 3.40 (m, 1 H) 3.46 - 3.56 (m, 1 H) 3.63 - 3.69 (m, 3 H) 3.78 (s, 1 H) 4.07 - 4.18 (m, 
1 H) 4.51 (q, J=7.42 Hz, 1 H) 5.20 (d, J=7.03 Hz, 1 H) 6.33 (s, 1 H) 6.77 (s, 1 H) 7.19 - 
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7.31 (m, 6 H) 13C NMR (101 MHz, CDCl3)  ppm 18.77, 28.31, 33.53, 34.83, 35.68, 
38.30, 50.14, 51.78, 54.48, 79.90, 126.91, 128.56, 129.15, 136.70, 155.41, 170.79, 
171.34, 172.56, 173.09,. 
 
Boc-Ala(L)-Bala-Ala(L)-Bala-OMe (2.39d) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O  
 
Yield 179mg, 38.8%. 1H NMR (200 MHz, DMSO-D6)  1.11 (d, J=2.93 Hz, 3 H) 
1.15 (d, J=2.93 Hz, 3 H) 1.36 (s, 9 H) 2.25 (t, J=6.78 Hz, 2 H) 2.39 - 2.46 (m, 1 H) 2.59 
(s, 1 H) 3.14 - 3.33 (m, 4 H) 3.58 (s, 3 H) 3.76 - 3.96 (m, 1 H) 4.09 - 4.26 (m, 1 H) 6.84 
(d, J=6.96 Hz, 1 H) 7.73 (t, J=5.13 Hz, 1 H) 7.92 (t, J=5.49 Hz, 1 H) 8.01 (d, J=7.33 Hz, 
1 H). 13C NMR (101 MHz, DMSO-D6)  18.16, 18.25, 28.15, 33.54, 34.68, 35.05, 35.16, 
48.08, 49.71, 31, 77.95, 158.65, 170.15, 171.54, 172.38, 172.53. 
Boc-Nap(L)-Bala-Nap(L)-Bala-OMe (2.39e) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
Yield 82.7%. 1H NMR (200 MHz, CDCl3)  1.27 - 1.38 (s, 9 H) 2.05 - 2.22 (m, 1 
H) 2.22 - 2.43 (m, 3 H) 3.06 (d, J=6.59 Hz, 2 H) 3.10 - 3.32 (m, 4 H) 3.39 - 3.46 (m, 3 H) 
3.47 - 3.70 (m, 2 H) 4.39 - 4.60 (m, 2 H) 5.31 (d, J=6.59 Hz, 1 H) 6.34 (s, 1 H) 6.48 (d, 
J=6.59 Hz, 1 H) 7.05 (t, J=5.49 Hz, 1 H) 7.33 (d, J=8.79 Hz, 1 H) 7.37 - 7.49 (m, 5 H) 
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7.58 (s, 1 H) 7.66 (s, 1 H) 7.70 - 7.75 (m, 3 H) 7.76 - 7.82 (m, 3 H). 13C NMR (101 MHz, 
CDCl3)  28.39, 33.57, 35.05, 36.23, 36.39, 38.41, 38.77, 51.88, 55.47, 56.27, 80.18, 
125.83, 125.95, 126.29, 126.44, 127.32, 127.70, 127.82, 127.94, 128.23, 128.31, 128.53, 
132.55, 133.58, 133.62, 134.40, 134.60, 155.94, 171.52, 172.16, 172.36, 172.81.  
 
Boc-Nap(L)-Bala-Nap(D)-Bala-OMe (2.39f) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
Yield 2.5g, 73.3%. 1H NMR (400 MHz, DMSO-D6)  1.22 (s, 9 H) 2.15 - 2.21 
(m, 1 H) 2.23 - 2.29 (m, 1 H) 2.33 - 2.42 (m, 2 H) 2.87 - 2.96 (m, 2 H) 3.06 - 3.17 (m, 4 
H) 3.54 (s, 3 H) 4.18 (td, J=9.22, 4.10 Hz, 1 H) 4.54 (td, J=8.49, 5.56 Hz, 1 H) 6.89 (d, 
J=8.49 Hz, 1 H) 7.37 - 7.48 (m, 7 H) 7.69 (s, 2 H) 7.78 (s, 2 H) 7.79 (d, J=5.56 Hz, 3 H) 
7.84 (d, J=8.49 Hz, 2 H) 7.92 (t, J=5.42 Hz, 1 H) 8.10 (t, J=5.42 Hz, 1 H) 8.20 (d, J=8.20 
Hz, 1 H). 13C NMR (101 MHz, DMSO-D6)  28.07, 33.47, 34.74, 35.08, 35.29, 37.84, 
38.04, 51.36, 53.99, 55.72, 78.00, 125.35, 125.93, 127.31, 127.37, 127.46, 127.81, 
131.80, 132.94, 135.63, 135.98, 155.18, 170.24, 171.16, 171.47, 171.66. 
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Boc-Phe(L)-Bala-Nap(L)-Bala-OMe (2.39g) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
Yield 700mg, 67.7%. MS: m/z calculated for C34H42N4O7 = 618.3053, actual m/z 
(M+Na) = 641.277. 1H NMR (200 MHz, CDCl3)  1.36 (s, 9 H) 2.13 - 2.28 (m, 1 H) 2.28 
- 2.45 (m, J=4.03 Hz, 3 H) 2.96 (s, 1 H) 3.06 - 3.29 (m, 5 H) 3.43 - 3.50 (m, 3 H) 3.51 - 
3.73 (m, 2 H) 4.28 - 4.46 (m, 1 H) 4.62 (q, J=7.20 Hz, 1 H) 5.25 (d, J=7.69 Hz, 1 H) 6.42 
(s, 1 H) 6.67 (d, J=6.96 Hz, 1 H) 7.08 (s, 1 H) 7.16 - 7.39 (m, 5 H) 7.40 - 7.53 (m, 3 H) 
7.64 (s, 1 H) 7.79 (d, J=6.96 Hz, 3 H). 13C NMR (101 MHz, CDCl3)  28.46, 33.57, 
35.05, 36.26, 36.50, 38.57, 51.93, 55.51, 56.35, 80.22, 126.02, 126.52, 127.03, 127.30, 
127.73, 127.86, 127.97, 128.65, 128.73, 129.52, 132.61, 133.62, 134.36, 137.05, 155.96, 
171.45, 172.20, 172.26, 172.89. 
 
Boc-Ala(L)-Bala-Nap(L)-Bala-OMe (2.39h) 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
Yield 720mg, 89.1%. 1H NMR (400 MHz, CDCl3)  1.32 (d, J=7.42 Hz, 3 H) 
1.37 - 1.45 (m, 9 H) 2.20 - 2.47 (m, 4 H) 3.15 - 3.27 (m, 4 H) 3.43 - 3.48 (m, 3 H) 3.48 - 
3.57 (m, 1 H) 3.63 - 3.73 (m, 1 H) 4.11 - 4.21 (m, 1 H) 4.70 (q, J=7.42 Hz, 1 H) 5.50 (d, 
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J=7.03 Hz, 1 H) 6.90 (t, J=5.47 Hz, 1 H) 7.20 (d, J=7.42 Hz, 1 H) 7.32 (d, J=8.20 Hz, 1 
H) 7.38 - 7.47 (m, 3 H) 7.61 (s, 1 H) 7.72 (t, J=4.49 Hz, 2 H) 7.73 - 7.78 (m, 1 H). 13C 
NMR (101 MHz, CDCl3)  18.46, 28.48, 33.62, 35.03, 36.35, 36.46, 38.51, 50.64, 51.82, 
55.59, 79.97, 125.87, 126.37, 127.38, 127.65, 127.76, 127.91, 128.41, 132.51, 133.54, 
134.48, 155.92, 171.81, 172.40, 172.68, 173.79. 
Boc-Phe(D)-Bala-Nap(L)-Bala-OMe (2.39i) 
 
NH
O
H
N
O
O
H
N
O
NHBoc
O
 
Yield 1.62g, 94.2%. 1H NMR (400 MHz, CDCl3)  1.31 (s, 9 H) 2.26 (m, 2 H) 
2.33 - 2.41 (m, 2 H) 2.89 - 3.01 (m, 2 H) 3.14 (d, J=7.42 Hz, 2 H) 3.19 - 3.31 (m, 2 H) 
3.37 (s, 2 H) 3.42 - 3.53 (m, 4 H) 4.40 (d, J=6.25 Hz, 1 H) 4.76 (q, J=7.29 Hz, 1 H) 5.57 
(d, J=7.03 Hz, 1 H) 6.89 (s, 1 H) 6.97 (s, 1 H) 7.11 - 7.17 (m, 3 H) 7.19 - 7.27 (m, 3 H) 
7.36 - 7.48 (m, 2 H) 7.56 (s, 1 H) 7.66 - 7.77 (m, 3 H). 13C NMR (101 MHz, CDCl3)  
28.41, 33.65, 35.05, 35.66, 35.72, 39.13, 39.50, 51.82, 54.78, 55.90, 79.91, 125.84, 
126.33, 126.82, 127.52, 127.70, 127.75, 128.01, 128.32, 128.53, 129.53, 132.50, 133.54, 
134.33, 137.08, 155.53, 171.05, 171.27, 171.83, 172.48. 
2.6.5 Tetrapeptide Ammonium Salt Synthesis. 
 
The tetrapeptide (1mmol) was dissolved in methanol (1 mL) and HCl in Methanol 
(1mL, 2mmol) or TFA (1ml, 20% in DCM) was added. This was stirred for 20-60 
minutes until all starting material was consumed as shown by TLC and the solvent 
removed in vacuo. 
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H-Phe(L)-Bala-Phe(L)-Bala-OMe (2.34a) 
 
NH
O
H
N
O
O
H
N
O
NH3.TFA
O
 
 
Yield 70%. MS: m/z calculated for C25H32N4O5 = 468.2373, actual m/z (M+Na) = 
491.105. 1H NMR (200 MHz, CD3OD)  2.14 - 2.32 (m, 1 H) 2.33 - 2.53 (m, 3 H) 2.78 - 
3.20 (m, 5 H) 3.33 - 3.44 (m, 3 H) 3.64 (s, 3 H) 3.97 (t, J=7.33 Hz, 1 H) 4.50 (dd, J=8.42, 
6.59 Hz, 1 H) 7.10 - 7.44 (m, 10 H). 13C NMR (50 MHz, CD3OD)  34.40, 35.85, 36.19, 
36.92, 38.62, 39.06, 52.22, 55.87, 56.24, 127.85, 128.86, 129.48, 130.10, 130.25, 130.46, 
135.67, 138.31, 169.62, 173.22, 173.71, 173.78, 
 
H-Phe(L)-Bala-Phe(D)-Bala-OMe (2.34b) 
 
NH
O
H
N
O
O
H
N
O
NH3.TFA
O
 
 
Yield 262mg, 80.5% 1H NMR (400 MHz, D2O)  2.27 - 2.35 (m, 3 H) 2.37 - 2.41 
(m, 1 H) 2.91 - 3.01 (m, 2 H) 3.09 (d, J=7.42 Hz, 2 H) 3.17 - 3.29 (m, 2 H) 3.29 - 3.41 
(m, 2 H) 3.56 - 3.67 (m, 3 H) 4.08 (t, J=7.42 Hz, 1 H) 4.45 (t, J=7.61 Hz, 1 H) 7.22 (t, 
J=7.22 Hz, 4 H) 7.27 - 7.38 (m, 6 H). 13C NMR (101 MHz, CD3OD)  34.40, 36.06, 
36.19, 36.95, 38.60, 39.02, 52.18, 55.83, 56.25, 127.79, 128.78, 129.44, 130.03, 130.24, 
130.48, 135.70, 138.28, 169.53, 173.17, 173.61, 173.71. 
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H-Nap(L)-Bala-Nap(L)-Bala-OMe (2.34c) 
 
NH
O
H
N
O
O
H
N
O
NH3.Cl
O
 
 
Yield 424mg, 93.6% MS: m/z calculated for C33H36N4O5 = 568.2686, actual m/z 
(M+Na) = 591.248. 1H NMR (200 MHz, CD3OD)  2.12 - 2.30 (m, 1 H) 2.30 - 2.50 (m, 
3 H) 3.04 (dd, J=13.92, 8.79 Hz, 1 H) 3.13 - 3.26 (m, 4 H) 3.33 - 3.46 (m, 3 H) 3.48 - 
3.55 (m, 3 H) 4.12 (m, 1 H) 4.61 (dd, J=8.61, 6.41 Hz, 1 H) 7.31 - 7.50 (m, 6 H) 7.68 (s, 
1 H) 7.71 - 7.88 (m, 7 H) 13C NMR (50 MHz, CD3OD)  34.34, 35.96, 36.17, 36.92, 
38.62, 39.09, 52.19, 55.71, 56.20, 126.58, 127.03, 127.09, 127.36, 128.11, 128.35, 
128.53, 128.65, 128.70, 128.85, 128.99, 129.56, 129.72, 133.01, 133.72, 134.11, 134.74, 
134.83, 135.78, 138.66, 169.53, 173.16, 173.55, 173.60. 
 
H-Ala(L)-Bala-Phe(L)-Bala-OMe (2.34d) 
 
NH
O
H
N
O
O
H
N
O
NH3.TFA
O
 
 
Yield 805mg, 95%. MS: m/z calculated for C19H28N4O5 = 392.206, actual m/z 
(M+Na) = 415.033. 1H NMR (200 MHz, CD3OD)  1.24 (d, J=6.96 Hz, 3 H) 2.09 - 2.30 
(m, 4 H) 2.66 (dd, J=12.45, 8.79 Hz, 1 H) 2.85 (dd, J=13.74, 6.78 Hz, 1 H) 3.07 - 3.27 
(m, 4 H) 3.42 (s, 3 H) 3.67 (q, J=6.96 Hz, 1 H) 4.31 (m, 1 H) 6.93 - 7.10 (m, 5 H). 13C 
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NMR (50 MHz, CD3OD)  17.56, 34.40, 36.20, 37.03, 38.99, 50.25, 52.22, 56.25, 
127.79, 129.43, 130.24, 138.31, 170.99, 173.28, 173.62, 173.74. 
 
H-Phe(D)-Bala-Nap(L)-Bala-OMe (2.35e) 
 
NH
O
H
N
O
O
H
N
O
NH3.HCl
O
 
 
Yield 1.5g, 95% 1H NMR (400 MHz, CD3OD)  2.27 - 2.38 (m, 4 H) 3.00 (dd, 
J=14.06, 8.20 Hz, 1 H) 3.04 (dd, J=13.67, 8.59 Hz, 1 H) 3.16 (dd, J=14.06, 7.03 Hz, 2 H) 
3.24 (dd, J=14.06, 7.42 Hz, 2 H) 3.32 - 3.43 (m, 4 H) 3.53 - 3.56 (m, 3 H) 4.00 (t, J=7.42 
Hz, 1 H) 4.62 (dd, J=8.59, 6.64 Hz, 1 H) 7.24 - 7.34 (m, 5 H) 7.34 - 7.40 (m, 2 H) 7.41 - 
7.44 (m, 3 H) 7.69 (s, 1 H) 7.73 - 7.81 (m, 4 H). 13C NMR (101 MHz, CD3OD)  34.36, 
35.90, 36.20, 36.89, 38.53, 39.20, 52.13, 55.83, 56.21, 126.67, 127.12, 128.35, 128.57, 
128.74, 128.87, 128.91, 129.07, 129.99, 130.45, 133.85, 134.86, 135.61, 135.82, 169.61, 
173.26, 173.69, 173.74. 
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H-Nap(D)-Bala-Nap(L)-Bala-OMe (2.35f) 
 
NH
O
H
N
O
O
H
N
O
NH3.Cl
O
 
 
Yield 481mg, 100% MS: m/z calculated for C33H36N4O5 = 568.2686, actual m/z 
(M+Na) = 591.248. 1H NMR (200 MHz, CD3OD)  2.12 - 2.30 (m, 1 H) 2.30 - 2.50 (m, 
3 H) 2.95 - 3.12 (m, 1 H) 3.13 - 3.26 (m, 4 H) 3.33 - 3.46 (m, 3 H) 3.48 - 3.55 (m, 3 H) 
4.06 - 4.19 (m, 1 H) 4.61 (dd, J=8.61, 6.41 Hz, 1 H) 7.31 - 7.50 (m, 7 H) 7.68 (s, 1 H) 
7.71 - 7.88 (m, 6 H). 13C NMR (50 MHz, CD3OD)  34.34, 35.96, 36.17, 36.92, 38.62, 
39.09, 52.19, 55.71, 56.20, 126.58, 127.03, 127.09, 127.36, 128.11, 128.35, 128.53, 
128.65, 128.70, 128.85, 128.99, 129.56, 129.72, 133.01, 133.72, 134.11, 134.74, 134.83, 
135.78, 138.66, 169.53, 173.16, 173.55, 173.60.  
, 
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CHAPTER 3 - Cyclization of Linear Peptides: - Isolation, 
Electrochemical Properties and Binding Studies of the 
Generated Nickel Cyclopeptide Complexes. 
3.1 Introduction. 
 
After the synthesis of linear peptides 2.29a-e and 2.35a-f we wished to utilize 
Beck’s cyclization protocol1 to generate several cyclopeptide metal complexes (Figure 
3.1), analyse them for stereochemical integrity and perform binding tests on them with 
aromatic substrates to see if they would undergo π-π or CH-π interactions.  
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Figure 3.1: - Cyclization of a dipeptides (2.29) and tetrapeptides (2.35) utilizing 
Beck’s metal templated technique. 
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Very little work has been performed on the metal assisted cyclization of peptides. 
Most notably several papers from Beck et al1 describe the synthesis of 14 membered ring 
structures from linear dipeptides utilizing Pd, Ni, and Cu metal templates. The 14 
membered rings that we were trying to synthesize are attainable using all three of the 
metals in good yield (Figure 3.1). In general metal templated cyclizations have been 
shown to be an effective method for the generation of cyclic systems2, open ligand 
systems3 and even for the generation of small cyclic rings4. These cyclizations generally 
occur though some kind of condensation reaction such as imine formation and are 
favored over the linear condensation (polymerization) due to the proximity of the reactive 
centers to one another. Complexes incorporating amido-metal bonds have been 
developed by Burrows et al for use as oxidation catalysts, and disulphide cross linkers5.  
Smaller ring sizes such as 12-14 membered rings were synthesized utilizing the 
nickel template as the smaller ionic radius of nickel(II) (63pm) allows the head to tail 
cyclization to occur (3.4 and 3.5b). Larger ring sizes such as 16-18 membered rings are 
accommodated only by the Pd(II) ion, ionic radius 78pm (3.6-3.7) (Figure 3.2). 
 
n = 0 M = Ni (3.4)
n = 1 M = Pd (3.5a, Ni(3.5b), Cu(3.5c)
n = 2 M = Pd(3.6)
n = 3 M = Pd(3.7)
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O
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n
n
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3.3 3.4-3.7
2) PPNCl
-2 2PPN+
 
Figure 3.2: - Metal templated cyclizations: - ring sizes vs. metal template used. 
 
In all cases high dilution of the reaction is not necessary as each peptide wraps 
around a metal ion, thus inducing a close proximity of head to tail (Figure 3.3). The 
formation of intramolecular 6-exo-trig cyclization products as seen by J. Jurczak et al6 is 
negated by the formation of a stable complex with the metal. This prevents the amide 
carbonyl from being attacked by locking the linear peptide in a planar conformation. 
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Figure 3.3: - Cyclization of open chain nickel peptide complex by “head to tail” 
amide bond formation. 
 
C2, C1 and Ci symmetric nickel cyclopeptide complexes can be synthesized using 
tetrapeptide-starting materials1c (2.39a-e). Each tetrapeptide has stereochemical 
information “dialed in” during its synthesis (depending on the R or S starting amino acid 
(2.36) used). Thus enabling a wide range of side arms and stereochemistry’s to be 
incorporated into the nickel cyclopeptide complex and ultimately the cyclam molecules. 
The position of the side arms in 3.1-3.4 (Figure 3.1) can be controlled by the 
cyclopeptides generated during the linear peptide cyclization. The formed cyclopeptide 
can be reduced to form the desired cyclams (Figure 2.10). 
 
3.1.1 Dipeptide Cyclizations. 
 
Perhaps even more useful than tetrapeptide cyclization is the fact that dipeptide 
esters can be cyclized to form the 14-membered cyclopeptides1 (Figure 4.8). In this case 2 
equivalents of the dipeptide form a complex with the metal ion. Here two head to tail 
amide bond formations occur to yield the cyclopeptide complex. 
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Figure 3.4: - (a) Crystal structure of Pd-(Bis-dipeptide) complex (3.8)1c (b) Dipeptide 
metal complex cyclization of 3.8 to yield 3.6 (c) Crystal structure of Pd-cyclopeptide 
complex. A sheet structure held together by hydrogen bonding to water molecules 
(PPN cations removed for clarity) as characterized by Beck1c . 
 
The cyclization of dipeptide complexes leads to the formation of C2 symmetric 
complexes only1c. The dipeptide has only one R group arranged in one stereochemistry 
(determined by the starting amino acid 2.36). Cyclization of this peptide leads to the 
formation of the C2 symmetric complex with a rotation axis though the metal. 
Most of the previous 14-membered ring cyclopeptides synthesized utilizing the 
metal templated techniques are simple C2 symmetric complexes derived from β-alanine 
and natural amino acids such as alanine, phenylalanine and leucine1. Yields after 
purification via recrystallization with PPN range from 17-96%. 
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3.2 Dipeptide Complex Formation. 
 
Initial trials into cyclopeptide metal complex formation focused on cyclization 
utilizing Na2PdCl4 and the MeO-βala-Phe-NH2.HCl dipeptide ammonium salt as 
described by Beck1. Under inert conditions using dry methanol Pd black would form after 
thirty minutes in the presence of NaOMe. Isolation and characterization of the dipeptide 
Pd complex or the cyclopeptide Pd complex proved impossible (Figure 4.9). Impure Pd 
salts or NaOMe used may be factors in explaining why this procedure was irreproducible 
in my hands. 
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Figure 3.5: - Failed attempts at dipeptide and cyclopeptide complex formation with 
Pd salts following Beck’s method1. 
 
 Due to the failure with PdCl2, Ni(II) dipeptide complexes were synthesized. The 
product drops out of solution after ten minutes at room temperature and can be 
crystallized from methanol to give X-ray quality crystals (Figure 3.7). Unfortunately 
these compounds tend to be highly insoluble at room temperature in MeOH, EtOH, ether, 
water, DCM, chloroform, acetonitrile, toluene and DMF. Some small solubility was 
noted in DMSO. 
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Figure 3.6: - Synthesis of dipeptide nickel complexes. 
 
Table 3.1: - Yields of dipeptide nickel complexes. 
R Compound 
Number 
Yield% 
Ph 3.1a 58 
4Me-Ph 3.1b 18 
2-Nap 3.1c 28.5 
 
3.2.1 X-ray Structures of Dipeptide Nickel Complexes. 
 
Several crystal structures indicate that the stereocenters on the dipeptides 
withstood the coupling reaction; Boc removal and the base promoted nickel complex 
formation (Figure 3.7). 
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(a)      b) 
Figure 3.7: - (a) X-ray crystal structure of trans-Bis(4-methyl-phenyl-dipeptide 
ester)NiII complex (3.1b). (b) X-ray crystal structure of trans-Bis(phenyl-dipeptide 
ester)NiII complex (3.1a). 
 
 
 
 
Table 3.2: - Table of selected bond lengths and angles for complexes 3.1a and 3.1b 
Selected Bond Lengths 
complex 3.1a 
Selected Bond Lengths complex 
3.1b 
Ni(1)-N(23) (1.882Å), Ni(1)-N(12) 
(1.909Å), C(11)-O(11) (1.250Å), C(11)-
N(23) (1.329Å), C(11)-C(12) (1.520Å), 
C121-N121, (1.479Å). 
N(1)-Ni(1) (1.892Å), N(2)-Ni(1) (1.895Å), 
N(3)-Ni(1) (1.896Å), N(4)-Ni(1) (1.894Å), 
C(19)-N(4) (1.334Å), C(5)-N(1) (1.330Å), 
C(5)-C(6)  (1.508Å), C(5)-O(1) (1.252Å), 
C(19)-C(20) (1.516Å), C(19)-O(4) 
(1.250Å), C(17)-O(5) (1.199Å) 
Selected Bond Angles 3.1a Selected Bond Angles 3.1b 
N23-Ni(1)-N23 (179.26o), N(23)-Ni(1)-
N(12-1) (95.53o), N(23-1)-Ni(1)-N(12-
1) (85.14o), N(23-2)-Ni(1)-N(12-2) 
(84.87o), N(23-1)-Ni(1)-N(12-2) 
(94.47o), N(12-1)-Ni(1)-N(12-2) 
(178.85o). 
N(1)-Ni(1)-N(4) (177.30o), N(1)-Ni(1)-N(2) 
(85.14o), N(4)-Ni(1)-N(2) (95.13o), N(1)-
Ni(1)-N(3) (95.98o), N(4)-Ni(1)-N(3) 
(83.70o), N(2)-Ni(1)-N(3) (178.37o) 
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Selected Torsion Angles 3.1a Selected Torsion Angles 3.1b 
Ni(1)-N(12)-C(12)-C(11) (19.26o), 
N(12)-C(12)-C(11)-N(23) (12.33o), 
Ni(1)-N(23)-C(11)-C(12) (-0.44o), 
Ni(1)-N(23)-C(11)-O(11) (176.68o), 
 
Ni(1)-N(1)-C(5)-C(6) (-32.61o), N(1)-C(5)-
C(6)-N(2) (20.02o), Ni(1)-N(2)-C(6)-C(5) (-
28.52o), Ni(1)-N(1)-C(5)-O(1) (-179.72o), 
N(3)-C(20)-C(19)-N(4) (13.81o), 
 
 
 
Interestingly the packing of the Ni complex 3.1a show an N-H--O hydrogen bond 
(2.014Å) to other complex molecules through the carbonyl in the five membered ring and 
the NH2 in the five membered ring (Figure 3.8). This differs from Beck’s findings as the 
complexes in which case hydrogen bonding is seen through bridging water molecules and 
the ester as in the Pd dipeptide complexes1a (Figure 3.9).  
 
 
Figure 3.8: - Bridging N-H---O hydrogen bonding between two molecules of 3.1a as 
seen in the crystal structure. 
 
Figure 3.9: - Part of the extended chain formed by Pd(Bis-dipeptide) complexes. 
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The crystal structures obtained show that stereochemical integrity is maintained in 
the presence of the base and nickel, although this chemistry is performed at room 
temperature and full cyclization occurs at higher temperatures. The dipeptide complex 
previously obtained by Beck (Figure 3.9) has no stereocenters that could possibly 
undergo racemization during the reaction thus this data is useful as stereochemical 
integrity is a priority in the synthesis of the cyclopeptides. 
 
3.2.2 Electrochemical Data For A Dipeptide Complex. 
 
Electrochemical data for the dipeptide complex 3.1a suggests that the complex 
dissociates upon oxidation from Ni(II) to Ni(III) (+0.773V) with no reverse wave seen 
(Figure 4.13). The uncyclized complexes are entropically less stable than that of a fully 
cyclized complex7. Further isolation of these intermediates was not pursued. 
 
Figure 3.10: - [NiIIL’2] (3.1a) < 2.3 mM (not dissolved completely in DMSO)- E (NiIIL’2 
to NiIIIL’2) = +0.773 V vs. Ag/AgCl  (irreversible, and thus cannot determine E0.).   
 
3.3 Isolated Nickel Cyclopeptide Complexes Derived From Linear 
Tetrapeptides.  
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Cyclization of dipeptides, in solution, using the metal template procedure (Figure 
3.2) gives 75-80% pure crude nickel complexes after the reaction (impurities may include 
uncyclized starting materials and saponified dipeptides). In these cases pure 
Bis(triphenylphosphine)iminium (PPN) or Ca salts of these compounds were never 
isolated. The amount of impurities in the product was simply too great to allow 
crystallization to occur. Other purification techniques including column chromatography, 
HPLC (C18 and cyano), and ion exchange chromatography proved as fruitless as the 
crystallization in the isolation of the complexes.  
To give an improved chance of isolating pure complexes the cyclization of 
tetrapeptides were performed (Figures 3.11). Tetrapeptides need only to undergo one 
amide bond-forming step, which is more efficient than the formation of two new amide 
bonds as in the dipeptide cyclization. This would lead to fewer side products (including 
saponification of the ester).  
Tetrapeptide cyclization reactions worked fairly well after several modifications 
to Beck’s original procedure, and it became obvious that this methodology was 
significantly cleaner than that of the dipeptide cyclization for C2 symmetric complexes 
(crude 1HNMR showing purities between 70-90%).  
Cyclizations required between 1.2 and 2eq of base per NH to minimize the 
amount of unreacted starting material and complete the cyclization, whereas Beck used 
1eq of base per NH. Beck’s isolated yields range between 17-94% whilst yields obtained 
under the modified conditions ranges from 8-47.5% for isolated complexes. 
Adjustments were also made to the crystallization procedure. Beck’s papers 
suggest that simply mixing the crude Na salt with CaCl2 or PPN-Cl then adding water 
would give pure crystalline product through simply crashing it out of solution. This 
procedure failed to give any pure product in my hands with lots of impurities trapped in 
the precipitate isolated from these procedures. 
In order to achieve purification the crude Na salt was mixed with 
Bis(triphenylphosphine)iminium chloride (PPN-Cl) in a mixture of acetone:methanol 
(1:1, roughly 10mL per 0.1mmol) and water was slowly added until the mixture started to 
become turbid. The flask was then placed in the fridge overnight where crystallization 
occurred giving a 8-47% yield of very pure PPN salts generated from these slow 
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crystallization conditions (Figure 3.11, Table 3.2). Beck’s procedure involved adding the 
PPN-Cl to his reaction crude reaction mixture in methanol then diluting with water to 
obtain his crystals. This procedure gave impure sandy solids in my hands and sometimes 
just the PPN-Cl was recovered, even when attempted under inert conditions. 
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Figure 3.11: - Cyclization of tetrapeptides 2.34a-f using a nickel template. 
 
Table 3.3: - Complexes synthesized and isolated from tetrapeptides. 
Compound 
Name/Number 
Yield % 
Compound 
Name/Number 
Yield % 
[ -(Phe(L)-ßala-
Phe(L)-ßala)-Ni(II)]-2 
(3.2a) 
47.5 
[ -(2-Nap(L)-ßala-2-
Nap(L)-ßala)-Ni(II)]-2 
(3.2d) 
8 
[ -(Ala(L)-ßala-
Ala(L)-ßala)-Ni(II)]-2 
(3.2b) 
38 
[ -(2-Nap(L)- ßala-2-
Nap(D)-ßala)-Ni(II)]-2 
(3.2e) 
30 
[ -(Phe(L)-ßala-
Ala(L)-ßala)-Ni(II)]-2 
(3.2c) 
26.8 
[ -(Phe(L)-ßala-
Phe(D)-ßala)-Ni(II)]-2 
(3.2f) 
28.5 
 
3.3.1 NMR Data Showing Cyclopeptide Nickel Complex Formation from 
Solution Phase Reactions. 
 
The solution phase cyclization reaction was followed by 1HNMR and takes 
between 5-24 hours to complete using 2eq of NaOMe per NH bond. Larger naphthyl side 
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groups take longer to cyclize than the simple natural amino acids and are harder to 
crystallize.  
The crystallization of the products 3.2a-f occurs over a period of 24 hours at 5oC 
using a mixture of acetone:MeOH and water and leads to crystals which are 1HNMR pure 
(Figure 4.15) and suitable for X-ray crystallography.  
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Figure 3.12: - (a) NMR of complex 3.2a (b) COSY of complex 3.2a. 
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The NMR and COSY of complex 3.2a allow us to identify each of the signals 
within the spectra. The multiplet at 4.14ppm, corresponds to the alpha C-H next to the 
phenyl arm and interacts with the protons at 2.79ppm (dd) and the protons at 2.99ppm 
(dd), both the benzyl C-H’s. Interactions between the C-H groups at 3.09ppm and the 
multiplets in the 2.1-2.3ppm regions and the multiplet at the 2.82ppm show these to be 
the C-H groups in the β-alanine part of the ring. Symmetry is maintained in the molecule 
that doubles the integration for each peak.  
3.3.2 Solid Phase Cyclization Reactions. 
 
Although cyclizations of compounds on solid support have previously been 
demonstrated utilizing cyclization release mechanisms8 and external stimuli such as 
enzymes9 or electrocycliztion10, little work has been performed on metal mediated 
cyclizations on solid support. We wished to cyclize the peptides synthesized on resin to 
generate cyclopeptide complexes. 
When the tetrapeptides on resins are treated with a solution of Ni(II)X2 (X = ClO4-, 
Cl-) or Ni(II)(NH3)6 in the presence of a base (NaOMe, TEA) the resin changes color to a 
light yellow. It would appear that the peptide on the resin is coordinating to the metal 
center in a similar way to the metals in the solution phase reactions. Further treatment of 
these metalated resins, after extensive washing, with NaOMe at 60oC for 12 hours, leads 
to the formation of an orange solution and a lightening of the hydroxymethyl resin 
(Figure 3.13).  
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Figure 3.13: - On resin tetrapeptide cyclization. 
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Purification methods including HPLC’s utilizing C18 (reverse phase) columns 
proved ineffective at purifying the materials as they eluted with the solvent front.  Ion 
exchange columns, amine terminated column, normal phase silica column 
chromatography and recrystallization from various solvents also proved ineffective in the 
purification of the compounds. Crystallization induced by PPN addition analogous to the 
solution studies in figure 3.11 was not attempted. 
Although these compounds were not purified their presence was confirmed by 
MALDI mass spectroscopy and the major peaks correspond to either the main mass of 
the complex or a fragment (minus acid sensitive protecting groups) (Table 4.3). 
Mechanistic studies for the cyclization/release of the nickel complexes were not 
performed however could proceed through one of two routes, cyclization-release or 
transesterification-cyclization (Figure 3.14) 
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Figure 3.14: - The two possible mechanisms for cyclization products obtained from 
the cyclization of tetrapeptides on resins. 
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Table 3.4: - Mass spectrum results for on resin cyclizations. 
Compound 
Name/Number 
Mass Peak(s) m/z 
Compound 
Name/Number 
Mass Peak(s) 
[ -(His(L)(Trt)- 
ßala-Phe(L)- 
ßala)-Ni(II)]-2 
(3.2g) 
Calculated for 
C40H36N6NiO4 = 
722.215 
Actual = 725.564 
(M+3H+) 
483.279 (M-Trt +3H+) 
[ -(Tyr(L)(tBut)- 
ßala-Phe(L)- 
ßala)-Ni(II)]-2 
(3.2j) 
Calculated for 
C28H32N4NiO5 = 
562.173 
Actual = 565.145 
(M-+3H+) 
509.042 (M-tBut + 
3H+) 
[ -
(Asp(L)(tBut)- 
ßala-Phe(L)- 
ßala)-Ni(II)]-2 
(3.2h) 
Calculated for 
C23H28N4NiO6 = 
514.136 
Actual = 461.254 
(M- tBut +3H+) 
401.153  
(M-Asp +2H+) 
[ -(Phe(L)- ßala-
Phe(L)- ßala)-
Ni(II)]-2 
(3.2a) 
Calculated for 
C24H24N4NiO4 = 
490.115 
Actual = 493.066 (M 
+ 3H+) 
[ -
(Lys(L)(Boc)- 
ßala-Phe(L)- 
ßala)-Ni(II)]-2 
(3.2i) 
Calculated for 
C26H55N5NiO6 = 
571.194 
Actual = 574.465 
(M+3H+) 
474.322 (M-Boc 
+3H+) 
[ -(Ser(L)(tBut)- 
ßala-Phe(L)- 
ßala)-Ni(II)]-2 
(3.2k) 
Calculated for 
C22H28N4NiO5 = 
486.141 
Actual = 
489.366(M+3H+) 
433.254 (M – tBut 
+3H+)  
 
Several other metals (Fe, Zn, Pd) were utilized in the cyclization reaction but 
failed to produce any sign of the cyclopeptide complex under inert conditions in a trident 
synthesizer. The Pd templated cyclization did not occur as in Beck’s solution phase 
synthesis for dipeptides1. This result is somewhat perplexing but may have been a result 
of impure PdCl2. Iron and zinc cyclizations attempted in solution phase did not produce 
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cyclic complexes. This may be due to an incompatibility with the ionic radius of these 
metals and the 14 membered rings formed. The failed cyclizations also failed to show any 
sign of the tetrapeptide starting material by MS. These cases may show that complexation 
of the nickel is required for the cyclization or release of the tetrapeptide to occur. Simple 
transesterification/saponification was not observed under these basic conditions or in the 
presence of these Lewis acids (Fe, Pd, Zn). 
This work was interesting as it shows that rapid generation of the cyclopeptide 
complexes can be achieved utilizing solid phase bound tetrapeptides. Our work on 
tetrapeptides generated in the solution phase showed that the cyclopeptides could be 
isolated by treatment of the impure nickel cyclopeptide complex with HCl. This 
methodology could be applied to the impure peptide complexes isolated from on resin 
cyclizations. 
 
3.3.3 Stereochemical Integrity: - Racemization of Peptides/Peptide Complexes 
and X-ray Crystal Structure analysis of Cyclopeptide Nickel Complexes. 
 
Beck’s previously synthesized cyclopeptide complexes were never fully 
characterized in terms of their stereochemistry. Only 1HNMR, 13CNMR, IR and MS were 
performed on Beck’s isolated products, non of which allow for the determination of the 
absolute stereochemistry in the case of the C2 symmetric complexes he hoped to generate. 
If racemization occurred Ci symmetric complexes would be generated and would have 
1HNMR data very similar to the C2 symmetric complexes. When dealing with strong 
bases at elevated temperatures it is possible to racemize α-protons on amino acid and 
peptides11. 
Our own studies at racemization of tetrapeptides show that the aromatic phenyl 
side chain can stabilize the formation of an anion at the alpha position in the side chain. 
H/D exchange reactions in CD3OD over 28 hours under basic conditions for tetrapeptide 
H-Ala(L)-ßala-Phe(L)-ßala-OMe (2.34d). The alpha proton on the phenyl side chain 
(4.5ppm) exchanges whilst the alpha CH from the alanine shows no racemization (this 
can be seen in the retention of the doublet at 1.2ppm) (Figure 3.15). This racemization is 
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due to the electron withdrawing nature of the phenyl group. The phenyl increases the 
acidity (decreases the pKa) of the alpha proton and also provides some inductive 
stabilizing effect for the anion formed after deprotonation. The methyl group on alanine 
is an electron donor, inductively, and causes a pKa increase in the alpha proton when 
compared to the phenyl side group, making it more difficult to deprotonate. The alpha 
protons on the β alanine also undergo racemization under these conditions (2.3-2.5ppm), 
however due to the lack of a stereocenter this is of little concern in the stereochemical 
integrity of the final product. 
This racemization of phenylalanine was very worrisome for the maintenance of 
stereochemical integrity in our aromatically functionalized systems. If racemization can 
occur at the alpha position of phenylalanine then it is likely that the effect will be 
increased as the electron withdrawing nature of the side arm is increased, meaning that 2-
naphthylalanine would racemize more quickly than phenyl alanine under basic conditions 
combined with heat.  In this case stereochemical control would be lost and racemic 
mixtures would be isolated as our product. 
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Figure 3.15: - (1) HCl salt of MeO-Bala-Phe-Bala-ala-NH2 (blue), (2) NaOMe added 
to the MeO-Bala-Phe-Bala-ala-NH2 salt t=0 (green), (3) NaOMe plus  MeO-Bala-
Alpha CH 
from 
phenylalanine 
Benzyl CH2 from 
phenylalanine 
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The doublet 
remains in tact 
O
O
N
H
O
H
N
O
H
N
O
NH2
 115 
Phe-Bala-ala-NH2 t= 4 hours (red), (4) NaOMe plus  MeO-Bala-Phe-Bala-ala-NH2 
t= 28 hours (purple). 
 
A racemization experiment was carried out on the complex formed from the 
tetrapeptide 3.2c after cyclization. This experiment showed that cyclization of the 
complexes leads to a stereochemically stable complex even after 80 hours under basic 
conditions with heat (Figure 3.16). 
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Figure 3.16: - NaOMe plus the cyclopeptide nickel complex 3.2c. (1) T=0 (blue), (2) 
T=1h 45m (green),  (3) t=24h (red), (4) t=80h (black). 
 
 Dipeptide complex formation occurs in ten minutes under basic conditions with 
no loss of stereochemistry at RT, and a similarly rapid tetrapeptide complex formation is 
expected, followed by cyclization.  
Whilst the cyclopeptide nickel complex 3.2c does not undergo proton exchange 
the intermediates before cyclization may still do so. The only way to fully characterize 
the stereochemical information on nickel cyclopeptide complexes is to grow crystals and 
analyse them by X-ray crystallography.  
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N
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3.3.3.1 [–(βala-Phe(L)-βala-Phe(L))-]Ni 2PPN (3.2a) Crystal Structure. 
 
X-ray data for 3.2a was generated from isolated crystals and is shown in figure 
3.17. 
 
Figure 3.17: - Crystal structure of the 3.2a (PPN and solvent molecules removed for 
clarity). 
 
 
Figure 3.18: - Crystal structure of 3.2a showing the intramolecular π-CH bond (PPN 
and solvent molecules remove for clarity). 
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(a) (b) 
Figure 3.19:- (a) A space filling diagram showing the interaction of [–(βala-Phe(L)-
βala-Phe(L))-]Ni-2 (red) with the PPN groups (violet) (b) A cap and stick diagram 
showing the interaction of [–(βala-Phe(L)-βala-Phe(L))-]Ni-2 (red) with the PPN 
groups (violet). 
 
Table 3.5: - Selected bond lengths, bond angles, torsion angles and ring alignment 
for complex 3.2a. 
Selected Bond Lengths Selected Torsion Angles 
Ni(1)-N(15) (1.858Å), Ni(1)-N(17) 
(1.863Å), Ni(1)-N(20) (1.857Å), Ni(1)-
N(12) (1.888Å), N(15)-C(16) (1.317Å), 
N(15)-C(15) (1.460Å), N(17)-C(17) 
(1.476Å), N(17)-C(18) (1.297Å), N(20)-
C(20) (1.461Å), N(20)-C(11) (1.338Å), 
N(12)-C(13) (1.306Å), N(12)-C(12) 
(1.455Å), C(16)-O(16) (1.281Å), C(18)-
O(18) (1.283Å), C(11)-O(11) (1.262Å), 
C(13)-O(13) (1.249Å). 
 
C(16)-N(15)-Ni(1)-N(17) (-10.33o), C(15)-
N(15)-Ni(1)-N(17) (-175.86o), C(14)-C(15)-
N(15)-Ni(1) (32.17o), C(17)-C(16)-N(15)-
Ni(1) (11.82o), N(12)-C(13)-C(14)-C(15) 
(48.58o), Ni(1)-N(12)-C(13)-C(14) (-0.66o), 
O(16)-C(16)-C(17)-C(37) (-75.50o), O(16)-
C(16)-C(17)-H on C(17) (-48.81o), N(17)-
C(17)-C(16)-N(15) (-13.48o), N(12)-C(12)-
C(11)-N(20) (-6.15o). 
C(20)-N(20)-C(11)-O(11) (2.22o), C(15)-
N(15)-C(16)-O(16) (3.71o), C(17)-N(17)-
C(18)-O(18) (0.20o), C(12)-N(12)-C(13)-
O(13) (0.65o),  
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Selected Bond Angles Six Membered Ring Alignment 
N(15)-Ni(1)-N(17) (84.88o), N(17)-
Ni(1)-N(20) (95.39o), N(20)-Ni(1)-
N(12) (83.84o), N(12)-Ni(1)-N(15) 
(95.79o), N(15)-Ni(1)-N(20) (176.38o), 
N(12)-Ni(1)-N(17) (178.17o). 
Cis 
 
 The bond angles show a slightly distorted square planar geometry with bond 
angles in between N-Ni-N ranging from 83.84-95.79o (Table 3.5). 3.2a’s X-ray crystal 
structure confirms the 1HNMR data in revealing that the cyclopeptide ligand system is in 
a square planner arrangement around the metal center.  
The stereochemistry in the crystal structure is shown to be S on C(17) and S on 
C(12). This SS arrangement is as was “dialled in” utilizing BOC protected (S) 
phenylalanine in the synthesis of the tetrapeptide 2.34a.    
In 3.2a the arrangement of the side arms appears to be that of a tweezer shaped 
cavity with both arms in an axial position, although the space between the two groups is 
under 4Å, far too short for intercalation with an aromatic guest.  
To avoid steric interactions 3.2a one might expect the side arms to be in an 
equatorial position. However the phenyl rings in 3.2a occupy the axial position. A 
possible reason the rings are orientated like this is a π-CH interaction located 
intramolecularly between a phenyl ring and the methylene linker of the opposite phenyl 
group. This interaction (on the order of 2.5-5.5KJ/mol for intermolecular π-CH 
interactions12) may provide enough energy to overcome the steric repulsion in the solid 
state (Figure 3.18). 
There are several π-CH intermolecular interactions in this crystal structure 
between the cyclopeptide complex and the PPN counter cation (6 per cyclopeptide nickel 
complex). These distances are between 3Å and 3.1Å and showed interactions are possible 
between the cyclopeptide complex and another π surface, a desired property for cyclam 
complexes to be generated from these intermediates (Figure 3.19). 
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3.3.3.2 [–(βala-Phe(L)-βala-Phe(D))-]Ni 2PPN (3.2f) Crystal Structure. 
 
X-ray data for 3.2f was generated from isolated crystals and is shown in figure 
3.20 (bond length and angle data in table 3.6). 
 
 
   (a)      (b) 
 
Figure 3.20: - X-ray crystal structure of 3.2f (PPN and solvents removed for clarity). 
(a) The two structures of the nickel complex in the solid state differing only by the 
direction of the peptide chain. (b) One molecule of 3.2f alone. 
 
(a)  (b) 
Figure 3.21: - (a) A space filling diagram showing the interaction of [–(βala-Phe(L)-
βala-Phe(D))-]Ni-2 (red) (3.2f) with the PPN groups (violet) (a) A cap and stick 
diagram showing the interaction of [–(βala-Phe(L)-βala-Phe(D))-]Ni-2 (red) (3.2f) 
with the PPN groups (violet). (Solvents removed for clarity). 
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Table 3.6: - Selected bond lengths, bond angles, torsion angles and ring alignment 
for complex 3.2f. 
Selected Bond Lengths Selected Bond Angles 
N(75A)-Ni(1)-N(72A) (84.55o), N(72A)-
Ni(1)-N(75B) (95.39o), N(20)-Ni(1)-
N(12) (83.84o), N(12)-Ni(1)-N(15) 
(95.79o), N(15)-Ni(1)-N(20) (176.38o), 
N(12)-Ni(1)-N(17) (178.17o). 
Six Membered Ring Alignment 
Trans 
Ni(1)-N(15A1#1) (1.8656Å), Ni(1)-
N(15A1) (1.8656Å), Ni(1)-N(15B1#1) 
(1.872Å), Ni(1)-N(15B1) (1.872Å), 
Ni(1)-N(12B1) (1.883Å), Ni(1)-
N(12B1#1) (1.883Å), Ni(1)-N(12A1#1) 
(1.8837Å), Ni11-N(12A1) (1.8837Å), 
C(11A1)-(N15A1#1) (1.306Å), 
C(12A1)-(N12A1) (1.464Å), N(12A1)-
(C(13A1) (1.331Å), C(11B1)-(O11B1) 
(1.290Å), C(13B1)-(O13B1) (1.290Å), 
C(11A2)-(O11A2) (1.297Å), C(13A2)-
(O13A2) (1.266Å). 
 
 
Crystals grown of 3.2f show a marked difference in the orientation of the phenyl 
rings in the solid state. As predicted the arms on the ligand periphery are in a pseudo 
equatorial position (Figure 3.20). An interesting structural development is the fact that the 
rotation of the ligand periphery (which way the amide bonds flow around the ring) is not 
static in the crystal structure. The two rotations can be seen in the solid state in an 83:17 
ratio. The structures of these compounds are identical  (a flip and rotation leads to the 
same molecule) and the alignment of many of the atoms is very close including the 
phenyl rings, Ni center and carbonyl oxygens.  
The stereochemistry in the crystal structure is shown to be R on C(72A) and S on 
C(1A). This SR arrangement is as was dialled in utilizing BOC protected (S) 
phenylalanine and BOC protected (R) phenylalanine in the synthesis of the tetrapeptide 
2.34b.    
3.2f has Ci symmetry with an inversion center through the Ni. A marked 
difference between this compound, the 3.2a and the Pd complexes shown by Beck et al is 
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the orientation of the 6 membered rings incorporating the Ni. In 3.2f the 6 membered 
rings are trans to each other but the rings on the other complexes are cis giving the 
molecule a saddle shape with a C2 axis passing through the nickel. 
3.2f the complexes interact with both layers of the PPN counter ions in the solid 
state, not just one as in the complex 3.2a did (Figure 3.21). As a consequence of both side 
arms of the cyclopeptide nickel complex 3.2f interacting with different layers of the PPN 
counter ion each phenyl ring now has 6 π-CH interactions (3.163-2.656Å), doubling that 
of 3.2a. 
3.3.3.3 [–(βala-Nap(L)-βala-Nap(D))-]Ni 2PPN (3.2e) Crystal Structure. 
 
X-ray data for 3.2e was generated from isolated crystals and is shown in figure 
3.22 (bond length and angle data in table 3.7). 
 
Figure 3.22: - X-ray Crystal Structure of –(βala-2-Nap(L)-βala-2-Nap(D))-Ni PPN 
complex (3.2e) (PPN Removed for Clarity). 
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(a) (b) (c) 
 (d) (e) 
Figure 3.23: - (a) A space filled diagram showing all PPN molecules interacting with 
the Nap(L)Nap(D) dimer (Green PPN interacts in the gap between dimers, violet 
PPN interact with the dimer on the outside edge, solvents removed for clarity) (b) A 
space filled diagram showing the PPN interacting with the pocket (several outer 
PPN molecules removed for clarity) (c) A space filled diagram showing the complex 
dimer formed in the crystal ( several outer PPN molecules and the interchelating π-
π stacking PPN molecules removed for clarity) (d) A space filled diagram showing 
the CH-π interaction of a PPN to the Nap(L)Nap(D) complex within the cavity (all 
other PPN molecules removed for clarity) (e) A space filled diagram showing the π-π 
stacking of the PPN inside the cavity to the Nap(L)Nap(D) complex (all other PPN 
molecules removed for clarity). 
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Table 3.7: - Selected bond lengths, bond angles, torsion angles and ring alignment 
for complex 3.2e 
Selected Bond Lengths Selected Bond Angles 
N(20)-Ni(1)-N(12) (85.46o), N(12)-Ni(1)-N(15) 
(95.13o), N(15)-Ni(1)-N(17) (84.34o), N(17)-Ni(1)-
N(20) (95.10o), N(20)-Ni(1)-N(15) (178.82o), 
N(17)-Ni(1)-N(12) (177.79o). 
Selected Torsion Angles 
O(11)-C(11)-C(12)-N(12) (174.22o), N(20)-
C(11)-C(12)-N(12) (-10.05o), C(12)-N(12)-C(13)-
O(13) (1.19o), C(20)-N(20)-C(11)-O(11) (3.25o), 
C(17)-N(17)-C(18)-O(18) (1.00o), C(15)-N(15)-
C(16)-O(16) (-0.35o), O(11)-C(11)-C(12)-C (41) (-
63.61o), O(16)-C(16)-C(17)-C (61) (72.15o), 
Six Membered Ring Alignment 
Ni(1)-N(20) (1.855Å), Ni(1)-
N(12) (1.888Å), Ni(1)-N(15) 
(1.861Å), Ni(1)-N(17) (1.869Å), 
N(20)-C(11) (1.311Å), N(12)-
C(13) (1.322Å), N(15)-C(16) 
(1.292Å), N(17)-C(18) (1.318Å), 
N(20)-C(20) (1.458Å), N(12)-
C(12) (1.455Å), N(15)-C(15) 
(1.455Å), N(17)-C(17) (1.468Å), 
C(11)-O(11) (1.281Å), C(13)-
O(13) (1.295Å), C(16)-O(16) 
(1.276Å), C(18)-O(18) (1.271Å). 
Trans 
 
Another Ci symmetric compound synthesized was 3.2e. 3.2e shows the trans 
orientation of the 6 membered rings in the cyclopeptide nickel complexes as shown in 
3.2f.  
The larger π surface in 3.2f might be expected to form π-π interactions between 
the naphthyl rings within the crystal, however this does not occur. Both side arms in this 
case are in the pseudo axial position, more so than in complex 3.2e and very closely rated 
to 3.2a, with its cis orientated side arms. The large size of the side arms, and the fact that 
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they are both on opposite sides to each other may mean that the steric interactions with 
the carbonyls on the ligand structure are minimized by the position they take up (Figure 
3.22).  
Perhaps an even more important consideration in the solid-state conformation can 
be seen when one looks at the overall interaction of the cyclopeptide complex in the 
crystal (Figure 3.23). Here we can see that two of the nickel complexes T-stack to each 
other in the solid state forming a distinctive dimer (Figure 3.23c) very similar to a dimer 
observed in a molecular tweezer synthesized by Klarner et al13 (Figure 3.24).  
 
 
Figure 3.24: - Klarners tweezer dimer. 
 
3.2f also interacts with the PPN counter ion to form multiple T-stacking 
interactions. All bond distances are around 3Å, well within the range for a π-CH 
interaction, this is visible in the space filled diagrams (Figures 3.23b and c). 3.2f shows 
the presence of π-π interactions between 2PPN molecules and the complex with C-C 
distances of 3.521Ǻ and 3.561Ǻ (Figure 3.23e). 
The crystal structures for 3.2a,e and f show that complex formation under basic 
conditions allows the formed complex to maintain the stereochemical integrity of the 
tetrapeptide used in their synthesis. Whilst free peptides undergo racemization (to 
different extents depending on side arms), complexed peptides do not and thus 
stereochemical information is maintained. This discovery also lends credence to Beck’s 
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interpretation of the stereochemical outcome of the dipeptide cyclizations performed in 
his lab. 
 
 
3.3.4 Electrochemical Data For Cyclopeptide Nickel Complexes. 
 
After the isolation of various nickel complexes electrochemical analysis was 
performed to determine the stability and usefulness of these complexes as single electron 
donors in respect to oxidation reactions with polyaromatic hydrocarbons (PAH’s)14. 
Amido donors from ligand systems are capable of stabilizing high oxidation states in 
metal centres15. It was therefore considered that these ligand systems maybe capable of 
performing the same task by oxidizing Ni(II) to Ni(III). Beck has previously noted a side 
chain oxidation with nickel cyclopeptide complexes in acetonitrile and air at elevated 
temperatures16.  
The CV tests showed that the ligands were indeed capable of being oxidized from 
Ni(II) to Ni(III) with a range of 0.321-0.478eV being noted for the complexes 3.2a-f 
(table 4.4) and each had a reverse wave indicating ligand and complex stability to 
electrochemistry (Figure 3.25).  
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A graph to show CV data for cyclopeptide Ni PPN complexes
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Figure 3.25: - Electrochemical data for complexes 3.2a, b, c, e and f -[NiIIL] = 0.6 
mM- E0(NiIIIL/NiIIL), vs. Ag/AgCl (in 3M KCl) solutions in DMSO:H2O with KCl 
(20:1, 0.1M).    
 
Table 3.8: - Cyclic voltammetry (CV) electrochemical data for complexes 3.2a, b, c, 
e and f. 
Complex 
Ni(II)/Ni(III) 
wave (eV) 
Ni(III)/Ni(II) 
wave (eV) 
Half wave (eV) 
Phe(S)Phe(S) (3.2a) 0.478 0.333 0.406 
Ala(S)Ala(S) (3.2b) 0.447 0.348 0.398 
Phe(S)Ala(S) (3.2c) 0.468 0.371 0.420 
Phe(S)Phe(R) (3.2f) 0.321 0.218 0.270 
Nap(S)Nap(R) (3.2e) 0.384 0.232 0.308 
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Table 3.9: - A table showing differences in Ni(II)-Ni(III) potentials (δeV) and the 
relative energies of stabilization between the different complexes 3.2a, b, c, e and f. 
Complex 
(3.2a) 
(SS) 
(3.2b) 
(SS) 
(3.2c) 
(SS) 
(3.2f) 
(SR) 
(3.2e) 
(SR) 
(3.2a) 
(SS) 
- 0.031eV 0.001eV 0.157eV 0.094eV 
(3.2b) 
(SS) 
2.99 
KJ/Mol 
- 0.021eV 0.126eV 0.063eV 
(3.2c) 
(SS) 
0.096 
KJ/Mol 
2.026 
KJ/Mol 
- 0.147eV 0.084eV 
(3.2f) 
(SR) 
15.148 
KJ/Mol 
12.157 
KJ/Mol 
14.183 
KJ/Mol 
- 0.063eV 
(3.2e) 
(SR) 
9.069 
KJ/Mol 
6.078 
KJ/Mol 
8.104 
KJ/Mol 
6.078 
KJ/Mol 
- 
 
 
Figure 3.26: - Energy diagram showing relative stabilities of the Ni(III) complexes 
as deduced from CV data. 
 
The oxidation values of complexes with cis orientated side arms  (3.2a, b and c) 
are higher than those with trans orientated side arms (3.2e and f) (Table 3.8, Figure 3.26). 
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This may be a result of the stability of the formed product. Ni(III) (56pm)17 has a smaller 
ionic radius than Ni(II) (69pm)13, this decrease in size may in turn shorten the N-Ni bond 
lengths brining the side arms in closer proximity and extra strain in the ring systems may 
lead to more sterics between the sidearm and the carbonyls in the five and six membered 
rings. For the cis functionalized complexes this would increase the steric repulsion felt by 
each side arm to a greater extent than the trans and thus the energy to perform the 
reduction of Ni(II) to Ni(III) for the cis would be greater than that of the trans 
functionalized complexes (energy difference between 3.2a-NiIII and 3.2f-NiIII = 15.14 
KJ/Mol in favor of 3.2f). There may also be some extra ring strain involved with having 
both side arms in the cis configuration forcing the 5 membered rings to be more out of 
planarity than the corresponding trans substituted rings (Figures 3.17 and 3.20). 
 
Table 3.10: - A table showing differences in Ni(III)-Ni(II) potentials (δeV) and the 
relative energies of stabilization between the different complexes 3.2a, b, c, e and f. 
Complex 
(3.2a) 
(SS) 
(3.2b) 
(SS) 
(3.2c) 
(SS) 
(3.2f) 
(SR) 
(3.2e) 
(SR) 
(3.2a) 
(SS) 
- 0.015eV 0.038eV 0.115eV 0.101eV 
(3.2b) 
(SS) 
1.447 
KJ/Mol 
- 0.023eV 0.13eV 0.116eV 
(3.2c) 
(SS) 
3.666 
KJ/Mol 
2.219 
KJ/Mol 
- 0.153eV 0.139eV 
(3.2f) 
(SR) 
11.096 
KJ/Mol 
12.543 
KJ/Mol 
14.762 
KJ/Mol 
- 0.014eV 
(3.2e) 
(SR) 
9.745 
KJ/Mol 
11.192 
KJ/Mol 
13.410 
KJ/Mol 
1.351 
KJ/Mol 
- 
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Figure 3.27: - Energy diagram showing relative stabilities of the Ni(II) complexes as 
deduced from CV data. 
 
The reduction values of the Ni(III) complexes with cis orientated side arms  (3.2a, 
b and c) are higher than those with trans orientated side arms (3.2e and f) (Table 3.9, 
Figure 3.27). This is a result of the stability of the formed product. The Ni(II) complexes 
experience steric hindrance to a lesser degree that the Ni(III) complexes however this 
effect is still present. For the cis functionalized complexes there is an increase the steric 
repulsion felt by each side arm to a greater extent than the trans and thus the energy to 
perform the reduction of Ni(III) back to Ni(II) for the cis would be greater than that of the 
trans functionalized complexes. In this case however there is a slight shift in the order of 
highest energy to lowest energy when compared to the oxidation values of the complexes. 
It appears that complex 3.2a is in fact more stable than complexes 3.2b-c. This is likely 
due to the presence of the internal CH-π interaction in 3.2a that is not present in 3.2b and 
less likely in 3.2c. The internal CH-π interaction in 3.2a stabilizes the complex by 
3.66KJ/mol when compared to 3.2c, this is close in value to the energy of a CH-π 
interaction, between 2KJ/Mol and 5.5KJ/Mol18. There may also be some extra ring strain 
involved with having both side arms in the cis configuration forcing the 5 membered 
rings to be more out of planarity than the corresponding trans substituted rings (Figures 
3.17 and 3.20). 
Cyclic voltammetry data can be utilized to ascertain the cis or trans relationship 
of side arms in the nickel complexes and thus gives us another tool in the identification of 
stereochemical configuration. Complexes with oxidation values (Ni(II)-Ni(III)) under 
0.4eV have a trans configuration (as analyzed by X-ray crystallography and dialed in 
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configurations) whilst complexes with oxidation values above 0.4eV have the cis 
configuration (as analyzed by X-ray crystallography and dialed in configurations). Th 
3.4 Binding Studies With Cyclopeptide Nickel Complexes. 
 
After the isolation of several nickel cyclopeptide complexes it was decided that 
several binding studies should be performed to see if these systems were capable of pre-
binding aromatic substrates. Although these systems were never intended to be used for 
hydrodehalogenations, similar systems (cyclic tetraamido iron complexes) had been 
previously used as oxidants19 and with the electrochemical data already gained we knew 
that these systems could be used as single electron donors.  
Several tests utilizing naphthalene and 1-hydroxy-naphthalene showed no binding 
induced chemical shift changes by 1HNMR titration experiments (Figure 3.28). 
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Figure 3.28: - Failed attempts at aromatic substrate binding. 
 
3.4.1 Binding Studies With 1,10-Phenanthroline, Pyrazino[1,2,3,4 
lmn][1,10]phenanthrolinediium 5,6-dihydro-dibromide, and 4,4'-Bipyridinium 
1,1'-dimethyl-diiodide (dimethyl viologen). 
 
After the binding studies with naphthalene and naphthol failed to produce π-π 
stacking it was decided that a larger, more electron poor aromatic substrate should be 
used to increase the probability of binding through having a larger surface to interact with 
and the electron poor nature of these compounds lowers the energy of the HUMO 
allowing stacking to occur more readily. 
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When phenanthroline was tested for binding to the complex 3.2a no chemical 
shift changes were observed, as was the case for the naphthalene and naphthol. We then 
turned our attention to pyrazino[1,2,3,4 lmn][1,10]phenanthrolinediium, 5,6-dihydro-, 
dibromide  (3.12) (Figure 3.29).  
N
N
2Br-
3.12  
Figure 3.29: - Structure of pyrazino[1,2,3,4 lmn][1,10]phenanthrolinediium, 5,6-
dihydro-, dibromide 3.12 
 
3.12 was chosen due to its extremely electron poor nature which is better for π-π 
interactions with the relatively electron rich aromatic rings in the cyclopeptide 
complexes20. It was hoped that the π surface and the charge attraction in this salt would 
show some binding in solution. Drastic changes were observable in the 1HNMR spectrum 
of 3.12 when complex 3.2a was titrated into the solution (Figure 3.30). 
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Figure 3.30: - Stack plot NMR of the complex 3.2a titrated into a solution of 3.12 in 
a DMSO-d6:D2O mixture (20:1). 1= Guest, 2= 0.1eq Host in Guest, 3 = 0.2eq Host in 
Guest, 4 = 0.3eq Host in Guest, 5 = 0.4eq Host in Guest, 6 = 0.5eq Host in Guest, 7 = 
0.6eq Host in Guest, 8 = 0.7eq Host in Guest, 9 = 0.8eq Host in Guest, 10 = 0.9eq 
Host in Guest, 11 = 1eq Host in Guest, 12 = 1.1eq Host in Guest, 13 = Host. 
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Figure 3.31: - ROSEY NMR of 3.12 combined with 3.2a in DMSO-D6:D2O (20:1) 
 
ROSEY NMR (Figure 3.31) confirms the closed nature of the bound 3.12 via 
cross peaks at 5.63ppm to 4.0ppm and 9.09ppm to 4.9-5.1ppm. No cross peaks between 
the bound 3.12 and 3.2a were observed in the spectra leading to the belief that no 
chemical bond forming/breaking process is involved in the generation of the new species 
and a strong ion pair interaction is occurring (although no interaction between 3.12 and 
3.2a is observed). Reaction of a mixture of 3.2a and 3.12 with phosphoric acid leads to 
the complete destruction of the newly formed salt interaction via protonation of the 3.2a 
dianion. 3.2a was seen to react readily with MeI to form metabolites however this 
reaction is retarded in the presence of 3.12 indicating that the tight ion pair reduces the 
nucleophilicity of the anion. 
N
N
4.0ppm
4.9-5.15ppm
6.8ppm
6.18ppm
5.63ppm
7.58ppm
7.76ppm
9.09ppm
7.94ppm
8.99ppm
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Figure 3.32: - COSY NMR of 3.12 mixed with 3.2a (DMSO-d6:D2O 20:1) 
 
Table 3.11: - Chemical Shift data for 3.12 and 3.12x (3.12 interacting with host) 
Compound Chemical shift in DMSO-d6:D2O (20:1)  
3.12 free 
5.64 (s, 4 H) 8.71 (dd, J=8.39, 5.66 Hz, 2 H) 8.79 (s, 2 H) 9.62 (dd, J=8.39, 1.37 
Hz, 2 H) 9.80 (dd, J=5.66, 0.98 Hz, 2 H) 
3.12 bound 
3.87 - 3.97 (m, 1 H) 3.97 - 4.05 (m, 1 H) 4.85 (m, 1 H) 5.08 (dt, J=14.25, 3.9 Hz, 
1 H) 5.63 (d, J=4.69 Hz, 1 H) 6.18 (dd, J=9.76, 4.69 Hz, 1 H) 6.98 (d, J=9.76 Hz, 
1 H) 7.58 (d, J=8.59 Hz, 2 H) 7.75 (d, J=8.59 Hz, 1 H) 7.95 (dd, J=8.20, 5.86 Hz, 
1 H) 8.99 (d, J=8.20 Hz, 1 H) 9.08 (d, J=5.08 Hz, 1 H)
N
N
4.0ppm
4.9-5.15ppm
6.8ppm
6.18ppm
5.63ppm
7.58ppm
7.76ppm
9.09ppm
7.94ppm
8.99ppm
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Table 3.12: - Binding constants of 3.12 with complexes 3.10a-d. 
Complex 
Binding/equilibrium 
constant (kobs) (M-1) of 
3.12 
ΔGo = -RTln(k)  
KJ/Mol 
3.2a 267.97 -13.85 
3.2b 217.79 -13.33 
3.2c 594.15 -15.82 
3.2d 280.00 -13.96 
 
The binding study experiment was repeated for complexes 3.2b-d with 3.12 and 
the binding constants were obtained (Table 3.12). The energy of this interaction was 
between -13.33 and –15.82KJ/Mol, far too much for the average π-π or π-CH (Figure 
3.33) but not for a tight ion pair interaction21 (Figure 3.31). Complexes 3.2b-d all show 
binding of 3.12, most unusual if π-π or π-CH host guest interactions are occurring due to 
the lack of aromatic side arms on complex 3.2b. Therefore binding of the nature shown in 
figure 3.33 was rejected in favor of the binding of the type shown in figure 3.34. 
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Figure 3.33: - Binding of the phenanthroline salt to the tweezer shaped cavity of the 
cyclopeptide nickel complex. 
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Figure 3.34: - The guest molecule in close proximity to the host molecule. 
 
After the binding study with 3.12 it was decided that performing a test on a 
similar di-cation would be useful. Methyl viologen (3.15) was chosen as a suitable 
aromatic di-cation for the binding studies. It has a π surface (the twist out of the plain for 
the pyridine rings is representative of PCB molecules) and the same charge as the 3.12. A 
mixture of 3.2a and 3.15 failed to produce any discernable interactions in solution with 
no changes in 1HNMR (Figure 3.35). It was therefore considered that the ion pair 
interaction may occur with 3.12 due to a preferred alignment of charges. 3.12 has a flat 
surface and charges that are approximately 2.84Å apart. 3.15 has a slightly bent surface 
and a charge separation of approximately 6.98Å. The distance between the nitrogens (N-
Ni-N) in complex 3.2a is around 3.715Å whilst the carbonyl oxygens have an 
approximate separation of 7.58Å. With this information it may be logical to assume that 
the charge-charge interactions occur closer to the nitrogens in both 3.12 and 3.2a rather 
than between the carbonyl oxygens and the nitrogens in 3.15 and 3.2a. Thus cationic 
charge separation plays an important role in the tight ion pair formation in this series of 
complexes. 
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Figure 3.35: - Possible binding of methyl viologen to a nickel cyclopeptide complex 
through ion pair formation. 
 
 Although binding of 3.15 to 3.2a was not observed via 1HNMR preparation of a 
mixture of 3.2a and 3.15 in DMSO led to the generation of a blue colored solution (in 
air). When shaken in air the blue color quickly disappeared and an orange color was 
observed.  
The blue color that was observed in the 1HNMR tube before mixing with air 
became of some interest, as this color is usually associated with viologen radicals. When 
the experiment was repeated under inert conditions the deep blue color remained stable 
for at least 24 hours (later UV studies showed the blue color to be stable for over a 
month). The 1HNMR of 3.2a and 3.15 under inert conditions showed no sign of the 
methyl viologen indicating the formation of radicals in solution. 
The Ni(II) complex 3.2a loses an electron to form a stabilized Ni(III) complex 
3.16 and forms the viologen radical 3.17 which is 1HNMR inactive (Figure 3.36). 
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Figure 3.36: - Reduction of viologen utilizing a nickel cyclopeptide complex (3.2a). 
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UV spectra of a mixture of 3.2a and 3.15 shows peaks at 268, 389, 400, 485 and 
610nm. The peak at 610nm represents the methyl viologen radical (Figure 3.37). 
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Figure 3.37: - UV trace of complex 4.4 with viologen in DMSO under inert 
conditions. 
 
The addition of triethanolamine (TEOA) to the reaction mixture of complex 3.2a 
and 3.15 gives a marked increase in the UV absorption at 610nm. In this case the TEOA 
acts as a sacrificial donor22 to regenerate the Ni(II) complex from the Ni(III). Once this is 
done the electron can then be used to reduce another viologen molecule and the cycle can 
continue (Figure 3.38). It must be noted that once the radical of TEOA is formed from the 
initial reduction of 3.16 the radical cation can be utilized to reduce 3.15 as well. 
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Figure 3.38: - Possible catalytic cycle observed using TEOA. 
 
3.5 Conclusions. 
 
In this chapter we can see that dipeptide nickel complexes can be isolated in low 
to moderate yield and show that the configuration of the dipeptides/tetrapeptides utilized 
in the synthesis is imparted to the generated complexes in the presence of a strong base at 
room temperature. Metal templated cyclization of dipeptides did not yield pure products 
in our hands. Tetrapeptide metal templated cyclizations on the other hand proved 
extremely effective. Not only are the cyclizations cleaner and faster using tetrapeptides, 
crystallizations utilizing PPN allowed the isolation of very pure X-ray quality products.  
Cyclizations on solid support have been shown to be effective, although yields 
were not determined. Purification of these complexes was not achieved, however mass 
spectrum data clearly shows product formation. 
X-ray quality crystals allowed for the determination of stereochemistry in the 
products. It was seen that all the products analyzed by X-ray crystallography showed 
retention of configuration imparted to them through the tetrapeptides synthesized in 
chapter 2. C2, Ci and C1 symmetric complexes were all synthesized using these 
 140 
conditions. Although racemization of free peptides was shown, cyclized peptide 
complexes do not undergo racemization reactions under the reaction conditions. 
Looking at the crystal structures we can see that the aromatic side arms of the 
cyclopeptide complexes interact with the aromatic rings in the PPN. This allows for the 
formation of interacting layers in complexes 3.2a and 3.2f with no interactions occurring 
between individual cyclopeptide complexes.  
The complex 3.2e, having larger aromatic sidearms, show a significantly 
increased amount of CH-π interactions when compared to complexes 3.2a and 3.2f. This 
complex also shows π-π interactions with the PPN and interestingly CH-π interactions 
with another cyclopeptide complex to form discreet dimers in the crystal. This complex 
loses the ordered layer structure shown by the other two complexes with counter ion 
interactions occurring all throughout the crystal.  
The CH-π and π-π interactions shown by these molecules in the crystal structure 
gave us great hope that similar interactions would be possible with other aromatic 
substrates. However I was unable to identify π-π stacking in solution with 2-3 suitable 
guest molecules. 
Electrochemical data was utilized to determine the relative stabilities of 
complexes 3.2a, b, c, e and f. The data shows that cis functionalized cyclopeptide 
complexes are more difficult to oxidize than trans functionalized cyclopeptide 
complexes, probably due to the extra steric hindrance observed when the metal center 
contracts from Ni(II) to Ni(III), although differences in ring strain energies may also play 
a part in the energy differences. 
 Tight ion pair interactions shown between complexes 3.2a-d and 3.12 have been 
identified and charge separation has been theorized as to the reason why 3.15 does not 
undergo the same type of ion pair formation. 
A novel use for the cyclopeptide nickel complexes was found when they were 
seen to act as good single electron donors to viologen in DMSO, with a possible catalytic 
cycle being established in the presence of TEOA. 
All together the isolation and characterization of the cyclopeptide metal 
complexes allowed us to fulfill one part of the overall goal of this project, the control of 
stereochemical integrity for cyclam precursors from affordable starting materials.  
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3.6 Experimental. 
 
All chemicals were purchased from Aldrich, Acros Organics or Fisher Scientific 
and used without further purification.   
3.6.1 General Synthesis of Dipeptide Nickel Complexes. 
 
To a mixture of the dipeptide HCl salt (1.0 mmol) and NiCl2.(H2O)6 (118.85mg, 
0.5mmol) in methanol (10mL) is slowly added NaOMe (216mg, 4.0mmol) in methanol 
(3.0mL). Between 10 minutes and an hour of stirring at RT an orange solid drops out of 
solution. The solid is collected by centrifugation/filtration and recrystallized form hot 
methanol. 
 
(MeO-Bala-Phe-NH2)2Ni (3.1a) 
 
N
H2
N
N
H2
NO
O
Ni
OO
O O  
 
Yield 110mg, 59.3%. 1H NMR (200 MHz, DMSO-D6)  2.03 - 2.46 (m, 9 H) 
2.54 - 2.75 (m, 2 H) 2.83 - 2.99 (m, 3 H) 3.02 (d, J=3.30 Hz, 1 H) 3.15 (d, J=4.40 Hz, 1 
H) 3.55 (s, 6 H) 3.65 - 3.86 (m, 2 H) 7.16 - 7.35 (m, 10 H). 13C NMR (101 MHz, DMSO-
D6)  30.67, 33.98, 37.68, 51.20, 56.70, 126.35, 128.30, 129.27, 137.91, 173.20, 179.95. 
See X-ray crystal structure for stereochemical analysis. 
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(MeO-Bala-4methylPhe-NH2)2Ni (3.1b) 
 
N
H2
N
N
H2
NO
O
Ni
OO
O O  
 
Yield 70mg, 18%. 1H NMR (400 MHz, DMSO-D6)  2.08 - 2.20 (m, 4 H) 2.26 
(s, 6 H) 2.29 - 2.40 (m, 4 H) 2.63 (dd, J=8.2, 14.68 Hz, 2 H) 2.86 (broad s, 2 H) 2.96 (dd, 
J=3.71, 13.86 Hz, 2 H) 3.57 (s, 6 H) 3.77 (m, 2 H) 7.12 (d, J=8.20 Hz, 4 H) 7.16 (d, 
J=8.20 Hz, 4 H). 13C NMR (101 MHz, DMSO-D6)  20.66, 33.98, 37.68, 38.22, 51.17, 
56.81, 128.92, 129.18, 134.65, 135.33, 173.12, 179.98. MS: m/z calculated for 
C28H38N4O6 = 584.2145, actual m/z (M+H) = 585.139. See X-ray crystal structure for 
stereochemical analysis. 
 
(MeO-Bala-Nap-NH2)2Ni (3.1c) 
 
N
H2
N
N
H2
NO
O
Ni
OO
O O  
 
 
Yield 50mg, 28.5%. MS: m/z calculated for C34H38N4O6 = 656.2145, actual m/z 
(M+H) = 657.150. 1H NMR (400 MHz, DMSO-D6)  2.03 - 2.14 (m, 4 H) 2.24 - 2.35 
(m, 4 H) 2.35 - 2.44 (m, 2 H) 2.69 (dd, J=13.86, 8.39 Hz, 2 H) 2.97 (s, 2 H) 3.08 (dd, 
J=13.86, 2.93 Hz, 2 H) 3.36 - 3.44 (m, 6 H) 3.80 - 3.91 (m, 2 H) 7.35 (d, J=8.59 Hz, 2 H) 
7.40 - 7.46 (m, 2 H) 7.49 (t, J=7.42 Hz, 2 H) 7.62 (s, 2 H) 7.79 (d, J=8.20 Hz, 2 H) 7.86 
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(t, J=7.81 Hz, 4 H). 13C NMR (101 MHz, DMSO-D6)  33.96, 37.74, 38.65, 51.01, 
56.63, 125.41, 125.96, 127.38, 127.45, 127.60, 127.75, 127.87, 131.90, 133.02, 135.39, 
172.98, 179.86. 
 
3.6.2 Synthesis of Cyclopeptide Complexes. 
 
[(-Bala-Phe(L)-Bala-Phe(L)-)NiII]-22PPN+ (3.2a) 
 
N
N
N
N
O
O
O
O
Ph
Ph
Ni
-2
2PPN+
 
 
The H-Phe(L)-Bala-Phe(L)-Bala-OMe (2.34a) (845mg, 1.45mmol) and 
NiCl2(H2O)6 (345mg, 1.45mmol) were dissolved in methanol (20mL) and NaOMe 
(470mg, 8.7mmol) was added all at once. The mixture was then stirred and heated to 
65oC for between 24 hours. The solution was cooled and the precipitate that had formed 
was filtered off. To the orange solution was added the PPN-Cl (1.66g, 2.9mmol). The 
solvent was then removed and the solid taken up into acetone (~30mL). To this solution 
was added water until it was seen that a cloudy precipitate was about to drop out of 
solution. The mixture was then placed in the fridge at +5oC for 24 hours. The crystals that 
had formed were then filtered off to give pure product. The filtrate was again placed in 
the fridge and the process of crystallization repeated two more times. Total yield 1.09g, 
47.9%. 1H NMR (400 MHz, CD3OD)  1.82 (d, J=15.28 Hz, 2 H) 2.09 - 2.19 (m, 2 H) 
2.17 - 2.32 (m, 2 H) 2.79 (dd, J=13.05, 5.41 Hz, 2 H) 2.99 (dd, J=12.89, 5.25 Hz, 2 H) 
3.08 (d, J=12.41 Hz, 2 H) 4.09 - 4.20 (m, 2 H) 7.07 - 7.15 (m, 2 H) 7.16 - 7.26 (m, 8 H) 
7.42 - 7.76 (m, 60 H). 13C NMR (101 MHz, CD3OD)  39.41, 40.14, 40.93, 65.43, 
126.72, 128.09, 128.10, 128.39, 129.16, 129.18, 130.55, 130.61, 130.68, 131.57, 133.41, 
133.47, 133.53, 134.88, 140.64, 174.38, 180.93. See X-ray crystal structure for 
stereochemical analysis. 
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[(-Bala-Nap(L)-Bala-Nap(L)-)NiII]-22PPN+ (3.2b) 
 
N
N
N
N
O
O
O
O
Ni
-2
2PPN+
 
 
The H-Ala(L)-Bala-Ala(L)-Bala-OMe (2.39g) (113mg, 0.263mmol) and the NiCl2 
salt (62.5mg, 0.263mmol) with the NaOMe (freshly prepared 216mg, 4mmol) were 
vigorously dried under vacuum and dissolved in methanol (15ml). The reaction was then 
heated to 60 °C for between 12 hours. The PPN-Cl was added and any ppt was removed 
via centrifugation. The solvent was removed and the complex taken up in 
acetone/methanol and water added until just before the cloudy ppt appeared. The mixture 
was placed in the fridge. White crystals ppt out of solution these were removed via 
filtration. The solvent was removed until there was just a little water remaining and the 
solid was allowed to crystallize from the solution. The orange solid was then filtered off 
and washed with water, then dried in vacuo. Yield 142mg, 38%. 1H NMR (400 MHz, 
CD3OD) 1.21 - 1.32 (d, J=6.64 Hz 6 H) 1.95 (m, 2 H) 2.14 (m, 2 H) 2.17 - 2.27 (m, 2 H) 
2.32 (m, 2 H) 3.21 (m, 2 H) 3.95 (q, J=6.25 Hz, 2 H) 7.53 (m, 24 H) 7.59 (m, 24 H) 7.69 
(t, J=7.03 Hz, 12 H). 13C NMR (101 MHz, CD3OD)  20.55, 39.50, 40.43, 60.65, 28.11, 
129.20, 130.55, 130.62, 130.69, 133.43, 133.49, 133.54, 134.89, 175.14, 183.16.  
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[(-Bala-Phe(L)-Bala-Ala(L)-)NiII]-22PPN+ (3.2c) 
 
N
N
N
N
O
O
O
O
Ph
Ni
-2
2PPN+
 
 
The H-Ala(L)-Bala-Phe(L)-Bala-OMe (2.34d) (52.6mg, 0.1mmol) and 
NiCl2(H2O)6 (23.8mg, 0.1mmol) were dissolved in methanol (5mL) and NaOMe (43mg, 
0.8mmol) was added all at once. The mixture was then stirred and heated to 65oC for 12-
24 hours. The solution was cooled and the precipitate that had formed was filtered off. To 
the orange solution was added the PPN-Cl (115mg, 2mmol). The solvent was then 
removed and the solid taken up into acetone (~10mL). To this solution was added water 
until it was seen that a cloudy precipitate was about to drop out of solution. The mixture 
was then placed in the fridge at -5oC for 24 hours. The crystals that had formed were then 
filtered off to give pure product. Yield 40mg, 26.8%.23 1H NMR (400 MHz, CD3OD) 
1.15 (d, J=6.64 Hz, 3 H) 1.60 - 1.70 (m, 2 H) 1.92 - 2.00 (dt, J=1.4 Hz, J=12 Hz, 1 H) 
2.01 - 2.09 (m, 2 H) 2.29 (t, J=12.69 Hz, 1 H) 2.93 (dd, J=12.88, 3.12 Hz, 1 H) 3.03 (dd, 
J=12.88, 4.69 Hz, 1 H) 3.15 (dt, J=12.79, 3.37 Hz, 1 H) 3.72 (q, J=6.51 Hz, 1 H) 4.16 - 
4.26 (t, 4 Hz, 1 H) 7.12 - 7.20 (m, 1 H) 7.20 - 7.30 (m, 4 H) 7.47 (m, 9 H) 7.48 - 7.51 (m, 
17 H) 7.52 - 7.60 (m, 23 H) 7.66 (t, J=6.83 Hz, 12 H) 13C NMR (101 MHz, CD3OD)  
20.63, 38.66, 39.00, 39.53, 39.78, 39.92, 60.74, 65.47, 127.03, 128.11, 128.37, 129.18, 
130.68, 131.87, 133.52, 134.90, 139.94, 174.67, 175.03, 179.55, 182.61. 
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[(-Bala-Nap(L)-Bala-Nap(L)-)NiII]-22PPN+ (3.2d) 
 
N
N
N
N
O
O
O
O
Ni
-2
2PPN+
 
 
The Cl.H3N-Nap(L)-Bala-Nap(L)-Bala-OMe (2.34c) (134mg, 0.22mmol) and 
NiCl2(H2O)6 (52.5mg, 0.22mmol) were dissolved in methanol (15mL) and NaOMe 
(96.2mg, 1.78mmol) was added all at once. The mixture was then stirred and heated to 
65oC for 24 hours. The solution was cooled and the precipitate that had formed was 
filtered off. To the orange solution was added the PPN-Cl (254mg, 442mmol). The 
solvent was then removed and the solid taken up into acetone (~20mL). To this solution 
was added water until it was seen that a cloudy precipitate appeared. The mixture was 
then placed in the fridge at +5oC for 24 hours. The crystals that had formed were then 
filtered off to give pure product. Yield 33mg, 8.9%. 1H NMR (400 MHz, CD3OD)  2.12 
(td, J=14.54, 4.10 Hz, 2 H) 2.28 (t, J=12.88 Hz, 2 H) 2.54 (dd, J=12.69, 6.05 Hz, 2 H) 
2.92 (dd, J=12.88, 4.69 Hz, 2 H) 3.08 (dt, J=12.79, 2.78 Hz, 2 H) 4.16 (t, J=5.27 Hz, 2 H) 
7.18 (t, J=7.03 Hz, 2 H) 7.24 - 7.34 (m, 4 H) 7.36 (s, 2 H) 7.50 (td, J=7.61, 3.51 Hz, 27 
H) 7.53 - 7.61 (m, 23 H) 7.61 - 7.69 (m, 16 H) 7.74 (d, J=8.20 Hz, 2 H). 13C NMR (101 
MHz, CD3OD)  39.34, 40.19, 41.24, 65.39, 125.58, 126.21, 127.47, 128.08, 128.56, 
128.71, 129.16, 129.67, 130.54, 130.61, 130.67, 133.40, 133.46, 133.52, 133.76, 134.88, 
138.36, 174.24, 180.94. 
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[(-Bala-Nap(L)-Bala-Nap(D)-)NiII]-22PPN+ (3.2e) 
 
N
N
N
N
O
O
O
O
Ni
-2
2PPN+
 
 
The Cl.H3N-Nap(L)-Bala-Nap(D)-Bala-OMe (185mg, 0.305mmol) and 
NiCl2(H2O)6 (72.5mg, 0.305mmol) were dissolved in methanol (15mL) and NaOMe 
(96.2mg, 1.78mmol) was added all at once. The mixture was then stirred and heated to 
70oC in a schlenk flask for 24 hours. To the orange solution was added the PPN-Cl 
(254mg, 442mmol). The solvent was then removed and the solid taken up into acetone 
(~20mL). To this solution was added water until it was seen that a cloudy precipitate was 
observed. The mixture was then placed in the fridge at +5oC for 24 hours. The crystals 
that had formed were then filtered off to give pure product. Yield 150mg, 30%. 1H NMR 
(400 MHz, CD3OD)  1.37 - 1.48 (m, 2 H) 1.67 (m 2 H) 2.14 (m, 2 H) 2.97 - 3.09 (m, 4 
H) 3.15 (m 2 H) 4.00 (m, 2 H) 7.28 (m 4 H) 7.40 (d, J=8.59 Hz, 2 H) 7.48 (d, J=1.95 Hz, 
15 H) 7.49 (m, 9 H) 7.56 (m, 23 H) 7.61 - 7.68 (m, 15 H) 7.68 - 7.74 (m, 6 H)) 13C NMR 
(50 MHz, CD3OD)  38.71, 38.96, 39.58, 65.23, 125.67, 126.28, 127.45, 128.54, 129.60, 
129.64, 129.78, 130.39, 130.46, 130.58, 130.72, 130.77, 130.90, 133.24, 133.30, 133.41, 
133.53, 133.60, 133.77, 134.85, 137.73, 174.45, 179.17. See X-ray crystal structure for 
stereochemical analysis. 
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[(-Bala-Phe(L)-Bala-Phe(D)-)NiII]-22PPN+ (3.2f) 
 
N
N
N
N
O
O
O
O
Ph
Ph
Ni
-2
2PPN+
 
 
The H-Phe(L)-Bala-Phe(D)-Bala-OMe (100mg, 0.172mmol) and NiCl2(H2O)6 
(40.9mg, 0.172mmol) were dissolved in methanol (15mL) and NaOMe (81mg, 1.5mmol) 
was added all at once. The mixture was then stirred and heated to 70oC for 24 hours. The 
solution was cooled and the precipitate that had formed was filtered off. To the orange 
solution was added the PPN-Cl (197mg, 0.344mmol). The solvent was then removed and 
the solid taken up into acetone (~30mL). To this solution was added water until it was 
seen that a cloudy precipitate was about to drop out of solution. The mixture was then 
placed in the fridge at -5oC for 24 hours. The crystals that had formed were then filtered 
off to give pure product. Total yield 76.8mg, 28.5%. 1H NMR (400 MHz, CD3OD)  1.66 
(dd, J=13.08, 4.10 Hz, 2 H) 1.70 - 1.77 (m, 2 H) 2.13 (t, J=12.49 Hz, 2 H) 2.87 (dd, 
J=12.88, 3.51 Hz, 2 H) 2.92 (dd, J=13.27, 5.08 Hz, 2 H) 3.14 (dt, J=12.49, 3.51 Hz, 2 H) 
4.00 - 4.09 (m, J=3.51, 3.51 Hz, 2 H) 7.13 - 7.24 (m, 10 H) 7.50 (td, J=7.71, 3.32 Hz, 24 
H) 7.55 - 7.61 (m, 24 H) 7.68 (td, J=7.32, 1.76 Hz, 12 H). 13C NMR (101 MHz, CD3OD) 
 38.67, 39.13, 39.59, 65.21, 126.91, 128.08, 128.27, 129.17, 130.54, 130.61, 130.67, 
131.80, 133.41, 133.46, 133.52, 134.88, 139.95, 174.57, 179.14. See X-ray crystal 
structure for stereochemical analysis. 
 
3.6.3 General Synthesis of Cyclopeptide Nickel Complexes From Resins 
 
To the amine terminated tetrapeptide (general formula PS-CO-β-ala-X-β-ala-X-
NH2) on the hydroxymethyl resin (0.1mmol) was added a solution of NiCl2.6H2O 
(47.4mg, 0.2mmol) in H20:NH4OH:AcCN (1:1:1) (5ml). The solution was shaken for 1 
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hour at RT and the resin was drained and washed 4 times with DMF (20mL) and 4 times 
with DCM (20mL). To the resin was added methanol (1mL) and NaOMe (10.8mg, 
0.2mmol)). This was then heated at 60oC for 24 hours. The resin was filtered off and the 
orange solution analyzed by MS directly. 
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CHAPTER 4 - Isolation of Cyclopeptides, Their Reduction to 
Form Cyclams and Nickel Insertion to Form Novel C-
Functionalized Cyclam Nickel(II) Complexes. 
4.1 Introduction 
 
The synthesis of 1,6 Bis-substituted cyclams from dipeptide esters has previously 
been reported by Beck (Figure 4.1)1. However stereochemical analysis of the 
functionalized carbons was never performed. 
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Figure 4.1: - Beck’s route to C-substituted cyclams1. 
 
 The liberated cyclopeptides (4.1) fall out of the methanol solution and can be 
isolated by simple filtration followed by minimal washing. These peptides were 
characterized by 1HNMR using TFA:MeOH (80:20) mixtures1. Beck then reduced the 
cyclopeptide to the cyclams utilizing LAH1. 
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4.2 Isolation of Cyclopeptides From Nickel Cyclopeptide Complex 
Precursors. 
 
Metal free cyclopeptides were generated from Ni-cyclopeptide complexes (3.2a, 
b and e) via protonation with HCl. Taking advantage of the low solubility of the 
cyclopeptides2 even impure samples of the Ni-cyclopeptide complexes (70-80% purity) 
were successfully converted to pure cyclopeptides (Figure 4.2, Table 4.1). 
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NaOMe
2) HCl in 
Methanol
 
Figure 4.2: - Cyclization of dipeptides followed by liberation of cyclopeptides. 
 
Table 4.1: - Isolated cyclopeptides from dipeptide cyclizations. 
R Compound Number Yield% 
Ph 4.1a 45.7 
2-Nap 4.1b 83.5 
H 4.1c 87.8 
 
 Unsymmetrical cyclopeptides can be synthesized in a similar manner to C2 
symmetric ones utilizing tetrapeptide starting materials (Figure 4.3, Table 4.2). 
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Figure 4.3: - Liberation of cyclopeptides from tetrapeptide cyclizations. 
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Table 4.2: - Isolated cyclopeptides from tetrapeptide cyclizations. 
R1 R2 
Compound 
Number Yield% 
Ph (D)-CH2Ph 
4.1d 77.8 
2-Nap (D)-CH2-2-Nap 4.1e 85.3 
2-Nap (L)- CH2Ph 
4.1f 64.4 
2-Nap (L)- CH3 4.1gb 54.5 
2-Nap H 4.1hb 54.5 
b NMR insoluble characterization by IR and MS only. 
 
4.2.1 Insertion of Other Metals into the Cyclopeptide. 
 
Insertion of other metals such as iron into the cyclopeptide allows the formation 
of Collins3 TAML® type complexes. Reaction of the cyclopeptides is very difficult due to 
their innate insolubility in almost all organic solvents (THF, MeOH, DMSO, DMF, ether, 
DCM). Previous efforts at metal insertion into TAML ligands include the use of BuLi in 
THF at –108oC4 and the use of NaOH in water5. These methods are inconsistent with the 
solubility of our cyclopeptides and with the production of Fe complexes due to the 
formation of iron oxides. However when the cyclopeptide is suspended in DMSO and 
reacted with KH a soluble salt is formed. Reacting this salt with MCl2 (M = Fe, Co) then 
allows the formation of a metal complex (Figure 4.4). The excess Fe is removed by 
treating the solution with water and filtering off the formed iron oxides (Figure 4.5). 
Crystal structure analysis prove the structure of the complex and shows stereochemical 
retention. Quick reaction times at RT prevent the isomerization of the stereocenters even 
in the presence of the very strong KH base. Some examples of larger peptide metal 
complexes are available in the literature6. However these systems show little practical use 
in catalysis or as reagents. 
 155 
HN
HN
NH
NH
O
O
O
O
KH/DMSO
MCl2 
MeOH/H2O
N
N
N
N
O
O
O
O
M
4.3a M = Fe. 
4.3b M = Co.
 
Figure 4.4:- Reaction of cyclopeptide 4.1a with KH and MCl2 in DMSO. 
 
 
Figure 4.5: - X-ray crystal structure of 4.3a (PPN removed for clarity) 
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Table 4.3: - Selected crystal structure data for complex 4.3a 
Selected Bond Lengths Selected Torsion Angles 
Fe(1)-N(15) (1.886Å), Fe(1)-N(17) 
(1.912Å), Fe(1)-N(20) (1.875Å), Fe(1)-
N(12) (1.918Å), Fe(1)-O(1) (2.116Å),  
C(11)-O(11)  (1.245Å), C(11)-N(20) 
(1.321Å) N(12)-C(13) (1.330Å), C(13)-
O(13) (1.264Å),C(13)-C(14) (1.475Å), 
C(15)-N(15) (1.459Å), N(15)-C(16) 
(1.341Å), C(16)-O(16) (1.238Å), C(17)-
N(17) (1.440Å), N(17)-C(18) (1.328Å), 
C(18)-O(18) (1.284Å). 
 
Fe(1)-N(17)-C(17)-C(16) (-6.16o), 
Fe(1)-N(17)-C(18)-C(19) (19.84o) 
N(17)-C(17)-C(16)-N(15) (-10.11o), 
N(15)-C(15)-C(14)-C(13) (-67.36o), 
Fe(1)-N(12)-C(13)-C(14) (-14.38o), 
Fe(1)-N(12)-C(13)-O(13) (-163.56o), 
O(13)-C(13)-C(14)-C(15) (-144.82o). 
 
Selected Bond Angles Six Membered Ring Alignment 
N(20)-Fe(1)-N(15) (163.0o), N(20)-Fe(1)-
N(17) (95.2 o), N(15)-Fe(1)-N(17) (83.2 o), 
N(20)-Fe(1)-N(12) (83.6 o), N(15)-Fe(1)-
N(12) (95.2 o), N(17)-Fe(1)-N(12) (170.5 o), 
N(20)-Fe(1)-O(1) (94.1 o), N(15)-Fe(1)-
O(1) (102.9 o), N(17)-Fe(1)-O(1) (94.82 o), 
N(12)-Fe(1)-O(1) (94.6 o). 
Cis 
 
 Insertion of cobalt into the cyclopeptide and treatment of the crude solution with 
PPN also lead to the formation of crystals suitable for X-ray analysis (Figure 4.6).  
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Figure 4.6: - X-ray crystal structure of 4.3b (PPN removed for clarity) 
 
Table 4.4: - Selected crystal structure data for complex 4.3b 
Selected Bond Lengths Selected Torsion Angles 
Co(2)-N(15/15A) (1.867Å), Co(2)-N(12/12A) 
(1.852Å), C(13)-O(13)  (1.241Å), C(13A)-O(13A)  
(1.241Å), C(13)-N(12) (1.393Å), C(13A)-N(12A) 
(1.393Å), N(12)-C(12) (1.503Å), N(12A)-C(12A) 
(1.503Å), O(11)-C(11) (1.242Å), O(11A)-C(11A) 
(1.242Å),  N(15)-C(11) (1.331Å), N(15A)-C(11A) 
(1.331Å). 
Co(2)-N(12)-C(12)-C(11) (5.87o),   Co(2)-
N(12)-C(13)-C(14) (8.45o), Co(2)-N(15)-C(15)-
C(14) (-44.10o), N(12)-C(12)-C(11)-N(15A) (-
9.59o), N(112A)-C(13A)-C(14A)-C(14A) (-
53.42o), Co(2)-N(12A)-C(13A)-O(13A) (-
172.99o), Co(2)-N(15)-C(11A)-O(11A) (-
175.26o). 
Selected Bond Angles Six Membered Ring Alignment 
N(15)-Co(2)-N(15A) (173.12o), N(12)-Co(2)-
N(12A) (164.41o), N(15A)-Co(2)-N(12A) (95.75 o), 
N(12A)-Co(1)-N(15) (85.19 o), Co(2)-N(12A)-C(12) 
(115.93o), Co(2)-N(15)-C(11) (116.41o), N(15)-
C(11)-C(12) (115.93o), N(12)-C(13)-C(14) 
(115.71o). 
Cis 
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 With the insertion of other metals into cyclopeptides novel complexes with 
controllable stereochemistry can be obtained. These complexes have possible uses in 
oxidation chemistry, similar to that performed with the nickel complexes. Possible 
polyaromatic hydrocarbon degradation utilizing the iron complex could be achieved 
following Collins methodology2 and substrate pre-binding with aromatic sidearms. 
 
4.3 Reduction of the Cyclopetides to Cyclams. 
 
Various attempts to reduce cyclopeptides with lithium aluminum hydride (LAH) 
(4 equivalents, work up with Na2SO4 solution) according to Beck’s original report1 as 
well as equivalent reductions using BH37, produced complex mixtures. Successful 
generation of cyclams (in moderate yields) was eventually accomplished using a large 
excess of LAH (16eq) followed by a workup with NaOH/H2O8 (Figure 4.7, Table 4.4). 
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Figure 4.7: - Reduction of cyclopeptides, using LAH in THF with a NaOH workup. 
 
Table 4.5: - Yields of cyclopeptide reductions with LAH. 
R Compound Number Yield% 
Ph 4.2a 38.3 
2-Nap 4.2b 79.1 
H 4.2c 26 
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4.4 Nickel Insertion into Cyclam ligands. 
 
Ni cyclam complexes were successfully generated from cyclams 4.2a-b and NiCl2 
in boiling methanol, along with complex 4.4c that was generated through the 
crystallization of an impure sample of the cyclam after reaction with NiCl2 (Figure 4.8). 
In one case 4.4d, a perchlorate complex was successfully synthesized in that manner as 
well (Figure 4.8). However I was unable to produce pure Ni perchlorate complexes or 
BPh4- complexes from cyclams 4.2a-b and Ni(ClO4)2 or Ni(ClO4)2/NaBPh4 mixtures. 
Several nickel tetraazamacrocyclic complexes (similar in nature to the complexes 
generated here) have previously been isolated by Burrows et al and utilized in the 
epoxidation of alkenes9, for the oxidative cleavage of DNA molecules10 and for 
associative binding to guanine in DNA11. Other nickel cyclam complexes generated by 
the stereoselective reduction of planar imine complexes over Raney Ni show 
stereoselectively but no aromaticity12. 
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Figure 4.8: - Isolation of nickel cyclam Bis-chloride complexes. 
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Figure 4.9: - Nickel incorporation into the cyclam 5.12 utilizing nickel perchlorate.  
Table 4.6: - Yield of C-functionalized nickel chloride cyclam complexes. 
R Compound Number Yield% 
Ph (SS) 4.4a 38.3 
2-Nap (SS) 4.4b 35.8 
2-Nap (SR) 4.4c - 
H (SS) 4.4d 9.4 
 
4.4.1 Structural Characterization of C-Functionalized Nickel Cyclam 
Complexes. 
 
Despite previous report on Ni-cyclam napthoates that are devoid of intermolecular 
π-π stacking interactions13 in the solid state (Figure 4.9) π-π stacking was observed when 
isonicotinic acid was used as an axial ligand in a trans(III) cyclam complex14 (Figure 
4.10). Encouraged by this finding we anticipated that the side arms in the complexes 
4.4a-c would be suitably positioned for π-π or CH-π interactions within the crystal lattice 
as observed with the cyclopeptide nickel complexes 3.2a, 3.2f and 3.2e, leading to the 
possible formation of these interactions with aromatic substrates in solution. 
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Figure 4.10: - X-ray crystal structure of a Ni-cyclam with 2 axial naphthoic acid 
groups that show no π-π interactions in the solid state5. 
 
Figure 4.11: - X-ray crystal structure of a Ni-cyclam with 2 axial nicotinic acid 
groups that show π-π interactions in the solid state6. 
 
Generation of Ni-cyclam complexes with C-functionalized cyclam molecules 
allowed the structural determination of a variety of interactions such as π-π and CH-π and 
shall be discussed as follows. 
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4.4.1.1 X-ray Crystal Structure Analysis of Cyclam Nickel Complex 4.4a. 
 
  
Figure 4.12: - X-ray Crystal Structure of the complex 4.4a (solvents removed for 
clarity). 
 
 
Figure 4.13: - Space filled model showing CH-π interactions in one dimension within 
the crystal lattice for complex 4.4a (solvents removed for clarity). 
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Figure 4.14: - Space filling X-ray crystal structure shows the CH-π interactions 
between four complexes in a two-dimensional sheet in the lattice for complex 4.4a 
(solvents removed for clarity). 
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Table 4.7: - Selected X-ray crystal data for complex 4.4a. 
Selected Bond Lengths Selected Torsion Angles 
Ni(1)-N(1) (2.0633Å), Ni(1)-N(4) 
(2.0636Å),Ni(1)-N42 (2.0689Å), 
Ni(1)-N12 (2.0732Å), Ni(1)-Cl(2) 
(2.4940Å), Ni(1)-Cl(1) (2.5826Å), 
N(1)-H(1) (0.90Å), N(4)-H(4) 
(0.82Å), N12-H12 (0.82Å), N42-H42 
(0.87Å). 
N(4)-Ni(1)-N(1)-C72 (-142.85o), N42-Ni(1)-N(1)-C72 (40.75o), 
N12-Ni(1)-N(1)-(C72 95.6o), Cl(2)-Ni(1)-N(1)-C72 –(54.53o), 
Cl(1)-Ni(1)-N(1)-C72 (124.80 o), N(4)-Ni(1)-N(1)-C(2) (-8.04o), 
N42-Ni(1)-N(1)-C(2) (175.56o), N12-Ni(1)-N(1)-C(2) (-129.6o), 
Cl(2)-Ni(1)-N(1)-C(2) (80.28o), Cl(1)-Ni(1)-N(1)-C(2) (-
100.39o), C72-N(1)-C(2)-C(17) (42.8o), Ni(1)-N(1)-C(2)-C(17) 
(-91.75o), N(1)-Ni(1)-N(4)-C(5) –(145.20o), N42-Ni(1)-N(4)-
C(5) (-89.3o), N12-Ni(1)-N(4)-C(5) (32.80o), Cl(2)-Ni(1)-N(4)-
C(5) (120.18o), Cl(1)-Ni(1)-N(4)-C(5) (-58.25o), N(1)-Ni(1)-
N(4)-C(3) (-19.09o), N42-Ni(1)-N(4)-C(3) (36.8o), N12-Ni(1)-
N(4)-C(3) (158.90o), Cl(2)-Ni(1)-N(4)-C(3) (-113.72o), Cl(1)-
Ni(1)-N(4)-C(3) (67.86o) 
Selected Bond Angles Configuration: - Trans(III) 
π-π interactions: - No 
CH-π interactions: - Yes (2D), 2.829Å and 
2.819Å 
N(1)-Ni(1)-N(4) (83.75o), N(1)-Ni(1)-N42 (93.80o), 
N(4)-Ni(1)-N42 (175.66o), N(1)-Ni(1)-N12 (177.67o), 
N(4)-Ni(1)-N12 (97.47o), N42-Ni(1)-N12 (84.86o), N(1)-
Ni(1)-Cl(2) (94.47o), N(4)-Ni(1)-Cl(2) (88.82o), N42-
Ni(1)-Cl(2) (94.95o), N12-Ni(1)-Cl(2) (87.56o), N(1)-
Ni(1)-Cl(1) (87.19o), N(4)-Ni(1)-Cl(1) (92.03o), N42-
Ni(1)-Cl(1) (84.26o), N12-Ni(1)-Cl(1) (90.77o), Cl(2)-
Ni(1)-Cl(1) (178.209o) 
Side Arm Positioning: - 1 axial, 1 
equatorial. 
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4.4.1.2 X-ray Crystal Structure Analysis of Cyclam Nickel Complex 4.4b. 
 
Figure 4.15: - X-ray Crystal Structure of 4.4b (solvents removed for clarity). 
 
Figure 4.16: - Crystal packing of complex 4.4b in two dimensions (solvents removed 
for clarity). 
 
 
Figure 4.17: - Space filled X-ray structure showing the crystal packing of complex 
4.4b in three dimensions (one solvent included to show the blocked position above 
the central naphthyl ring, the complex on the bottom right T-stacks to the complex 
on the top left). 
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Table 4.8: - Selected X-ray crystal data for complex 4.4b. 
Selected Bond Lengths Selected Torsion Angles 
Ni(1)-N(18) (1.991Å), Ni(1)-N(15) (2.035Å), 
Ni(1)-N(22) (2.110Å), Ni(1)-N(11) (2.137Å), 
Ni(1)-Cl(1) (2.503Å), 
Ni(1)-Cl(2) (2.587Å). 
Ni(1)-N(18)-C(16)-C(17) (44.42o), 
Ni(1)-N(11)-C(24)-C(23) (-39.02o), 
N(11)-C(24)-C(23)-N(2) (-50.46o), 
N(11)-C(24)-C(23)-N(2) (55.24o), 
N(22)-C(23)-C(24)-C(26) (159.21o), 
N(15)-C(16)-C(17)-C(25) (73.94o), 
Selected Bond Angles Configuration: - Trans(III) 
π-π interactions: - No 
CH-π interactions: - Yes (3D), 
2.916Å, 2.996Å, 2.739Å and 3.071Å 
N(18)-Ni(1)-N(15) (84.0o), N(18)-Ni(1)-
N(22) (92.5o), N(15)-Ni(1)-N(22) (175.1o), 
N(18)-Ni(1)-N(11) (176.7o), N(15)-Ni(1)-N(11) 
(97.5o), N(22)-Ni(1)-N(11) (85.8o), N(18)-Ni(1)-
Cl(1) (95.6o), N(15)-Ni(1)-Cl(1) (88.88o), N(22)-
Ni(1)-Cl(1) (94.91o), N(11)-Ni(1)-Cl(1) (87.38o), 
N(18)-Ni(1)-Cl(2) (85.9o), N(15)-Ni(1)-Cl(2) 
(92.57o), N(22)-Ni(1)-Cl(2) (83.72o), Cl(1)-
Ni(1)-Cl(2) (178.00o), 
Side Arm Positioning: - 1 axial, 1 
equatorial. 
4.4.1.3 X-ray Crystal Structure Analysis of Cyclam Nickel Complex 4.4c. 
 
 
Figure 4.18: - X-ray crystal structure of complex 4.4c. 
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(a) 
 
(b) 
Figure 4.19: - (a) Diagram showing the π-π interactions in the complex 4.4c from a 
side on view (solvents removed for clarity) (b) Diagram showing the π-π interactions 
in the complex 4.4c from an end on view (solvents removed for clarity). 
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Table 4.9: - Selected X-ray crystal data for complex 4.4c. 
Selected Bond Lengths Selected Torsion Angles 
Ni(1)-N(15) (2.052Å), Ni(1)-N(22) 
(2.056Å), Ni(1)-N(11) (2.073Å), Ni(1)-
N(18) (2.078Å), Ni(1)-Cl(2) (2.4893Å), 
Ni(1)-Cl(1) (2.5016Å). 
Ni(1)-N(1)-C(24)-C(23) (38.62o), Ni(1)-
N(15)-C(16)-C(17) (-45.47o), N(11)-
C(24)-C(23)-N(22) (-54.83o), N(15)-
C(16)-C(17)-N(18) (57.96o), N(22)-
C(23)-C(24)-C(61) (-177.75o), N(15)-
C(16)-C(17)-C(41) (156.90o), 
Selected Bond Angles Configuration: - Trans(III) 
π-π interactions: - Yes, 3.519Å 
CH-π interactions: - No 
N(15)-Ni(1)-N(22) (178.50o), N(15)-Ni(1)-
N(11) (95.28o), N(22)-Ni(1)-N(11) (84.65o), 
N(15)-Ni(1)-N(18) (84.30o), N(22)-Ni(1)-
N(18) (95.81o), N(11)-Ni(1)-N(18) (178.42o), 
N(15)-Ni(1)-Cl(2) (88.79o), N(22)-Ni(1)-
Cl(2) (92.70o), N(11)-Ni(1)-Cl(2) (86.42o), 
N(18)-Ni(1)-Cl(2) (92.05o), N(15)-Ni(1)-
Cl(1) (91.40o), N(22)-Ni(1)-Cl(1) (87.11o), 
N(11)-Ni(1)-Cl(1) (94.04o), N(18)-Ni(1)-
Cl(1) (87.50o), Cl(2)-Ni(1)-Cl(1) (179.49o) 
Side Arm Positioning: - 2 equatorial. 
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4.4.1.4  X-ray Crystal Structure Analysis of Cyclam Nickel Complex 4.4d. 
 
Figure 4.20:- X-ray crystal structure of complex 4.4d. 
 
Figure 4.21: - X-ray crystal structure of complex 4.4d, showing the N-H…O 
interaction, Ni…O interactions and C-H…O interactions forming a network within 
the crystal. 
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Table 4.10: - Selected X-ray crystal data for complex 4.4d 
Selected Bond Lengths Selected Torsion Angles 
Ni(1)-N(11) (1.922Å), Ni(1)-N(18) 
(1.923Å), Ni(1)-N(22) (1.937Å), Ni(1)-
N(15) (1.938Å), N(11)-H(11) (0.9300Å), 
N(15)-H(15) (0.9300Å), N(18)-H(18) 
(0.9300Å), N(22)-H(22) (0.9300Å), 
Ni(1)-O(5A) (2.909Å), Ni(1)-O(1A) 
(3.108Å), H(22)-O(7A) (2.141Å), H(18)-
O(8A) (2.318Å). 
Ni(1)-N(15)-C(16)-C(17) (35.82o), Ni(1)-
N(18)-C(19)-C(20) (-40.03o), N(15)-
C(16)-C(17)-N(18) (-50.80o), N(11)-
C(22)-C(23)-N(22) (49.76o), Ni(1)-
N(15)-C(16)-C(24) (-84.80o), Ni(1)-
N(22)-C(23)-C(26) (-161.39o), 
Selected Bond Angles Configuration: - Trans(I) 
π-π interactions: - No 
CH-π interactions: - No 
N(11)-Ni(1)-N(18) (175.97o), N(15)-
Ni(1)-N(22) (175.97o), N(11)-Ni(1)-N(22) 
(88.22o), N(18)-Ni(1)-N(22) (95.80o), 
N(11)-Ni(1)-N(15) (88.48o), N(18)-Ni(1)-
N(15) (87.50o). 
Side Arm Positioning: - 1 axial, 1 
equatorial. 
 
 Complexes 4.4a-b show intermolecular CH-π building a 2D network in the case 
of 4.4a  (Figures 4.12 and 4.13) and a 3D network in the case of 4.4b (Figures 4.15 and 
4.16). These complexes both have axial and equatorial sidearms with an octahedral 
geometry around the nickel center. Complex 4.4c shows differences from complexes 
4.4a-b. By having two equatorial sidearms, no CH-π interactions are evident, however a 
new π-π interaction has been detected within the crystal structure. These CH-π and π-π 
interactions are exactly what we had hoped would be accomplished by incorporating the 
aromatic sidearms onto the ligand framework. All complexes 4.4a-c show the trans(III) 
geometry of the nitrogens around the metal center. The complex 4.4d having no aromatic 
sidearms shows no CH-π or π-π interactions. The different counter ion (perchlorate) also 
allows the formation of a trans(I) conformation with a slight shortening of the N-Ni 
bonds and the formation of O--H hydrogen bonding throughout the crystal structure (both 
N-H…O and C-H…O interactions are observed). The RS version of complex 4.4d shows 
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both side arms to be in the equatorial position and the configuration of the complex is 
trans(III) as the perchlorate salt15. 
 
4.5 Reduction Tests Using C-functionalized Nickel Cyclams. 
  
Reduction runs using different halogenated aromatic substrates were performed 
utilizing both C-functionalized and non-functionalized nickel complexes in DMSO:EtOH 
(1:1) mixtures with the NaBH4 co-reductant and 1,3-dimethoxybenzene (DMB) was 
utilized as the internal standard. Monitoring of the reactions was performed over time by 
the removal of a small aliquot of the reaction mixture, quenching with ammonium 
chloride and extraction with ethyl acetate. The extracted sample was subjected to HPLC 
analysis and the conversion of the starting material to product was determined relative to 
the internal standard. These reactions were not reproducible and gave large variations in 
rate constants under the same conditions. 
 
N
N
N
N
R
R
DMSO:EtOH 
(1:1)
H H
H H
Ni
Cl
Cl
NaBH4 (10eq)
+
X
H
X = Cl, Br.                
R = H, 2-Napthyl
DMB
 
Figure 4.22: - Reduction of aromatic substrates utilizing complexes 1.6a and 4.3b. 
 
The follow arguments are based solely on experimental data obtained in our lab 
and may not actually reflect the true nature of the mechanism or catalytic pathway as a 
more in depth analysis of the reaction is necessary: -  
Rates of reduction were calculated based on the assumption that k3 is the rate 
determining step (RDS) in the reduction (Figure 4.23). The first step in the reduction k1 is 
shown to be the formation of complex 1.6d from 1.6a. This step appears to be fast via the 
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generation of a purple solution in the DMSO:EtOH (1:1) mixture within minutes from the 
original suspension of 1.6a. The rate of generation of the proposed intermediate 1.6x is 
unknown but seems likely to be slower than the formation of 1.6d. The rates of k2 and k3 
maybe close, however attack of the complex 1.6x on aromatic substrates is believed to be 
slower than its formation. This hypothesis is supported by the differences in rates 
between all the aromatic substrates for the same catalysts 1.6a or 4.4b (Table 4.11).  
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N
N
H H
H H
Ni
R
R
ClH
1.6a
1.6d
1.6x
+ 1.6a
k1
k2
k3 (RDS)
R = H or BH4  
Figure 4.23: - Possible reduction pathway for the dehalogenation of 
bromonaphthalene. 
 
 From the reaction data gathered (Table 4.11) it is assumed that the rate law would 
be as shown in equation 1. Since the formation of 1.6x is not thought to be the RDS and 
its concentration is assumed to not alter during the course of the reaction (in the presence 
of an excess of the borohydride) we have assumed this reaction to be pseudo first order 
(equation 2). This assumption bears fruit in the generation of graphs plotting Ln([Aryl-
halide t = X]/[ Aryl-halide t=0]) against time (s) leading to straight lines (Figure 4.24) 
and the slope of which gives us kobs. kobs is converted to k by dividing by the amount of 
catalyst concentration (equation 3) although this is not necessarily the case and must not 
be taken as a fully defined rate law. 
1 Rate = k[1.6x][Aryl-halide] 
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2 Rate = k[Aryl-halide] 
3 k = kobs/[cat] 
A graph to show Ln([ClNap]/[ClNAp t = 0]) vs time (s) for JT-I-1288 
y = -4.65565E-05x - 0.020893025
R2 = 0.992325665
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Figure 4.24: - A graph showing Ln([Clnap t = X]/[ClNap t = 0]) vs time (s) 
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Table 4.11: - Reduction data for complexes 1.6b and 4.3a with various halogenated 
compounds using DMB as an internal standard at 23oC. 
Compound Complex K
obs 
k(s-1) R2 krel 
1-Bromonaphthalene 1.6a 3.569 X10
-4 0.0327 90.9 1 
1-Bromonaphthalene 4.4b 1.283 X10-4 0.024 96.6 -1.36 
1-Chloronaphthalene 1.6a 4.656 X10-5 0.00637 99.2 1 
1-Chloronaphthalene 4.4b 1.469 X10-4 0.0108 97.7 1.69 
M-Bromobiphenyl 1.6a 7.602 X10-5 0.00644 97.1 1 
M-Bromobiphenyl 4.4b 1.473 X10-5 0.00295 98.8 -2.25 
P-Bromobiphenyl 1.6a 4.426 X10-5 0.00226 92.0 1 
P-Bromobiphenyl 4.4b 8.274 X10-6 0.00146 96.4 -1.54 
2-Bromofluroene 1.6a 4.252 X10
-5 0.00914 99.2 1 
2-Bromofluroene 4.4b 9.909X10-6 0.00194 99.47 -4.71 
Bromobenzene 1.6a 2.3759 X10-5 0.00102 96.6 - 
 
The fact that chloronaphthalene reacts more slowly than bromonaphthalene may 
indicate that SNR1, or SET mechanisms. If SNAr were the mechanism one might expect 
that chloronaphthalene would react more quickly as it is more electronegative than 
bromine (bearing in mind the RDS is the attack of the hydride), however it is slower. 
Although we do not see any aryl coupling products from the reaction this maybe 
due to the fact that the rather than being a radical chain mechanism the reaction may 
involve the combination of the generated radical intermediate species more rapidly than 
separation can occur16. It is also noteworthy that Ni(I) species isolated in acetonitrile do 
not react with bromonaphthalene to induce hydrodehalogenation indicating that the H- 
ion plays an important role as the reductant whether as the electron source or as a 
stabilizing factor in the Ni(I) complex.  
It appears that the presence of aromatic sidearms reduces the rates of reduction for 
almost all substrates tested, except for chloronaphthalene where 4.4b shows an increased 
rate of 1.69 over 1.6a (Table 4.11). In this case the more electron poor chloronaphthalene 
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ring maybe able to undergo pre-concentration with the active complex though mutual π-π 
or CH-π interactions. Again it must be noted that the reduction tests performed are 
irreproducible and the rates of reduction shown are not reliable. 
The reduction in rates in all other complexes could simply be due to steric 
hindrance blocking one side of the active complex making hydride/SET attack more 
difficult, effectively halving the concentration of active complex 1.6x as only one side of 
the active intermediate would be available for attack.  
After the failure to observe rate increases in DMSO:EtOH mixtures reactions in 
water were attempted. However substrate and catalyst insolubility led to this reaction 
being impossible to perform. The synthesis of a water-soluble glyme ester of 
bromonaphthalene was achieved however no reduction was observed utilizing complex 
1.6a. 
4.6 Conclusions. 
 
Cyclization of linear dipeptides and tetrapeptides followed by nickel removal 
from impure nickel cyclopeptide complexes leads to the formation of a highly insoluble 
cyclopeptide product than can be isolated by filtration. These cyclopeptides have proven 
difficult to fully characterize by 13CNMR due to the extreme solvent conditions needed to 
dissolve them (100% TFA) leading to some breakdown of the compounds over time. 
1HNMR, mass spectra and IR data have been obtained for the majority of the compounds. 
Reduction of the cyclopeptides to the cyclam molecules gave pure products for 
the C2 symmetric compounds after the reaction without chromatography whilst the 
impure Ci Bis naphthyl compound was not purified but carried though to the next step.  
Nickel insertion into the cyclam molecules proceeded smoothly. Trans(III) 
isomers were isolated for the chloride salts whilst the perchlorate salt yielded the trans(I) 
isomer, all in the desired SS or SR configuration dialed in during the peptide synthesis.  
Increased CH-π interactions were observed in the solid state when the π surfaces 
of the side arms were increased from complex. Complex 4.4a shows a two dimensional 
layered structure held together by CH-π interactions between the phenyl side arms whilst 
the larger naphthyl side arms in complex 4.4b allows the formation of a three 
 176 
dimensional structure, utilizing CH-π interactions. In both cases π-π interactions in the 
solid state were not observed as was originally envisioned. Complex 4.4c showed π-π 
interactions in the solid state whilst complex 4.4d formed no intermolecular interactions 
however hydrogen bonding was seen through the perchlorate counter ion. 
Data for the aromatic substrates chosen shows reduction in rates for the complex 
4.4b over 4.4a. Unfortunately meaning that the pre-concentration idea was not viable (at 
least in DMSO:EtOH mixtures) for the majority of substrates. 
The chloronaphthalene substrate whilst being more difficult to reduce due to 
strong C-Cl bonds, has a more electron poor ring system and thus should interact more 
favorably with an electron rich π system such as the naphthalene rings in complex 4.4b 
than the more electron rich bromonaphthalene substrate. Longer residence times in the 
presence of the catalyst should allow for the reduction to occur at a greater rate, which is 
shown by the results gained for chloronaphthalene reduction utilizing 4.4b over 1.6a.  
Overall the stereo controlled synthesis of aromatic C-functionalized nickel cyclam 
complexes has been accomplished. Reduction rates in the DMSO:EtOH solvent mixture 
show that the C-functionalized Ni complex 4.4b have a slower rate of reduction over the 
unfunctionalized complex 1.6a for all substrates tested except chloronaphthalene 
although these reactions need to be repeated in order to fully assess the nature of the 
dehalogenation pathway. 
4.7 Experimental. 
All chemicals were purchased from Aldrich, Peptech Corp, Aroz technologies, 
Acros Organics or Fischer and used without further purification.   
 
4.7.1  General Synthesis of Cyclopeptides From Dipeptides. 
 
All following work was performed under nitrogen: - The dipeptide (1mmol) and 
nickel chloride (0.5mmol) were mixed in methanol 25mL. To this solution was slowly 
added a solution of fresh NaOMe (12mmol) in 50mL methanol and then the reaction was 
slowly heated to 70 °C. The reaction was stopped after 5hours, concentrated and filtered 
over celite to remove any NaCl formed. To the solution was added HCl in ether 
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(20mmol) and stirred for between 20 minutes and 24 hours until a white solid dropped 
out of solution. The solid was filtered and washed with cold methanol, water and ether 
then dried in vacuo. 
 
cyclo-[βala-L-Phe-βala-L-Phe] (4.1a) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 359mg, 45%. 1H NMR (400 MHz, tfa)  ppm 2.68 (s, 2 H) 2.95 (s, 2 H) 
3.05 - 3.17 (m, 2 H) 3.17 - 3.28 (m, 2 H) 3.51 (s, 2 H) 3.85 (s, 2 H) 4.83 (s, 2 H) 7.14 - 
7.24 (m, 4 H) 7.30 - 7.40 (m, 6 H). 13C NMR (101 MHz, tfa)  ppm 35.99, 38.06, 38.39, 
58.55, 129.94, 130.96, 131.16, 136.79, 206.61. MS: m/z calculated for C24H28N4O4 = 
436.2111, actual m/z (M+Na) = 459.172. IR (KBr pellet): υ 3457, 3303, 3047, 2934, 
1644, 1541, 1439, 1357, 1111, 697cm-1. 
 
cyclo-[βala-L-(2)Nap-βala-L-(2)Nap] (4.1b) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 2.15g, 83.5%. 1H NMR (400 MHz, CD3OD)  ppm 1.86 (dt, J=16.01, 4.49 
Hz, 2 H) 2.20 (dd, J=15.23, 7.03 Hz, 2 H) 2.56 (dd, J=14.25, 8.78 Hz, 2 H) 2.71 (dd, 
J=14.06, 6.64 Hz, 2 H) 2.87 (s, 4 H) 2.89 - 2.95 (m, 4 H) 4.10 - 4.21 (m, J=7.61, 7.61 Hz, 
2 H) 6.68 (dd, J=8.20, 1.56 Hz, 2 H) 6.74 - 6.84 (m, 4 H) 7.02 (s, 2 H) 7.07 - 7.18 (m, 6 
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H). MS: m/z calculated for C32H32N4O4 = 536.2424, actual m/z (M+H) = 537.085. IR 
(KBr pellet): υ 3441, 3308, 3062, 2914, 1644, 1541, 1439, 1357cm-1. 
 
cyclo-[βala-L-ala -βala-L-ala] (4.1c) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 1.11g, 86.5%. 1H NMR (400 MHz, CDCl3)  ppm 1.29 (d, J=7.03 Hz, 6 H) 
2.43 (ddd, J=15.81, 3.90, 3.71 Hz, 2 H) 2.77 (ddd, J=15.71, 11.03, 4.49 Hz, 2 H) 3.41 - 
3.48 (m, 2 H) 3.49 - 3.55 (m, 2 H) 4.44 (q, J=7.03 Hz, 2 H). MS: m/z calculated for 
C12H20N4O4 = 284.1485, actual m/z (M+H) = 285.066. IR (KBr pellet): υ 3297, 3098, 
2965, 2906, 1666, 1639, 1553, 1440, 1387, 1348, 1255, 1003, 691, 665cm-1. 
4.7.2  General Synthesis of Cyclopeptides From Tetrapeptides. 
 
All following work was performed under nitrogen: - The tetrapeptide (1mmol) 
and nickel chloride (1mmol) were mixed in methanol 25mL. To this solution was slowly 
added a solution of fresh NaOMe (12mmol) in 50mL methanol and then the reaction was 
slowly heated to 70 °C. The reaction was stopped between 3 and 24 hours (usually 
around 12 hours), concentrated and filtered over celite to remove any NaCl formed. To 
the solution was added HCl in ether (10mL, 2M, 20mmol) and stirred for between 20 
minutes and 24 hours until a white solid dropped out of solution. The solid was filtered 
and washed with cold methanol, water and ether then dried in vacuo. 
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cyclo-[βala-L-Phe-βala-D-Phe] (4.1d) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 110mg, 77.8%. 1H NMR (400 MHz, tfa)  2.35 - 2.74 (m, 3 H) 2.90 - 3.13 
(m, 2 H) 3.12 - 3.32 (m, 3 H) 3.33 - 3.66 (m, 4 H) 4.36 - 4.56 (m, 1 H) 4.64 - 4.79 (m, 1 
H) 7.02 - 7.38 (m, 10 H) 7.40 - 7.58 (m, 2 H) 7.73 - 7.92 (m, 2 H). MS: m/z calculated for 
C24H28N4O4 = 436.2111, actual m/z (M+H) = 437.22. IR (KBr pellet): υ 3482, 3290, 
3078, 2919, 1653, 1546, 1454, 1367, 1261, 1222, 1062, 751, 711cm-1. 
cyclo-[βala-L-(2)Nap-βala-D-(2)Nap] (4.1e) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 364mg, 85.3%. 1H NMR (400 MHz, tfa)  ppm 2.43 (s, 4 H) 3.03 (dd, 
J=14.18, 7.75 Hz, 2 H) 3.10 - 3.21 (m, 2 H) 3.49 (s, 4 H) 4.72 (d, J=6.81 Hz, 2 H) 7.09 
(d, J=8.70 Hz, 2 H) 7.25 - 7.37 (m, 5 H) 7.38 - 7.50 (m, 6 H) 7.52 - 7.64 (m, 5 H). MS: 
m/z calculated for C32H32N4O4 = 536.2424, actual m/z (M+H) = 537.217. IR (KBr pellet): 
υ 3482, 3297, 3051, 2919, 1639, 1540, 1454, 1261, 1235, 1202, 744cm-1  
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cyclo-[βala-L-(2)Nap-βala-L-Phe] (4.1f) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 237mg, 64.4%. 1H NMR (400 MHz, tfa)  ppm 2.61 (s, 2 H) 2.94 (s, 2 H) 
3.06 (s, 1 H) 3.20 (s, 2 H) 3.35 (s, 1 H) 3.45 - 3.56 (m, 2 H) 3.74 (s, 2 H) 4.77 (s, 1 H) 
4.89 (s, 1 H) 7.15 (s, 2 H) 7.26 (d, J=7.03 Hz, 4 H) 7.43 (s, 2 H) 7.62 (s, 1 H) 7.75 (s, 3 
H)  
 
cyclo-[βala-L-(2)Nap-βala-gly] (4.1g) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 100mg, 15.3%. IR (KBr pellet): υ 3436, 3317, 2939, 1686, 1653, 1553, 
1540, 1427, 1049cm-1. MS: m/z calculated for C21H24N4O4 = 396.1798, actual m/z 
(M+Na) = 419.166.  
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cyclo-[βala-L-(2)Nap-βala-L-Ala] (4.1h) 
 
HN
HN
NH
NH
O
O
O
O
 
 
Yield 246mg, 54.5%. IR (KBr pellet): υ 3409, 3270, 2952, 1739, 1639, 1560, 
1440, 1381, 1275, 1096, 1023, 804cm-1. MS: m/z calculated for C22H26N4O4 = 410.1954, 
actual m/z (M+Na) = 433.170.  
 
4.7.3 Synthesis of Metal Complexes from Liberated Cyclopeptides. 
 
cyclo-[βala-L-Phe-βala-L-Phe]Fe(III) (4.3a) 
 
N
N
N
N
Fe
OH2
O
O
O
O
- PPN+
 
 
The following was performed in the glove box under a nitrogen atmosphere: - The 
cyclo-[βala-L-Phe-βala-L-Phe] (150mg, 0.344mmol) was suspended in DMSO and KH 
(66.2mg, 1.65mmol) added. The mixture was left to react for 10 minutes by which time 
all of the cyclopeptide had dissolved. To this mixture was added the FeCl2 (43.6mg, 
0.344mmol) and shaken for ten minutes. The color went to a dark orange. The vial was 
removed from the glove box and methanol and water were added. The flask was allowed 
to sit for 1 hour then the rust that had formed was filtered off. The DMSO was removed 
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in vacuo and the remaining solid was taken up in methanol and re-filtered. PPN-Cl 
(197mg, 0.344mmol) was then added to the methanol and slow evaporation lead to the 
formation of crystals. Yield 205mg, 58.1%. IR: υ 3056, 3019, 2912, 2839, 1568, 1442, 
1376, 1254, 1102, 1000, 772, 686, 538cm-1. Structure confirmed by X-ray crystal 
analysis. 
 
cyclo-[βala-L-Phe-βala-L-Phe]Co(III) (4.3a) 
 
N
N
N
N
O
O
O
O
PPN+
Co
 
 
The following was performed in the glove box under a nitrogen atmosphere: - To 
cyclo-[βala-L-Phe-βala-L-Phe] (50mg, 0.115mmol) in DMSO (5mL) was added KH 
(20.1mg, 0.5mmol) and stirred for 5 minutes. To this mixture was added the CoCl2 
(14.9mg, 0.115mmol) in DMSO (2mL) the mixture then went green and was stirred for a 
further ten minutes. The mixture was removed from the glove box and sonicated for two 
minutes. To this solution was then added methanol (1ml) and the solution then went red. 
To the solution was added PPN-Cl (132mg, 0.23mmol) and the mixture was crystallized 
from water:methanol:ethanol (1:1:1) mixture. Yield 90mg, 76%. IR: υ 3060, 3019, 2937, 
1715, 1609, 1585, 1564, 1474, 1446, 1372, 1270, 1213, 1102, 1000, 747, 726, 696, 
534cm-1. Structure confirmed by X-ray crystal analysis. 
 
4.7.4 General Synthesis of Cyclams From Cyclopetides. 
 
The cyclopeptide (1mmol) is placed in a Schlenk flask and THF (30mL) is added 
via vacuum transfer. To this was added LAH (12mmol) at –78oC and the reaction mixture 
is stirred for 1 hour at until the flask reaches RT and the initial bubbling stops. The flask 
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is then heated to 60 °C for 24-48 hours. The reaction is allowed to cool to RT and NaOH 
(15% w/w, 5-10mL) was added slowly and the mixture stirred for 1 hour. The mixture 
was diluted with wet THF (20ml) and filtered through celite to remove the solid waste. 
The celite is then washed with DCM and the organics dried over magnesium sulfate. The 
solvent is removed in vacuo and taken up in DCM and filtered to remove any solid 
particles. The solvent is removed in vacuo to yield product. 
 
2S,9S-Dibenzyl-1,4,8,11-tetraazacyclotetradecane (4.2a) 
 
HN
HN
NH
NH
 
 
Yield 141mg, 38.3% 1H NMR (400 MHz, CDCl3)  ppm 1.60 - 1.72 (m, 4 H) 
2.08 (s, 4 H) 2.39 - 2.47 (m, 2 H) 2.47 - 2.53 (m, 2 H) 2.56 - 2.67 (m, 8 H) 2.80 - 2.87 (m, 
2 H) 2.87 - 2.96 (m, 4 H) 7.12 - 7.19 (m, 6 H) 7.22 - 7.28 (m, 4 H). 13C NMR (101 MHz, 
CDCL3-D)  ppm 29.54, 39.38, 47.32, 50.09, 52.85, 58.86, 126.17, 128.52, 129.35, 
139.83.  
 
2S,9S-Di(2-naphthyl)-1,4,8,11-tetraazacyclotetradecane (4.2b) 
 
HN
HN
NH
NH
 
 
Yield 117mg, 65.1%. 1H NMR (400 MHz, CDCl3)  1.75 (s, 4 H) 2.58 (dd, 
J=11.91, 8.78 Hz, 4 H) 2.62 - 2.74 (m, 12 H) 2.94 - 3.10 (m, 4 H) 3.14 (dd, J=13.47, 5.27 
Hz, 2 H) 7.33 (d, J=8.20 Hz, 2 H) 7.40 - 7.51 (m, 4 H) 7.62 (s, 2 H) 7.74 - 7.84 (m, 6 H). 
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13C NMR (101 MHz, CDCl3)  29.03, 39.36, 47.46, 50.15, 52.80, 58.63, 125.54, 126.22, 
127.67, 127.70, 127.83, 127.89, 128.22, 132.31, 133.75, 137.08.  
 
2S,9S-Dimethyl 1,4,8,11-tetraazacyclotetradecane (4.2c) 
 
HN
HN
NH
NH
 
 
Yield 118mg, 26%. 1H NMR (400 MHz, CDCl3)  1.00 (s, 6 H) 1.76 (s, 4 H) 2.55 
(s, 6 H) 2.75 (s, 6 H) 2.98 (s, 2 H). 13C NMR (101 MHz, CDCl3)  17.79, 28.86, 48.56, 
50.77, 52.38, 55.62. 
 
4.7.5  General Synthesis of Nickel Cyclams Complexes. 
 
The cyclam (1mmol) is dissolved in methanol (20ml) and the nickel salt (1mmol) 
is added in methanol (10ml). The reaction mixture is heated to reflux for ten minutes and 
allowed to cool. A purple crystalline solid falls out of solution and is collected by 
filtration. (For the perchlorate salt recrystallization occurs in water after the removal of 
methanol) 
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2S,9S-Dibenzyl-1,4,8,11-tetraazacyclotetradecane  nickel Bis-chloride (4.4a) 
 
N
N
N
N
H H
H H
Ni(II)
Cl
Cl
 
 
Yield 35mg, 37.3%. MS: m/z calculated for C24H36N4 = 438.2293 actual m/z (M-
H) = 437.151. IR: υ 3252, 3219, 2921, 2855, 1446, 1086, 1000, 943, 869, 755, 739, 714, 
690, 637, 510cm-1. Structure confirmed by X-ray analysis. 
 
2S,9S-Di(2-naphthyl)-1,4,8,11-tetraazacyclotetradecane  nickel Bis-chloride (4.4b) 
 
N
N
N
N
H H
H H
Ni(II)
Cl
Cl
 
 
Yield 70mg, 68%. MS: m/z calculated for C32H40N4 = 538.2606, actual m/z (M-H) 
= 537.178. IR: υ 3207, 3178, 2913, 2843, 1458, 1421, 1115, 1094, 1041, 939, 874, 812, 
747, 735, 637, 592cm-1. Structure confirmed by X-ray analysis. 
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2S,9R-Di(2-naphthyl)-1,4,8,11-tetraazacyclotetradecane  nickel Bis-chloride (4.4c) 
 
N
N
N
N
H H
H H
Ni(II)
Cl
Cl
 
 
Yield 5mg, 3% over two steps.. Structure confirmed by X-ray analysis. 
 
2S,9S-Dimethyl-1,4,8,11-tetraazacyclotetradecane  nickel Bis-perchlorate (4.4d) 
 
N
N
N
N
H H
H H
Ni(II)
2ClO4-
 
 
Yield 2mg, 9.41% Structure confirmed by X-ray analysis. 
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Appendix A - 1HNMR and 13CNMR Data. 
Figure A.1: - (a) 1HNMR (b) 13CNMR of 1.1 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
1.973.891.01
Chloroform-d
M00(17)
M02(5)
M04(12)
M03(10,3,8)
M01(13,9,2,6)
5.
31
7.
99
8.
00
8.
02
8.
03
8.
06
8.
20
8.
21
8.
35
8.
37
 
(a) 
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
Chloroform-d
M07
M06
M05
M01
M02
M15
M11
M10
M09
M00
M14
M13
M12
13
1.
95
13
1.
14
12
8.
35
12
7.
99
12
7.
64
12
5.
62
12
2.
71
44
.7
5
 
(b) 
 
15
16
4
7
5
6
14
13
11
12
13
2
108
9
17
Cl
18
 190 
Figure A.2: - (a) 1HNMR (b) 13CNMR of 1.2a 
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Figure A.3: - (a) 1HNMR (b) 13CNMR of 1.2b 
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Figure A.4: - (a) 1HNMR (b) 13CNMR of 1.2c 
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Figure A.5: - (a) 1HNMR 1.4 
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Figure A.6: - (a) 1HNMR of 1.5 
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Figure A.7: - (a) 1HNMR of 1.6a 
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Figure A.8: - (a) 1HNMR (b) 13CNMR of 2.35 
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Figure A.9: - (a) 1HNMR (b) 13CNMR of 2.37a 
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Figure A.10: - (a) 1HNMR (b) 13CNMR of 2.37b 
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Figure A.11: - (a) 1HNMR (b) 13CNMR of 2.37c 
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Figure A.12: - (a) 1HNMR (b) 13CNMR of 2.37d 
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Figure A.13: - (a) 1HNMR (b) 13CNMR of 2.37e 
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Figure A.14: - (a) 1HNMR (b) 13CNMR of 2.37f 
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Figure A.15: - (a) 1HNMR (b) 13CNMR of 2.29a 
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Figure A.16: - (a) 1HNMR (b) 13CNMR of 2.29b 
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Figure A.17: - (a) 1HNMR (b) 13CNMR of 2.29c 
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Figure A.18: - (a) 1HNMR (b) 13CNMR of 2.29d 
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Figure A.19: - (a) 1HNMR (b) 13CNMR of 2.29e 
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Figure A.20: - (a) 1HNMR (b) 13CNMR of 2.38a 
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Figure A.21: - (a) 1HNMR (b) 13CNMR of 2.38b 
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Figure A.22: - (a) 1HNMR (b) 13CNMR of 2.38c 
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Figure A.23: - (a) 1HNMR (b) 13CNMR of 2.38d 
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Figure A.24: - (a) 1HNMR (b) 13CNMR of 2.38e 
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Figure A.25: - (a) 1HNMR (b) 13CNMR of 2.39a 
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Figure A.26: - (a) 1HNMR (b) 13CNMR of 2.39b 
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Figure A.27: - (a) 1HNMR (b) 13CNMR of 2.39c 
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Figure A.28: - (a) 1HNMR (b) 13CNMR of 2.39d 
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Figure A.29: - (a) 1HNMR (b) 13CNMR of 2.39e 
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Figure A.30: - (a) 1HNMR (b) 13CNMR of 2.39f 
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Figure A.31: - (a) 1HNMR (b) 13CNMR of 2.39g 
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Figure A.32: - (a) 1HNMR (b) 13CNMR of 2.39h 
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Figure A.33: - (a) 1HNMR (b) 13CNMR of 2.39i 
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Figure A.34: - (a) 1HNMR (b) 13CNMR of 2.35a 
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Figure A.35: - (a) 1HNMR (b) 13CNMR of 2.35b 
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Figure A.36: - (a) 1HNMR (b) 13CNMR of 2.35c 
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Figure A.37: - (a) 1HNMR (b) 13CNMR of 2.35d 
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Figure A.38: - (a) 1HNMR (b) 13CNMR of 2.35e 
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Figure A.39: - (a) 1HNMR (b) 13CNMR of 2.35f 
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Figure A.40: - (a) 1HNMR (b) 13CNMR of 3.1a 
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Figure A.41: - (a) 1HNMR  (b) 13C NMR of 3.1b 
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Figure A.42: - (a) 1HNMR (b) 13CNMR of 3.1c 
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Figure A.43: - (a) 1HNMR (b) 13CNMR of 3.2a 
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Figure A.44: - (a) 1HNMR (b) 13CNMR of 3.2b 
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Figure A.45: - (a) 1HNMR (b) 13CNMR of 3.2c 
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Figure A.46: - (a) 1HNMR (b) 13CNMR of 3.2d 
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Figure A.47: - (a) 1HNMR (b) 13CNMR of 3.2e 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
1.671.651.783.561.613.8514.66
Methanol-d4
Methanol 
M09
M08
M05
M07
M12
M11
M10
M01
M06
M04
M02 M00
M03
7.
72 7
.7
0
7.
65
7.
57
7.
48
7.
47
7.
41 7.
28
7.
26
7.
25
4.
00
3.
17
3.
14
3.
09
3.
07 3
.0
5
3.
04 3.
01
3.
01
2.
98
2.
17 2.
14
2.
10 1.
69 1.
65
1.
46
1.
45 1.
42
1.
39
1.
38
9
N
8
O
29
7
6
N
5
4
3
2
N
1
14
13
N
12
11
10
1 8
31
32
33
41
34
40
35
O
3 0
O
17
O
1 6
39
38
3 6
3 7
19
20
28
21
27
22
26
25
23
24
Ni2-
15
51
50
5 2
4 9
53
54
43
42
44
47
45
46
P
48
58
57
59
56
60
55
N+
61
P
62
63
64
68
65
6 7
6 6 70
71
69
72
74
73
77
78
76
79
7 5
8 0
90
89
91
88
92
93
82
81
83
86
84
85
P
87
9 7
9 6
98
95
99
94
N +
100
P
101
102
103
107
104
10 6
10 5
109
110
1 08
1 11
113
112
116
117
115
118
11 4
11 9
 
(a) 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
Methanol-d4
M05
M06
M04
M03
M02
M01
M00
M25
M26
M24
M22
M16
M10
M09
M08
M07
17
9.
17 1
74
.4
5
13
7.
73
13
4.
85
13
3.
53
13
3.
41
13
3.
30
13
0.
72
13
0.
46
13
0.
39
12
8.
54
12
7.
45
12
6.
28
12
5.
67
65
.2
3
39
.5
8
38
.9
6
38
.7
1
 
(b) 
 235 
Figure A.48: - (a) 1HNMR (b) 13CNMR of 3.2f 
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Figure A.49: - (a) 1HNMR (b) 13CNMR of 4.1a 
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Figure A.50: - (a) 1HNMR of 4.1b 
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Figure A.51: - (a) 1HNMR of 4.1c 
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Figure A.52: - (a) 1HNMR of 4.1d 
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Figure A.53: - (a) 1HNMR of 4.1e 
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Figure A.54: - (a) 1HNMR of 4.1f 
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Figure A.55: - (a) 1HNMR (b) 13CNMR of 4.2a 
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Figure A.56: - (a) 1HNMR (b) 13CNMR of 4.2b 
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Figure A.57: - (a) 1HNMR (b) 13CNMR of 4.2c 
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Appendix B - IR Data 
Figure B.1: - IR of 1.6a 
 
 
Figure B.2: - IR of 1.6d 
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Figure B.3: - IR of 2.37a 
 
 
Figure B.4: - IR of 3.1a 
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Figure B.5: - IR of 3.1c 
 
 
Figure B.6: - IR of 3.2a 
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Figure B.7: - IR of 4.1a 
 
 
Figure B.8: - IR of 4.1b 
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Figure B.9: - IR of 4.1c 
 
Figure B.10: - IR of 4.1d 
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Figure B.11: - IR of 4.1e 
 
Figure B.12: - IR of 4.1g 
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Figure B.13: - IR of 4.1h 
 
 
 
Figure B.14: - IR of 1.3 
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Figure B.15: - IR of 1.5 
 
 
Figure B.16: - IR of 4.4a 
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Figure B.17: - IR of 4.4b 
 
 
Figure B.18: - IR of 4.3a 
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Figure B.19: - IR of 4.3b 
 
N
N
N
N
Co
O
O
O
O
- PPN+
 253
Appendix C - Mass Spectrum Data. 
 
Figure C.1: - Mass spectrum of 1.6a 
 
 
 
 
 
Figure C.2: - Mass spectrum of 1.3 
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Figure C.3: - Mass spectrum of 1.4 
 
 
 
  
Figure C.4: - Mass spectrum of 1.5 
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Figure C.5: - Mass spectrum of 2.37a 
 
 
 
 
 
 
 
Figure C.6: - Mass spectrum of 2.37b 
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Figure C.7: - Mass spectrum of 2.37e 
 
 
 
 
 
 
 
Figure C.8: - Mass spectrum of 2.37f 
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Figure C.9: - Mass spectrum of 2.29a 
 
 
 
 
 
 
Figure C.10: - Mass spectrum of 2.29b 
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Figure C.11: - Mass spectrum of 2.38a 
 
 
 
 
 
 
 
Figure C.12: - Mass spectrum of 2.38b 
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Figure C.13: - Mass spectrum of 2.39a 
 
 
 
 
 
 
 
 
Figure C.14: - Mass spectrum of 2.39g 
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Figure C.15: - Mass spectrum of 2.34a 
 
 
 
 
 
Figure C.16: - Mass spectrum of 2.34c 
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Figure C.17: - Mass spectrum of 2.34d 
 
 
 
 
 
 
 
Figure C.18: - Mass spectrum of tripeptide 
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Figure C.19: - Mass spectrum of 2.40a 
 
 
 
Figure C.20: - Mass spectrum of 2.40b 
 
 
 
 
 
 
 
 
 
 
 
 263
Figure C.21: - Mass spectrum of 2.40c 
 
 
 
Figure C.22: - Mass spectrum of 2.40d 
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Figure C.23: - Mass spectrum of 2.40e 
 
 
 
Figure C.24: - Mass spectrum of 2.40f 
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Figure C.25: - Mass spectrum of 2.40g 
 
 
 
Figure C.26: - Mass spectrum of 2.40h 
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Figure C.27: - Mass spectrum of 2.40i 
 
 
 
Figure C.28: - Mass spectrum of 3.1b 
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Figure C.29: - Mass spectrum of 3.1c 
 
 
 
 
 
 
Figure C.30: - Mass spectrum of 3.2a 
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Figure C.31: - Mass spectrum of 3.2c 
 
 
 
 
Figure C.32: - Mass spectrum of 3.2b 
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Figure C.33: - Mass spectrum of BocTrpPhe 
 
 
 
 
Figure C.34: - Mass spectrum of 3.2g 
 
 
 
Figure C.35: - Mass spectrum of 3.2h 
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Figure C.36: - Mass spectrum of 3.2i 
 
 
Figure C.37: - Mass spectrum of 3.2j 
 
 
Figure C.38: - Mass spectrum of 3.2a 
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Figure C.39: - Mass spectrum of 3.2k 
 
 
 
Figure C.40: - Mass spectrum of NapNapNi cyclized from 
resin 3.2b 
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Figure C.41: - Mass spectrum of 4.1a 
 
 
 
 
Figure C.42: - Mass spectrum of 4.1c 
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Figure C.43: - Mass spectrum of 4.1c 
 
 
Figure C.44: - Mass spectrum of 4.1d 
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Figure C.45: - Mass spectrum of 4.1e 
 
 
 
Figure C.46: - Mass spectrum of 4.1h 
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Figure C.47: - Mass spectrum of 4.1g 
 
 
 
 
 
 
Figure C.48: - Mass spectrum of 4.4a 
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Figure C.49: - Mass spectrum of 4.4b 
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Appendix D - X-ray Crystal Data 
Figure D.1: - X-ray data for 1.4 
Table 1.  Crystal data and structure refinement for jt0708m. 
Identification code  jt0708m 
Empirical formula  C25 H34 Cl2 N4 Ni O8 
Formula weight  648.17 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 11.4094(17) Å = 90°. 
 b = 11.8597(16) Å = 96.815(5)°. 
 c = 20.544(3) Å  = 90°. 
Volume 2760.3(7) Å3 
Z 4 
Density (calculated) 1.560 g/cm3 
Absorption coefficient 0.953 mm-1 
F(000) 1352 
Crystal size 0.25 x 0.20 x 0.10 mm3 
Theta range for data collection 1.80 to 31.47°. 
Index ranges -16<=h<=15, -17<=k<=16, -30<=l<=30 
Reflections collected 36141 
Independent reflections 9092 [R(int) = 0.0426] 
Completeness to theta = 31.47° 99.3 %  
Absorption correction None 
Max. and min. transmission 0.9108 and 0.7967 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9092 / 0 / 370 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0437, wR2 = 0.1092 
R indices (all data) R1 = 0.0705, wR2 = 0.1228 
Largest diff. peak and hole 0.646 and -0.422 e.Å-3 
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Figure D.2: - X-ray data for 1.6b 
Table 1.  Crystal data and structure refinement for jt0502m. 
Identification code  jt0502m 
Empirical formula  C66 H76 B2 N8 Ni 
Formula weight  1061.68 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 16.2945(13) Å = 90°. 
 b = 10.2253(7) Å = 114.774(4)°. 
 c = 19.1985(13) Å  = 90°. 
Volume 2904.4(4) Å3 
Z 2 
Density (calculated) 1.214 g/cm3 
Absorption coefficient 0.382 mm-1 
F(000) 1132 
Crystal size 0.40 x 0.25 x 0.20 mm3 
Theta range for data collection 2.16 to 27.48°. 
Index ranges -20<=h<=20, -12<=k<=13, -24<=l<=24 
Reflections collected 18147 
Independent reflections 6015 [R(int) = 0.0941] 
Completeness to theta = 27.48° 90.5 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6015 / 0 / 351 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0578, wR2 = 0.1487 
R indices (all data) R1 = 0.0826, wR2 = 0.1689 
Largest diff. peak and hole 0.322 and -1.117 e.Å-3 
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Figure D.3: - X-ray data for 1.6d 
Table 1.  Crystal data and structure refinement for jt0811m. 
Identification code  jt0811m 
Empirical formula  C10 H32 B2 N4 Ni 
Formula weight  288.73 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.1327(5) Å = 90°. 
 b = 12.8026(9) Å = 109.978(3)°. 
 c = 8.6770(5) Å  = 90°. 
Volume 744.68(9) Å3 
Z 2 
Density (calculated) 1.288 g/cm3 
Absorption coefficient 1.288 mm-1 
F(000) 316 
Crystal size 0.20 x 0.15 x 0.15 mm3 
Theta range for data collection 2.96 to 31.51°. 
Index ranges -10<=h<=10, -17<=k<=18, -12<=l<=12 
Reflections collected 8351 
Independent reflections 2482 [R(int) = 0.0233] 
Completeness to theta = 31.51° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.8302 and 0.7827 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2482 / 0 / 97 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0248, wR2 = 0.0638 
R indices (all data) R1 = 0.0301, wR2 = 0.0669 
Largest diff. peak and hole 0.447 and -0.440 e.Å-3 
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Figure D.4: - X-ray data for 2.37a 
Table 1.  Crystal data and structure refinement for jt0809m. 
Identification code  jt0809m 
Empirical formula  C36 H54 N4 O11 
Formula weight  718.83 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 12.5832(9) Å = 90°. 
 b = 17.6865(12) Å = 90°. 
 c = 18.0311(12) Å  = 90°. 
Volume 4012.9(5) Å3 
Z 4 
Density (calculated) 1.190 g/cm3 
Absorption coefficient 0.088 mm-1 
F(000) 1544 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.57 to 32.57°. 
Index ranges -18<=h<=16, -26<=k<=17, -27<=l<=25 
Reflections collected 28685 
Independent reflections 7696 [R(int) = 0.0372] 
Completeness to theta = 25.00° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9869 and 0.9783 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7696 / 0 / 486 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0449, wR2 = 0.0898 
R indices (all data) R1 = 0.0772, wR2 = 0.1013 
Absolute structure parameter -1.3(7) 
Largest diff. peak and hole 0.205 and -0.234 e.Å-3 
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Figure D.5: - X-ray data for 3.1a 
  Table 1.  Crystal data and structure refinement for jt0701m. 
Identification code  jt0701m 
Empirical formula  C26 H34 N4 Ni O6 
Formula weight  557.28 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 10.8295(7) Å = 90°. 
 b = 10.8356(7) Å = 90°. 
 c = 45.297(3) Å  = 90°. 
Volume 5315.4(6) Å3 
Z 8 
Density (calculated) 1.393 g/cm3 
Absorption coefficient 0.777 mm-1 
F(000) 2352 
Crystal size 0.25 x 0.25 x 0.06 mm3 
Theta range for data collection 1.80 to 29.57°. 
Index ranges -15<=h<=14, -15<=k<=15, -62<=l<=62 
Reflections collected 284919 
Independent reflections 8256 [R(int) = 0.0949] 
Completeness to theta = 29.57° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9549 and 0.8294 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8256 / 377 / 746 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0475, wR2 = 0.1056 
R indices (all data) R1 = 0.0595, wR2 = 0.1115 
Absolute structure parameter 0.43(2) 
Largest diff. peak and hole 1.137 and -0.805 e.Å-3 
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Figure D.6: - X-ray data for 3.1b 
Identification code JT-1-547 
Empirical formula C28H38N4O6Ni 
Formula weight 
Temperature 
585.33 
150 K 
Wavelength 0.71073 Ǻ 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 10.1769(8) Å 
 b = 9.1013(8) Å 
 c = 15.1983(12) Å 
 α = 90° 
 β = 92.735(4) ° 
 γ = 90° 
Volume 1406.1(2) Å3 
Z 2 
Calculated density 1.382 g/cm3 
Absorption coefficient 0.738mm-1 
F(000) 620 
Crystal size 0.22 x 0.20 x 0.06 mm 
Crystal habit Plate 
Crystal color Orange 
 range for data collection 3.43 to 26.00o 
Limiting indices 
-12 ≤ h ≤ 12 
-11 ≤ k ≤ 11 
-18 ≤ l ≤ 18 
Reflections collected / unique 27340/5518 [R(int) = 0.0680] 
Completeness to  = 26.00 99.6 % 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5518 / 1 / 356 
Refinement threshold I>2(I) 
Data > threshold 4240 
Goodness-of-fit on F2 1.012 
Final R indices [I>2(I)] R1 = 0.0402, wR2 = 0.0742 
R indices (all data) R1 = 0.0660, wR2 = 0.0830 
Largest diff. peak and hole 0.364 and -0.409 e.A-3 
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Figure D.7: - X-ray data for 3.3a 
Table 1.  Crystal data and structure refinement for jt0707m. 
Identification code  jt0707m 
Empirical formula  C193.50 H172.50 N12 Ni2 O31.50 P8 
Formula weight  3535.11 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 17.3668(11) Å = 64.893(3)°. 
 b = 22.7993(15) Å = 83.504(3)°. 
 c = 25.3453(17) Å  = 84.426(3)°. 
Volume 9015.5(10) Å3 
Z 2 
Density (calculated) 1.302 g/cm3 
Absorption coefficient 0.355 mm-1 
F(000) 3691 
Crystal size 0.30 x 0.25 x 0.15 mm3 
Theta range for data collection 0.99 to 30.06°. 
Index ranges -24<=h<=24, -32<=k<=32, -33<=l<=35 
Reflections collected 239493 
Independent reflections 89022 [R(int) = 0.0763] 
Completeness to theta = 30.06° 96.5 %  
Absorption correction None 
Max. and min. transmission 0.9486 and 0.9009 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 89022 / 3 / 3757 
Goodness-of-fit on F2 0.972 
Final R indices [I>2sigma(I)] R1 = 0.0573, wR2 = 0.1363 
R indices (all data) R1 = 0.1048, wR2 = 0.1639 
Absolute structure parameter -0.010(6) 
Largest diff. peak and hole 1.361 and -0.744 e.Å-3 
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Figure D.8: - X-ray data for 3.2f 
Table 1.  Crystal data and structure refinement for jt0801m. 
Identification code  jt0801m 
Empirical formula  C60 H58 N5 Ni O6 P2 
Formula weight  1065.76 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 10.4869(9) Å = 115.667(4)°. 
 b = 16.9295(14) Å = 104.894(4)°. 
 c = 17.1207(14) Å  = 95.491(5)°. 
Volume 2571.7(4) Å3 
Z 2 
Density (calculated) 1.376 g/cm3 
Absorption coefficient 0.498 mm-1 
F(000) 1118 
Crystal size 0.25 x 0.15 x 0.08 mm3 
Theta range for data collection 2.42 to 32.58°. 
Index ranges -15<=h<=15, -25<=k<=25, -25<=l<=25 
Reflections collected 102256 
Independent reflections 18624 [R(int) = 0.0429] 
Completeness to theta = 32.58° 99.5 %  
Absorption correction None 
Max. and min. transmission 0.9612 and 0.8855 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 18624 / 108 / 739 
Goodness-of-fit on F2 1.104 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1319 
R indices (all data) R1 = 0.0749, wR2 = 0.1438 
Largest diff. peak and hole 1.962 and -0.593 e.Å-3 
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Figure D.9: - X-ray data for 3.2e 
Table 1.  Crystal data and structure refinement for jt0806m. 
Identification code  jt0806m 
Empirical formula  C68 H58 N5 Ni O4 P2 
Formula weight  1129.84 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 14.9124(5) Å = 90°. 
 b = 28.3252(9) Å = 101.860(2)°. 
 c = 26.0270(9) Å  = 90°. 
Volume 10759.0(6) Å3 
Z 8 
Density (calculated) 1.395 g/cm3 
Absorption coefficient 0.479 mm-1 
F(000) 4728 
Crystal size 0.30 x 0.20 x 0.15 mm3 
Theta range for data collection 1.08 to 31.00°. 
Index ranges -21<=h<=21, -40<=k<=40, -30<=l<=37 
Reflections collected 144435 
Independent reflections 32178 [R(int) = 0.0375] 
Completeness to theta = 31.00° 93.8 %  
Absorption correction None 
Max. and min. transmission 0.9317 and 0.8697 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 32178 / 25 / 1274 
Goodness-of-fit on F2 2.079 
Final R indices [I>2sigma(I)] R1 = 0.0928, wR2 = 0.2895 
R indices (all data) R1 = 0.1220, wR2 = 0.3029 
Largest diff. peak and hole 1.754 and -1.062 e.Å-3 
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Figure D.10: - X-ray data for 4.3a 
Table 1.  Crystal data and structure refinement for jt0901m. 
Identification code  jt0901m 
Empirical formula  C60 H62 Fe N5 O9.50 P2 
Formula weight  1122.94 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 10.6733(9) Å = 90°. 
 b = 13.4712(11) Å = 90°. 
 c = 38.259(3) Å  = 90°. 
Volume 5501.0(8) Å3 
Z 4 
Density (calculated) 1.356 g/cm3 
Absorption coefficient 0.396 mm-1 
F(000) 2356 
Crystal size 0.28 x 0.10 x 0.06 mm3 
Theta range for data collection 2.13 to 30.65°. 
Index ranges -15<=h<=8, -19<=k<=16, -54<=l<=42 
Reflections collected 93207 
Independent reflections 16670 [R(int) = 0.1950] 
Completeness to theta = 30.65° 99.2 %  
Absorption correction None 
Max. and min. transmission 0.9766 and 0.8972 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 16670 / 12 / 719 
Goodness-of-fit on F2 1.071 
Final R indices [I>2sigma(I)] R1 = 0.0917, wR2 = 0.1919 
R indices (all data) R1 = 0.2069, wR2 = 0.2399 
Absolute structure parameter 0.02(3) 
Largest diff. peak and hole 0.928 and -1.052 e.Å-3 
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Figure D.11: - X-ray data for 4.3b 
  Table 1.  Crystal data and structure refinement for jt0902m. 
Identification code  jt0902m 
Empirical formula  C60 H54 Co N5 O4 P2 
Formula weight  1029.95 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2 
Unit cell dimensions a = 15.6796(11) Å = 90°. 
 b = 8.9697(7) Å = 94.201(4)°. 
 c = 17.8778(13) Å  = 90°. 
Volume 2507.6(3) Å3 
Z 2 
Density (calculated) 1.364 g/cm3 
Absorption coefficient 0.461 mm-1 
F(000) 1076 
Crystal size 0.20 x 0.16 x 0.14 mm3 
Theta range for data collection 1.30 to 31.00°. 
Index ranges -22<=h<=22, -12<=k<=12, -25<=l<=25 
Reflections collected 39874 
Independent reflections 14883 [R(int) = 0.0860] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction None 
Max. and min. transmission 0.9383 and 0.9134 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14883 / 313 / 651 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0812, wR2 = 0.1559 
R indices (all data) R1 = 0.1664, wR2 = 0.1825 
Absolute structure parameter 0.11(3) 
Largest diff. peak and hole 0.960 and -0.977 e.Å-3 
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Figure D.12: - X-ray data for 4.4a 
Table 1.  Crystal data and structure refinement for jt0803m. 
Identification code  jt0803m 
Empirical formula  C26 H44 Cl2 N4 Ni O2 
Formula weight  574.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 6.8356(4) Å = 86.977(2)°. 
 b = 8.0965(4) Å = 81.399(2)°. 
 c = 12.9985(7) Å  = 82.068(2)°. 
Volume 704.12(7) Å3 
Z 1 
Density (calculated) 1.354 g/cm3 
Absorption coefficient 0.908 mm-1 
F(000) 306 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 2.54 to 33.11°. 
Index ranges -10<=h<=10, -12<=k<=12, -19<=l<=19 
Reflections collected 15175 
Independent reflections 9039 [R(int) = 0.0180] 
Completeness to theta = 33.11° 97.9 %  
Absorption correction None 
Max. and min. transmission 0.9146 and 0.8048 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9039 / 3 / 336 
Goodness-of-fit on F2 0.981 
Final R indices [I>2sigma(I)] R1 = 0.0251, wR2 = 0.0558 
R indices (all data) R1 = 0.0281, wR2 = 0.0568 
Absolute structure parameter 0.021(6) 
Largest diff. peak and hole 0.585 and -0.226 e.Å-3 
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Figure D.13: - X-ray data for 4.4b. 
Table 1.  Crystal data and structure refinement for jt0710m. 
Identification code  jt0710m 
Empirical formula  C34 H44 Cl2 N4 Ni O2 
Formula weight  670.34 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 6.872(4) Å = 89.33(4)°. 
 b = 8.172(6) Å = 86.34(4)°. 
 c = 15.032(8) Å  = 84.67(4)°. 
Volume 838.8(9) Å3 
Z 1 
Density (calculated) 1.327 g/cm3 
Absorption coefficient 0.774 mm-1 
F(000) 354 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.72 to 29.94°. 
Index ranges -9<=h<=9, -11<=k<=11, -21<=l<=20 
Reflections collected 24197 
Independent reflections 24197 [R(int) = 0.0000] 
Completeness to theta = 29.94° 98.7 %  
Absorption correction None 
Max. and min. transmission 0.8928 and 0.8301 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 24197 / 3 / 318 
Goodness-of-fit on F2 1.047 
Final R indices [I>2sigma(I)] R1 = 0.1038, wR2 = 0.2644 
R indices (all data) R1 = 0.2403, wR2 = 0.3355 
Absolute structure parameter 0.08(3) 
Largest diff. peak and hole1.020 and -1.294 e.Å-3 
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Figure D.14: - X-ray data for 4.4c. 
Table 1.  Crystal data and structure refinement for jt0812m. 
Identification code  jt0812m 
Empirical formula  C65 H84 Cl4 N8 Ni2 O 
Formula weight  1252.62 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 25.861(3) Å = 90°. 
 b = 6.6117(6) Å = 101.243(7)°. 
 c = 36.006(4) Å  = 90°. 
Volume 6038.3(11) Å3 
Z 4 
Density (calculated) 1.378 g/cm3 
Absorption coefficient 0.851 mm-1 
F(000) 2648 
Crystal size 0.18 x 0.12 x 0.06 mm3 
Theta range for data collection 3.06 to 30.51°. 
Index ranges -35<=h<=33, -9<=k<=9, -51<=l<=51 
Reflections collected 30422 
Independent reflections 8626 [R(int) = 0.1708] 
Completeness to theta = 27.50° 95.1 %  
Absorption correction None 
Max. and min. transmission 0.9507 and 0.8619 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8626 / 0 / 382 
Goodness-of-fit on F2 0.940 
Final R indices [I>2sigma(I)] R1 = 0.0736, wR2 = 0.1286 
R indices (all data) R1 = 0.2224, wR2 = 0.1746 
Largest diff. peak and hole 0.558 and -0.432 e.Å-3 
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Figure D.15: - X-ray data for 4.4d 
Table 1.  Crystal data and structure refinement for jt0808m. 
Identification code  jt0808m 
Empirical formula  C12 H28 Cl2 N4 Ni O8 
Formula weight  485.99 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.3101(4) Å = 90°. 
 b = 13.4696(6) Å = 90°. 
 c = 17.3408(8) Å  = 90°. 
Volume 1941.02(16) Å3 
Z 4 
Density (calculated) 1.663 g/cm3 
Absorption coefficient 1.323 mm-1 
F(000) 1016 
Crystal size 0.25 x 0.20 x 0.15 mm3 
Theta range for data collection 2.35 to 31.49°. 
Index ranges -12<=h<=12, -19<=k<=19, -25<=l<=25 
Reflections collected 27290 
Independent reflections 6371 [R(int) = 0.0631] 
Completeness to theta = 31.49° 99.6 %  
Absorption correction None 
Max. and min. transmission 0.8262 and 0.7333 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6371 / 40 / 275 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0626, wR2 = 0.1685 
R indices (all data) R1 = 0.0765, wR2 = 0.1781 
Absolute structure parameter 0.01(2) 
Largest diff. peak and hole2.870 and -0.980 e.Å-3 
 
